<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Antiplatelet agents for preventing thrombosis after peripheral arterial bypass surgery - Forster, RB - 2015 | Cochrane Library</title> <meta content="Antiplatelet agents for preventing thrombosis after peripheral arterial bypass surgery - Forster, RB - 2015 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD000535.pub3/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Antiplatelet agents for preventing thrombosis after peripheral arterial bypass surgery - Forster, RB - 2015 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD000535.pub3/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD000535.pub3" name="dc.identifier" scheme="DOI"/> <meta content="Antiplatelet agents for preventing thrombosis after peripheral arterial bypass surgery" name="citation_title"/> <meta content="Rachel B Forster" name="citation_author"/> <meta content="University of Edinburgh" name="citation_author_institution"/> <meta content="rbedenis@gmail.com" name="citation_author_email"/> <meta content="Anne Lethaby" name="citation_author"/> <meta content="University of Auckland" name="citation_author_institution"/> <meta content="Heather Maxwell" name="citation_author"/> <meta content="Stefan Acosta" name="citation_author"/> <meta content="Malmö University Hospital" name="citation_author_institution"/> <meta content="Martin H Prins" name="citation_author"/> <meta content="CAPHRI Research School, Maastricht University" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="2" name="citation_issue"/> <meta content="10.1002/14651858.CD000535.pub3" name="citation_doi"/> <meta content="2015" name="citation_date"/> <meta content="2015/02/19" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD000535.pub3/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD000535.pub3/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD000535.pub3/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Anastomosis, Surgical [adverse effects, methods]; Anticoagulants [therapeutic use]; Arteriosclerosis [surgery]; Aspirin [therapeutic use]; Dipyridamole [therapeutic use]; Graft Occlusion, Vascular [etiology, *prevention &amp; control]; Intermittent Claudication [surgery]; Peripheral Vascular Diseases [*surgery]; Platelet Aggregation Inhibitors [*therapeutic use]; Randomized Controlled Trials as Topic; Thrombosis [*prevention &amp; control]; Vascular Patency" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000535.pub3&amp;doi=10.1002/14651858.CD000535.pub3&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000535.pub3&amp;doi=10.1002/14651858.CD000535.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000535.pub3&amp;doi=10.1002/14651858.CD000535.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000535.pub3&amp;doi=10.1002/14651858.CD000535.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000535.pub3&amp;doi=10.1002/14651858.CD000535.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000535.pub3&amp;doi=10.1002/14651858.CD000535.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000535.pub3&amp;doi=10.1002/14651858.CD000535.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000535.pub3&amp;doi=10.1002/14651858.CD000535.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000535.pub3&amp;doi=10.1002/14651858.CD000535.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000535.pub3&amp;doi=10.1002/14651858.CD000535.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000535.pub3&amp;doi=10.1002/14651858.CD000535.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000535.pub3&amp;doi=10.1002/14651858.CD000535.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000535.pub3&amp;doi=10.1002/14651858.CD000535.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000535.pub3&amp;doi=10.1002/14651858.CD000535.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000535.pub3&amp;doi=10.1002/14651858.CD000535.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000535.pub3&amp;doi=10.1002/14651858.CD000535.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000535.pub3&amp;doi=10.1002/14651858.CD000535.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000535.pub3&amp;doi=10.1002/14651858.CD000535.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000535.pub3&amp;doi=10.1002/14651858.CD000535.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000535.pub3&amp;doi=10.1002/14651858.CD000535.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000535.pub3&amp;doi=10.1002/14651858.CD000535.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000535.pub3&amp;doi=10.1002/14651858.CD000535.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000535.pub3&amp;doi=10.1002/14651858.CD000535.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="STpJR8yz";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD000535\x2epub3\x26doi\x3d10\x2e1002\x2f14651858\x2eCD000535\x2epub3\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000535\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD000535\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","zh_HANT","ru","fa","ms"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD000535.pub3",title:"Antiplatelet agents for preventing thrombosis after peripheral arterial bypass surgery",firstPublishedDate:"Feb 19, 2015 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Vascular Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=STpJR8yz&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD000535.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD000535.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD000535.pub3/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD000535.pub3/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD000535.pub3%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD000535.PUB3" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]},{&quot;param&quot;: &quot;comments&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Comments&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD000535.pub3/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD000535.PUB3" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD000535.pub3/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD000535.pub3/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>2736 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD000535.pub3" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000535.pub3/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000535.pub3/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000535.pub3/full#CD000535-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000535.pub3/full#CD000535-sec-0101"> Authors' conclusions </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000535.pub3/full#CD000535-sec-0008"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000535.pub3/full#CD000535-sec-0012"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000535.pub3/full#CD000535-sec-0013"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000535.pub3/full#CD000535-sec-0036"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000535.pub3/full#CD000535-sec-0092"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000535.pub3/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000535.pub3/appendices#CD000535-sec-0106"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000535.pub3/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000535.pub3/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/supinfo/CD000535StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/supinfo/CD000535StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000535.pub3/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000535.pub3/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000535.pub3/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD000535.pub3/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD000535.pub3/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD000535.pub3/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2023 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Antiplatelet agents for preventing thrombosis after peripheral arterial bypass surgery</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD000535.pub3/information#CD000535-cr-0004"><i class="icon corresponding-author fa fa-envelope"></i>Rachel B Forster</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD000535.pub3/information#CD000535-cr-0005">Anne Lethaby</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD000535.pub3/information#CD000535-cr-0006">Heather Maxwell</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD000535.pub3/information#CD000535-cr-0007">Stefan Acosta</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD000535.pub3/information#CD000535-cr-0008">Martin H Prins</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/information/en#CD000535-sec-0114">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 19 February 2015 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD000535.pub3">https://doi.org/10.1002/14651858.CD000535.pub3</a> </div> </div> </header> <div class="editorialNote"> <section id="CD000535-note-0001"> <p> <b>Editorial note</b> </p> <p>This review has been superseded by Cochrane Reviews: 'Antithrombotics after infra‐inguinal bypass grafting' (<a href="https://doi.org/10.1002/14651858.CD015141" target="_blank">https://doi.org/10.1002/14651858.CD015141</a>) and 'Antithrombotics after infra‐inguinal peripheral endovascular treatment' (<a href="https://doi.org/10.1002/14651858.CD015142" target="_blank">https://doi.org/10.1002/14651858.CD015142</a>). </p> </section> </div> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD000535-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD000535-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD000535-abs-0010">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD000535-abs-0007">فارسی</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD000535-abs-0003">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD000535-abs-0001" lang="en"> <section id="CD000535-sec-0001"> <h3 class="title" id="CD000535-sec-0001">Background</h3> <p>Peripheral arterial disease (PAD) may cause occlusions (blockages) in the main arteries of lower limbs. One treatment option is bypass surgery using autologous (the patient's own tissue) vein graft or prosthetic (artificial) graft. A number of factors influence occlusion rates in these patients, including the material used. To prevent graft occlusion patients are usually treated with antiplatelet, antithrombotic drugs, or a combination of both. </p> </section> <section id="CD000535-sec-0002"> <h3 class="title" id="CD000535-sec-0002">Objectives</h3> <p>To determine the effects of antiplatelet agents for the prevention of thrombosis in people with lower limb atherosclerosis who were undergoing femoropopliteal or femorodistal bypass grafting. Outcomes included the overall success of therapy (graft patency and limb salvage rates) and complications of treatment. </p> </section> <section id="CD000535-sec-0003"> <h3 class="title" id="CD000535-sec-0003">Search methods</h3> <p>For this update the Cochrane Peripheral Vascular Diseases Group Trials Search Co‐ordinator searched the Specialised Register (last searched June 2014) and the Cochrane Central Register of Controlled Trials (CENTRAL) (2014, Issue 5). We sought additional trials through screening the reference lists of relevant papers. </p> </section> <section id="CD000535-sec-0004"> <h3 class="title" id="CD000535-sec-0004">Selection criteria</h3> <p>Two review authors, RB and AL, independently reviewed studies found in the search and evaluated them based on the inclusion and exclusion criteria, resolving disagreements through discussion. </p> </section> <section id="CD000535-sec-0005"> <h3 class="title" id="CD000535-sec-0005">Data collection and analysis</h3> <p>RB and AL independently extracted details of the selected studies for the update. We compared the treatment and control groups for important prognostic factors and differences described. If any data were unavailable, we sought further information from study authors. We synthesised data by comparing group results. We addressed unit of analysis issues by subgroup analysis. </p> </section> <section id="CD000535-sec-0006"> <h3 class="title" id="CD000535-sec-0006">Main results</h3> <p>We include 16 studies with 5683 randomised participants. Nine different treatment groups were evaluated: aspirin (ASA) or aspirin and dipyridamole (ASA/DIP) versus placebo or nothing (six studies); ASA or ASA/DIP versus pentoxifylline (two studies); ASA/DIP versus indobufen (one study); ASA or ASA/DIP versus vitamin K antagonists (two studies); ASA/DIP versus low molecular weight heparin (one study); ticlopidine versus placebo (one study); ASA versus prostaglandin E1 (one study); ASA versus naftidrofuryl (one study); and clopidogrel and ASA versus ASA alone (one study). The treatment comparisons were evaluated separately, and, where possible, we performed subgroup analysis for venous grafts and prosthetic grafts and at different follow‐up time points. The quality of evidence was low to moderate as many of the treatment comparisons had very few studies to contribute data, several of the included studies had unit of analysis issues, the treatment dosages varied between studies, and data for many outcomes important to this review were not given in any of the studies, or differed greatly between studies. Overall study quality was moderate, with the largest problem being that the majority of studies did not describe their methods of randomisation, allocation concealment or blinding of outcome assessors, leading to risk ratings of 'unclear'. The other main issue with study quality was studies not blinding participants or personnel. </p> <p>The treatment comparison with the most number of included studies, which allowed for robust conclusions, was that of aspirin (ASA) or ASA and dipyridamole (ASA/DIP) versus placebo or nothing, covered by six studies. For this treatment group, there was improved graft patency in the ASA or ASA/DIP treatment group, odds ratio (OR) 0.42 (95% confidence interval (CI) 0.22 to 0.83; P = 0.01; 952 participants). This effect was not seen for venous grafts alone at any of the time points, but was observed for all time points in prosthetic grafts, including the final time point of 12 months (OR 0.19, 95% CI 0.10 to 0.36; P &lt; 0.00001; 222 participants). Only a single study evaluated secondary patency, for which there was no difference between treatment groups. For the comparison ASA or ASA/DIP versus placebo or nothing there was no difference for any of the side effects, including general, gastrointestinal, bleeding and wound/graft infection. Amputations, cardiovascular events and mortality were also similar between the treatment groups. The comparison of ASA or ASA/DIP versus vitamin K antagonists included two studies, one of which was very large, with over 2000 participants. There were no differences between treatment for primary graft patency at three, six, 12 or 24 months, and there was also no evidence of a difference for limb amputation, cardiovascular events or mortality. One large study (851 participants) evaluated clopidogrel and ASA versus ASA alone, and for all grafts there was no evidence of a difference of primary patency at 24 months. There was evidence of increased total bleeding in the clopidogrel and ASA group (OR 2.65, 95% CI 1.69 to 4.15) from an increase in mild (OR 2.34, 95% CI 1.37 to 4.00), and moderate bleeding (OR 4.13, 95% CI 1.37 to 12.45), but no difference in severe or fatal bleeding. There was no difference between the treatment groups for limb amputation or mortality. For the remaining treatment comparisons there is not currently enough evidence to draw any robust conclusions about the efficacy or safety of the treatment on graft patency after peripheral bypass. </p> </section> <section id="CD000535-sec-0007"> <h3 class="title" id="CD000535-sec-0007">Authors' conclusions</h3> <p>Antiplatelet therapy with aspirin or with aspirin plus dipyridamole had a beneficial effect on primary patency of peripheral bypass grafts compared to placebo or no treatment. This effect was not evident when evaluating venous grafts alone, but antiplatelet therapy did have a beneficial effect on patency in those who had prosthetic grafts. There was no evidence of differences in side effects (including general, gastrointestinal, bleeding or infection), amputation, cardiovascular events or mortality between the treatment groups. However, the number of participants included in this analysis might be too small to detect a statistically significant effect for side effects, amputation, cardiovascular morbidity or mortality. We found no difference in primary graft patency when aspirin or aspirin with dipyridamole was compared to a vitamin K antagonist or when clopidogrel with aspirin was compared to aspirin alone. However, there was evidence of increase bleeding in the clopidogrel with aspirin group for the latter comparison. The remaining six treatment comparisons did not include enough data to draw any robust conclusions about their efficacy or safety at this time. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD000535-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD000535-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD000535-abs-0011">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD000535-abs-0008">فارسی</a> </li> <li class="section-language"> <a class="" href="full/ms#CD000535-abs-0009">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/ru#CD000535-abs-0006">Русский</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD000535-abs-0004">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD000535-abs-0005">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD000535-abs-0002" lang="en"> <h3>Antiplatelet agents for preventing failure of peripheral arterial grafts</h3> <p>Background</p> <p>Symptomatic peripheral arterial disease in people with atherosclerosis can present as intermittent claudication, disabling pain on walking, or as critical limb ischaemia with pain at rest, ulceration, gangrene and the risk of losing a leg. One treatment option is to implant a graft or makeshift blood vessel to bypass a blockage in the main artery of the thigh. Using a section of the vein from the patient's leg is often better than artificial or prosthetic materials such as Dacron or polytetrafluoroethylene, which take up platelets that could lead to clotting that could block the graft. Other factors affecting the patency of the graft (how long the bypass remains open) include length of the bypass, site where the graft connects to the existing artery and blood flow out of the graft. Stenosis (narrowing) of the graft most frequently occurs at the surgical connections because of hyperplasia, or an increase in the number of smooth muscle cells, into the inner layer of the vessel, often followed by the formation of a thrombosis (clot) at the stenotic site. </p> <p>Study characteristics</p> <p>We include 16 studies in this review with 5683 randomised participants. Nine different treatment groups were evaluated: Aspirin (ASA) or aspirin and dipyridamole (ASA/DIP) versus placebo or nothing (six studies); ASA or ASA/DIP versus pentoxifylline (two studies); ASA/DIP versus indobufen (one study); ASA or ASA/DIP versus vitamin K antagonists (two studies); ASA/DIP versus low molecular weight heparin (one study); ticlopidine versus placebo (one study); ASA versus prostaglandin E1 (one study); ASA versus naftidrofuryl (one study); and clopidogrel and ASA versus ASA alone (one study). We evaluated the different treatment comparisons separately, and, where possible, we evaluated separately those participants who received different types of grafts, venous or prosthetic. </p> <p>Quality of the evidence</p> <p>The quality of evidence from the review was low to moderate, as there were few studies to provide evidence for the different comparisons; several of the included studies randomised and analysed participants in a way that could introduce bias; and many of the prespecified outcomes of the review were not addressed within the studies, or were reported on in different ways between studies. Also, the treatment dosages varied between studies. Overall study quality was moderate, with the largest problem being that the majority of studies did not described their methods of randomisation or blinding of those that evaluated the outcomes. The other main issue with study quality was not blinding participants or personnel to the treatment received. </p> <p>Key results</p> <p>The comparison of ASA or ASA and dipyridamole (ASA/DIP) versus placebo or nothing, included the most studies (six), which allowed for robust analysis. For this treatment group, there was improved graft patency in the ASA or ASA/DIP treatment group. There was an improvement in those that received prosthetic grafts, but not in those that received venous grafts. Only a single study evaluated secondary patency, for which there was no difference between treatment groups. For this comparison there was no difference for any of the side effects, including general, gastrointestinal, bleeding and wound/graft infection. Amputations, cardiovascular events and death from any cause were also similar between the treatment groups. The comparison of ASA or ASA/DIP versus vitamin K antagonists included two studies, one of which was very large, with over 2000 participants. There were no differences between treatment for primary graft patency at three, six, 12 or 24 months, and there was also no evidence of a difference for limb amputation, cardiovascular events or mortality. One large study evaluated clopidogrel and ASA versus ASA alone, and for all grafts (including prosthetic and venous grafts) there was no evidence of a difference of primary patency at 24 months. There was evidence of increased total bleeding in the clopidogrel and ASA group, from an increase in mild and moderate bleeding, but there was no difference in severe or fatal bleeding. There was no difference between the treatment groups for limb amputation or death from any cause. For the remaining treatment comparisons there is not currently enough evidence to draw any robust conclusions about the efficacy or safety of the treatment on graft patency after peripheral bypass. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD000535-sec-0101" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD000535-sec-0101"></div> <h3 class="title" id="CD000535-sec-0102">Implications for practice</h3> <section id="CD000535-sec-0102"> <p>There is evidence to suggest that the administration of platelet inhibitors such as ASA or ASA/DIP will result in improved venous and prosthetic graft patency compared to no treatment. However, patients with a prosthetic graft may benefit more from ASA or ASA/DIP administration than those with a venous graft, but this needs further investigation. The results of this review should be interpreted with caution, due to the unit of analysis issues described within the review, as well as the fact that many of the comparisons were only reported in a single study, and that the dosages often differed between studies. </p> </section> <h3 class="title" id="CD000535-sec-0103">Implications for research</h3> <section id="CD000535-sec-0103"> <p>Further high‐quality randomised clinical trials, with adequate sample sizes, are required to evaluate the efficacy of antiplatelet medications for graft patency in infrainguinal venous and prosthetic grafts for all treatment comparisons. Presentation of data should be detailed and not only show survival curves for overall patency. Tables showing the raw data would improve the transparency of the trial performance and allow comparison of endpoints at consecutive time points. The reader would be able to identify the number of occlusions, or other endpoints, at different time points in each comparison group as well as in subgroups defined by bypass material, above‐ and below‐knee anastomosis, and inflow and outflow conditions. Other concerns for research within this area would be determining the optimal dosage of antiplatelet medications and also outcome stratification by co‐morbidities, such as diabetes. A more complete outcome profile should be evaluated, such as assisted primary patency. Uniformity of unit of analysis issues should be addressed in studies of peripheral vascular disease, as there needs to be clarity around single and multiple grafts and the time points at which these occurred. </p> </section> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD000535-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD000535-sec-0008"></div> <section id="CD000535-sec-0009"> <h3 class="title" id="CD000535-sec-0009">Description of the condition</h3> <p>Symptomatic, chronic peripheral arterial disease (PAD) of the lower extremities may present either as intermittent claudication (IC), pain on walking, or as critical limb ischaemia (CLI), which is a more progressive stage with pain at rest, ulceration and gangrene (<a href="./references#CD000535-bbs2-0039" title="BeckerF , Robert-EbadiH , RiccoJB , SetacciC , CaoP , De DonatoG . Guidelines for critical limb ischaemia and diabetic foot, Chapter I: Definitions, Epidemiology, Clinical presentation and Prognosis. European Journal of Vascular and Endovascular Surgery2011;42:4-12.">Becker 2011</a>). The implantation of a femoropopliteal or femorodistal bypass graft (a makeshift blood vessel used to bypass a blockage in the main artery of the thigh) is one treatment option for people who are at risk of losing a limb or whose walking ability is greatly impaired because of the disease. By placing a graft in the groin area (an infrainguinal graft) the blocked arterial segment is bypassed, thereby improving blood flow in the limb. This then relieves the symptoms of claudication or rest pain and decreases the potential for amputation due to ulceration and gangrene, termed limb salvage. </p> <p>The patency rate for femoropopliteal and femorodistal grafts, or the number of bypasses remaining open after a certain period of time, depends on several risk factors. These include whether or not the patient has acute lower limb ischaemia (<a href="./references#CD000535-bbs2-0038" title="BarilD , PatelV , JudelsonD , GoodneyP , McPheeJ , HeveloneN , et al. Outcomes of lower extremity bypass performed for acute limb ischemia. Journal of Vascular Surgery2013;58(4):949-56.">Baril 2013</a>), graft material, length of the bypass, site of the distal anastomosis (surgical connection of the graft to the existing artery), outflow conditions in the calf (flow of blood out of the graft) and female gender (<a href="./references#CD000535-bbs2-0041" title="CooperGG , AustinC , FitzsimmonsE , BranniganPD , HoodJM , D'SaAA . Outflow resistance and early occlusion of infrainguinal bypass grafts. European Journal of Vascular Surgery1990;4(3):279-83.">Cooper 1990</a>; <a href="./references#CD000535-bbs2-0049" title="TangelderMJ , AlgraA , LawsonJA , Eikelboom, BC. Risk factors for occlusion of infrainguinal bypass grafts. European Journal of Vascular and Endovascular Surgery2000;20(2):118-24.">Tangelder 2000</a>). Autologous saphenous vein (using a vein from the patient's calf or thigh or both) is superior to prosthetic (artificial) materials such as Dacron or polytetrafluoroethylene (PTFE) (<a href="./references#CD000535-bbs2-0047" title="RutherfordRB , JonesDN , BergentzSE , BergqvistD , ComerotaAJ , DardikH , et al. Factors affecting the patency of infrainguinal bypass. Journal of Vascular Surgery1988;8(3):236-46.">Rutherford 1988</a>). Where the distal anastomosis is above the knee there is a lower risk of graft failure, and patients with two or three patent calf arteries have a better outcome than those with only one patent artery. Graft failure most frequently occurs at the site of either the distal or proximal anastomosis, when smooth muscle cells of the medial (middle) layer of the vessel wall grow into the intimal (inner) layer, which is known as intimal hyperplasia. This in turn causes the diameter of the perfused graft to become smaller, known as stenosis. When blood flow through the vessel is significantly reduced intermittent claudication may be experienced. Graft occlusion (closure) can occur by formation of a thrombosis (clot) at the stenotic site. If blood flow in the failed graft cannot be restored and further bypass surgery is not possible, then blood flow may be so poor that the limb cannot remain viable and amputation is required. Successful prevention of graft failure and thus the need for surgical re‐intervention is of major clinical and economic importance. Occlusion rates one year after the operation vary between 15% and 75% depending on the various risk factors described above (<a href="./references#CD000535-bbs2-0037" title="AbbottWM , GreenRM , MatsumotoT , WheelerJR , MillerN , VeithFJ , et al. Prosthetic above-knee femoropopliteal bypass grafting: results of a multicenter randomized prospective trial. Above-Knee Femoropopliteal Study Group. Journal of Vascular Surgery1997;25(1):19-28.">Abbott 1997</a>; <a href="./references#CD000535-bbs2-0040" title="European Working Group on Critical Limb Ischemia Second European Consensus Document on Chronic Critical Leg Ischemia. Second European Consensus Document on Chronic Critical Leg Ischemia. Circulation1991;84 Suppl 4:1-26.">Consensus 1991</a>). In addition, patients with lower limb atherosclerosis (progressive hardening of the arteries) frequently experience increased platelet aggregation, leading to clot formation. Moreover, the body's physiological stress response to surgery is a prothrombotic state (where the body is preparing to form a blood clot). </p> </section> <section id="CD000535-sec-0010"> <h3 class="title" id="CD000535-sec-0010">Description of the intervention</h3> <p>Antiplatelet treatment is used to prevent formation of blood clots by preventing platelet aggregation (<a href="./references#CD000535-bbs2-0046" title="Anon. Antiplatelet treatment- summary. National Institue for Health and Care Excellence (NICE)2013;cks.nice.org.uk/antiplatelet-treatment#!topicsummary((Accessed July 1 2014)).">NICE 2013</a>). Antiplatelet agents work by improving blood rheology and also by suppressing the advancement of in‐ and outflow atherosclerosis (reducing the rate of development of stenosis) as well as coronary artery atherosclerosis, indirectly optimising cardiac function and circulation. </p> <p>For patients receiving bypass surgery, the intensity of platelet uptake by the graft material has been shown to be inversely related to graft patency at one year, indicating the need for antiplatelet intervention. In animal experiments, antiplatelet drug administration started before bypass surgery has been shown to increase patency in prosthetic grafts when compared to no treatment (<a href="./references#CD000535-bbs2-0042" title="FujitaniRM , NordestgaardAG , MarcusCS , WilsonSE . Perioperative suppression of platelet adherence to small-diameter polytetrafluoroethylene (PTFE) grafts. Journal of Surgical Research1988;44(4):455-60.">Fujitani 1988</a>). </p> <p>To prevent graft occlusion patients are usually treated with either an antiplatelet or an anticoagulant drug, or a combination of both. It is not known which regimen is best to prevent infrainguinal graft occlusion. The aim of this review was to evaluate whether antiplatelet treatment improves graft patency, limb salvage and survival in patients with chronic PAD who are undergoing infrainguinal bypass surgery. </p> </section> <section id="CD000535-sec-0011"> <h3 class="title" id="CD000535-sec-0011">Why it is important to do this review</h3> <p>Another Cochrane review was recently undertaken to also evaluate the prevention of thrombosis after infrainguinal arterial bypass, but this review focused on the use of antithrombotic therapies (<a href="./references#CD000535-bbs2-0043" title="GeraghtyAJ , WelchK . Antithrombotic agents for preventing thrombosis after infrainguinal arterial bypass surgery. Cochrane Database of Systematic Reviews2011, Issue 6. Art. No: CD000536. [DOI: 10.1002/14651858.CD000536.pub2]">Geraghty 2011</a>). Overall their findings were inconclusive, with a possible benefit of antithrombotics for autologous vein grafts. Also, there may be higher economic costs and adverse haemorrhagic events associated with the use of anticoagulants compared with antiplatelet therapy. If the efficacy of antiplatelets is acceptable then it may be a more economical alternative to anticoagulant therapy following bypass graft surgery in the legs. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD000535-sec-0012" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD000535-sec-0012"></div> <p>To determine the effects of antiplatelet agents for the prevention of thrombosis in patients with lower limb atherosclerosis who were undergoing femoropopliteal or femorodistal bypass grafting. Outcomes include the overall success of therapy (graft patency and limb salvage rates) and complications of treatment. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD000535-sec-0013" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD000535-sec-0013"></div> <section id="CD000535-sec-0014"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD000535-sec-0015"> <h4 class="title">Types of studies</h4> <p>Trials in which participants were randomly allocated to receive either antiplatelet therapy versus placebo, one antiplatelet regimen versus another or antiplatelet therapy versus an alternative treatment. We include trials using alternation (allocation of treatment alternating between two interventions) and consider them as quasi‐randomised clinical trials (qRCTs). </p> </section> <section id="CD000535-sec-0016"> <h4 class="title">Types of participants</h4> <p>All people undergoing femoropopliteal or femorodistal bypass grafting for the treatment of intermittent claudication and critical limb ischaemia. We excluded people undergoing bypass surgery for trauma. </p> </section> <section id="CD000535-sec-0017"> <h4 class="title">Types of interventions</h4> <p>Antiplatelet therapy versus placebo, one antiplatelet regimen versus another, or antiplatelet therapy versus an alternative treatment. We excluded studies that included the same antiplatelet agent in both treatment groups, unless another antiplatelet was also used, but in only one treatment arm. We recorded the type of therapy, dosage, time of starting compared to surgery (pre‐ or postoperatively) and duration of the therapy. </p> </section> <section id="CD000535-sec-0018"> <h4 class="title">Types of outcome measures</h4> <section id="CD000535-sec-0019"> <h5 class="title">Primary outcomes</h5> <p>(1) Primary graft patency: patency rates after surgery with no further intervention, as determined by clinical examination, measurement of the ankle‐brachial pressure index (ABPI), duplex ultrasonography, angiography.<br/>(2) Assisted primary patency: patency rates after intervention to improve blood flow in a graft which has not occluded. </p> <p>We analysed primary patency and primary assisted patency for all grafts and for venous or prosthetic (artificial) grafts separately. </p> </section> <section id="CD000535-sec-0020"> <h5 class="title">Secondary outcomes</h5> <p> <ol id="CD000535-list-0001"> <li> <p>Secondary graft patency: patency rates following secondary intervention to restore blood flow to the graft </p> </li> <li> <p>Objective assessment of lower limb blood flow: ABPI, exercise tolerance test</p> </li> <li> <p>Side effects of treatment and complications</p> </li> <li> <p>Limb salvage rate: survival rates with limb intact (or limb amputation)</p> </li> <li> <p>Incidence of other cardiovascular events and mortality</p> </li> <li> <p>Participants' quality of life</p> </li> </ol> </p> </section> </section> </section> <section id="CD000535-sec-0021"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD000535-sec-0022"> <h4 class="title">Electronic searches</h4> <p>For this update the Cochrane Peripheral Vascular Diseases Group Trials Search Co‐ordinator (TSC) searched the Specialised Register (last searched June 2014) and the Cochrane Central Register of Controlled Trials (CENTRAL) 2014, Issue 5, part of <i>The Cochrane Library</i> (<a href="http://www.thecochranelibrary.com" target="_blank">www.thecochranelibrary.com</a>). See <a href="./appendices#CD000535-sec-0107">Appendix 1</a> for details of the search strategy used to search CENTRAL. The Specialised Register is maintained by the TSC and is constructed from weekly electronic searches of MEDLINE, EMBASE, CINAHL, AMED, and through handsearching relevant journals. The full list of the databases, journals and conference proceedings which have been searched, as well as the search strategies used, are described in the <a href="http://www.mrw.interscience.wiley.com/cochrane/clabout/articles/PVD/frame.html" target="_blank">Specialised Register</a> section of the Cochrane Peripheral Vascular Diseases Group module in <i>The Cochrane Library</i>. </p> </section> <section id="CD000535-sec-0023"> <h4 class="title">Searching other resources</h4> <p>We scanned reference lists of studies and reviews identified by the search for relevant studies. </p> </section> </section> <section id="CD000535-sec-0024"> <h3 class="title" id="CD000535-sec-0024">Data collection and analysis</h3> <section id="CD000535-sec-0025"> <h4 class="title">Selection of studies</h4> <p>In this update, Rachel Bedenis (RB) and Anne Lethaby (AL) independently selected trials for inclusion or exclusion, resolving disagreements by discussion between them. </p> </section> <section id="CD000535-sec-0026"> <h4 class="title">Data extraction and management</h4> <p>For newly‐included studies RB and AL independently extracted the number of participants originally allocated to each treatment group and performed an intention‐to‐treat analysis. Data collection on each trial consisted of: inclusion and exclusion criteria; participant details (age, gender, co‐morbidity); severity of arterial occlusive disease (as determined by the ABPI and the European Consensus (<a href="./references#CD000535-bbs2-0040" title="European Working Group on Critical Limb Ischemia Second European Consensus Document on Chronic Critical Leg Ischemia. Second European Consensus Document on Chronic Critical Leg Ischemia. Circulation1991;84 Suppl 4:1-26.">Consensus 1991</a>) definition of critical limb ischaemia); type of graft (autologous vein, prosthetic, human umbilical vein, composite graft); level of proximal graft anastomosis (common superficial femoral artery) and distal anastomosis (above‐knee popliteal, below‐knee popliteal, distal arteries); type of antiplatelet therapy used (dose, commencement of therapy relative to surgery, duration of therapy, compliance); and outcome (as mentioned in the section '<a href="#CD000535-sec-0014">Criteria for considering studies for this review</a>'). We compared the treatment and control groups for important prognostic factors. If any of the above data were not available, we sought further information from the authors. </p> </section> <section id="CD000535-sec-0027"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>RB and AL independently assessed the methodological quality of included trials, using the 'Risk of bias' tool from The Cochrane Collaboration (<a href="./references#CD000535-bbs2-0045" title="HigginsJPT , Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.">Higgins 2011</a>). We assessed the following five domains: selection bias (random sequence generation, allocation concealment), performance bias (blinding of participants and personnel and blinding of outcome assessment), attrition bias (incomplete outcome data), reporting bias (selective reporting) and other potential sources of bias. We classified the domains as being at low risk of bias, high risk of bias or unclear risk of bias according to the guidelines in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD000535-bbs2-0045" title="HigginsJPT , Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.">Higgins 2011</a>). The two review authors assessing bias resolved disagreements by discussion. </p> </section> <section id="CD000535-sec-0028"> <h4 class="title">Measures of treatment effect</h4> <p>We extracted dichotomous data and transformed them into odds ratios (ORs) with 95% confidence intervals (CIs) in the meta‐analysis. </p> </section> <section id="CD000535-sec-0029"> <h4 class="title">Unit of analysis issues</h4> <p>The majority of the included studies use individual participants as the unit of analysis, although four studies were not consistent in this method (<a href="./references#CD000535-bbs2-0004" title="ClyneCA , ArcherTJ , AtuhaireLK , ChantAD , WebsterJH . Random control trial of a short course of aspirin and dipyridamole (Persantin) for femorodistal grafts. British Journal of Surgery1987;74(4):246-8. ">Clyne 1987</a>; <a href="./references#CD000535-bbs2-0006" title="DonaldsonDR , SalterMC , KesterRC , RajahSM , HallTJ , SreeharanN , et al. The influence of platelet inhibition on the patency of femoro-popliteal Dacron bypass grafts. Vascular Surgery1985;19(4):224-30. ">Donaldson 1985</a>; <a href="./references#CD000535-bbs2-0011" title="KohlerTR , KaufmanJL , KacoyanisG , ClowesA , DonaldsonMC , KellyE , et al. Effect of aspirin and dipyridamole on the patency of lower extremity bypass grafts. Surgery1984;96(3):462-6. ">Kohler 1984</a>; <a href="./references#CD000535-bbs2-0012" title="LucasMA . Prevention of post-operative thrombosis in peripheral arteriopathies. Pentoxifylline vs conventional antiaggregants: a six-month randomized follow-up study. Angiology1984;35(7):443-50. ">Lucas 1984</a>). <a href="./references#CD000535-bbs2-0011" title="KohlerTR , KaufmanJL , KacoyanisG , ClowesA , DonaldsonMC , KellyE , et al. Effect of aspirin and dipyridamole on the patency of lower extremity bypass grafts. Surgery1984;96(3):462-6. ">Kohler 1984</a> reported on grafts rather than participants: 14 participants were re‐entered and re‐randomised after graft failure; participants with bilateral reconstructions were followed for patency of both grafts but were randomised only after the first reconstruction. There were 102 grafts in 88 participants in this study. In <a href="./references#CD000535-bbs2-0006" title="DonaldsonDR , SalterMC , KesterRC , RajahSM , HallTJ , SreeharanN , et al. The influence of platelet inhibition on the patency of femoro-popliteal Dacron bypass grafts. Vascular Surgery1985;19(4):224-30. ">Donaldson 1985</a>, the aspirin group recorded 35 grafts in 33 participants and the placebo group recorded 38 grafts in 32 participants. These additional grafts were due to bilateral grafts. In <a href="./references#CD000535-bbs2-0004" title="ClyneCA , ArcherTJ , AtuhaireLK , ChantAD , WebsterJH . Random control trial of a short course of aspirin and dipyridamole (Persantin) for femorodistal grafts. British Journal of Surgery1987;74(4):246-8. ">Clyne 1987</a>, 148 grafts were undertaken in 140 participants. <a href="./references#CD000535-bbs2-0012" title="LucasMA . Prevention of post-operative thrombosis in peripheral arteriopathies. Pentoxifylline vs conventional antiaggregants: a six-month randomized follow-up study. Angiology1984;35(7):443-50. ">Lucas 1984</a> examined a mixture of single and multiple bypasses, using different materials, and also included thromboendarterectomy; there were considerable sources of heterogeneity within this study. The remaining papers appeared to report on one graft per individual. </p> <p>For the meta‐analyses, we used the number of participants randomised where possible and not the number of grafts, in order to maintain consistency with the majority of included studies. We have included the four studies using grafts as the unit of analysis (<a href="./references#CD000535-bbs2-0004" title="ClyneCA , ArcherTJ , AtuhaireLK , ChantAD , WebsterJH . Random control trial of a short course of aspirin and dipyridamole (Persantin) for femorodistal grafts. British Journal of Surgery1987;74(4):246-8. ">Clyne 1987</a>; <a href="./references#CD000535-bbs2-0006" title="DonaldsonDR , SalterMC , KesterRC , RajahSM , HallTJ , SreeharanN , et al. The influence of platelet inhibition on the patency of femoro-popliteal Dacron bypass grafts. Vascular Surgery1985;19(4):224-30. ">Donaldson 1985</a>; <a href="./references#CD000535-bbs2-0011" title="KohlerTR , KaufmanJL , KacoyanisG , ClowesA , DonaldsonMC , KellyE , et al. Effect of aspirin and dipyridamole on the patency of lower extremity bypass grafts. Surgery1984;96(3):462-6. ">Kohler 1984</a>; <a href="./references#CD000535-bbs2-0012" title="LucasMA . Prevention of post-operative thrombosis in peripheral arteriopathies. Pentoxifylline vs conventional antiaggregants: a six-month randomized follow-up study. Angiology1984;35(7):443-50. ">Lucas 1984</a>) in the meta‐analysis, but we have excluded them from a subsequent sensitivity analysis, to assess the influence these studies may have on the overall results. </p> </section> <section id="CD000535-sec-0030"> <h4 class="title">Dealing with missing data</h4> <p>Where data were missing, we contacted study authors for more information. Where possible, we performed analyses on an intention‐to‐treat basis. </p> </section> <section id="CD000535-sec-0031"> <h4 class="title">Assessment of heterogeneity</h4> <p>To test for heterogeneity, we used the I² statistic (<a href="./references#CD000535-bbs2-0044" title="HigginsJPT , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta-analyses. BMJ2003;327(7414):557-60.">Higgins 2003</a>). Where heterogeneity was high (I² &gt; 50%), we used a random‐effects model for data synthesis. </p> </section> <section id="CD000535-sec-0032"> <h4 class="title">Assessment of reporting biases</h4> <p>We obtained data from full papers, conference abstracts and unpublished sources, where found. If at least ten studies were included in a meta‐analysis, we constructed a funnel plot to look at issues around publication bias. </p> </section> <section id="CD000535-sec-0033"> <h4 class="title">Data synthesis</h4> <p>Where possible, we calculated the number of events occurring within the sample for each of the outcomes. We generated ORs with 95% CIs to evaluate the effect of treatment, using a fixed‐effect model. Where heterogeneity was high (I² &gt; 50%) we used a random‐effects model for data synthesis. </p> </section> <section id="CD000535-sec-0034"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We subgrouped data for graft patency at follow‐up (that is, at 1, 3, 6, 9, 12 and 24 months, where data were available) and for whether the graft was venous or prosthetic. </p> </section> <section id="CD000535-sec-0035"> <h4 class="title">Sensitivity analysis</h4> <p>We performed sensitivity analysis to evaluate the effect of studies with unit of analysis concerns. Please see <a href="#CD000535-sec-0029">Unit of analysis issues</a> for more detail. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD000535-sec-0036" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD000535-sec-0036"></div> <section id="CD000535-sec-0037"> <h3 class="title">Description of studies</h3> <section id="CD000535-sec-0038"> <h4 class="title">Results of the search</h4> <p>See <a href="#CD000535-fig-0001">Figure 1</a> for study flow diagram. </p> <div class="figure" id="CD000535-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD000535-fig-0001" src="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/image_n/nCD000535-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> <p>For the current update of the review, we considered 19 reports of 12 studies retrieved by the search. We included one additional study with four reports (<a href="./references#CD000535-bbs2-0003" title="Anonymous. Clopidogrel and acetyl salicylic acid in bypass surgery for peripheral arterial disease. clinicaltrials.gov/ct2/show/NCT00174759?term=CASPAR&amp;rank=2 (accessed 5 May 2014). Anonymous. Dual antiplatelet therapy benefits prosthetic but not venous grafts. Vascular News2009;Feb:17. BelchJJ , DormandyJ . Results of the randomized, placebo-controlled clopidogrel and acetylsalicylic acid in bypass surgery for peripheral arterial disease (CASPAR) trial. Journal of Vascular Surgery2010;52(4):825-33. The Caspar Investigators, BelchJ . Effect of adding clopidogrel to aspirin on the success of below knee arterial bypass grafts. A randomised placebo controlled study. In: Vascular Annual Meeting; 2007 Jun; Baltimore, USA. 2007. ">CASPAR 2010</a>). We deemed six studies with six citations not to be relevant, and we added another three studies with four reports to the excluded studies (<a href="./references#CD000535-bbs2-0018" title="BurdessA , NimmoA , GardenOJ , MurieJA , DawsonAR , FoxKA , et al. Dual antiplatelet therapy in surgery for critical limb ischaemia. The Vascular Society of Great Britain &amp; Ireland Yearbook 20082008:47. BurdessA , NimmoAF , GardenOJ , MurieJA , DawsonAR , FoxKA , et al. Randomized controlled trial of dual antiplatelet therapy in patients undergoing surgery for critical limb ischemia. Annals of Surgery2010;252(1):37-42. ">Burdess 2010</a>; <a href="./references#CD000535-bbs2-0021" title="EUCTR2007-003746-15-DE. Prospective randomized open study on the comparison of fondaparinux with the low-molecular-weight heparin enoxaparin in patients undergoing femoro-distal venous bypass operation. www.clinicaltrialsregister.eu/ctr-search/trial/2007-003746-15/DE2008. ">EUCTR2007 2008</a>; <a href="./references#CD000535-bbs2-0029" title="MonacoM , Di TommasoL , PinnaGB , LilloS , SchiavoneV , StassanoP . Combination therapy with warfarin plus clopidogrel improves outcomes in femoropopliteal bypass surgery patients. Journal of Vascular Surgery2012;56(1):96-105. ">Monaco 2012</a>). We added five new reports of two studies to previously included studies (<a href="./references#CD000535-bbs2-0002" title="AlgraA . A randomised trial of oral anticoagulants versus aspirin after infrainguinal bypass surgery. Tijdschrift voor Sociale Gezondheidszorg1999;77(4):11. AriesenMJ , TangelderMJD , LawsonJA , EikelboomBC , GrobbeeDE , AlgraA . Risk of major haemorrhage in patients after infrainguinal venous bypass surgery: Therapeutic consequences? The Dutch BOA (Bypass Oral Anticoagulants or Aspirin) study. European Journal of Vascular and Endovascular Surgery2005;30(2):154-9. Dutch Bypass Oral anticoagulants of Aspirin (BOA) Study Group. Efficacy of oral anticoagulants compared with aspirin after infrainguinal bypass surgery (The Dutch Bypass Oral anticoagulants or Aspirin study): a randomised trial. Lancet2000;355(9201):346-51. EikelboomBC . Prevention of occlusions after infrainguinal bypass surgery with oral anticoagulants or acetylsalicylic acid: A randomised trial. Nederlands Tijdschrift voor Geneeskunde2001;145(22):1060-7. OostenbrinkJB , TangelderMJ , BusschbachJJ , Van HoutBA , BuskensE , AlgraA , et al. Cost effectiveness of oral anticoagulants versus aspirin in patients after infrainguinal bypass grafting surgery. Journal of Vascular Surgery2001;34(2):254-62. SmeetsL , HoGH , TangelderMJ , AlgraA , LawsonJA , EikelboomBC , et al, Dutch BOA Study Group. Outcome after occlusion of infrainguinal bypasses in the Dutch BOA Study: comparison of amputation rate in venous and prosthetic grafts. European Journal of Vascular and Endovascular Surgery2005;30(6):604-9. TangelderMJ , AlgraA , LawsonJA , EikelboomBC . Risk factors for occlusion of infrainguinal bypass grafts. European Journal of Vascular and Endovascular Surgery2000;20(2):118-24. TangelderMJ , AlgraA , LawsonJA , HennekesS , EikelboomBC . Optimal oral anticoagulant intensity to prevent secondary ischemic and hemorrhagic events in patients after infrainguinal bypass graft surgery. Dutch BOA Study Group. Journal of Vascular Surgery2001;33(3):522-7. TangelderMJ , EikelboomBC , LawsonJA , AlgraA . Prevention of occlusion following peripheral bypass surgery using oral anticoagulants or acetylsalicylic acid: a randomized comparison within the Dutch BOA study [Preventi van occlusies na perifere bypass-chirurgie met orale anticoagulantia of acetylsalicylzuur: een gerandomiseerde vergelijking in het Nederlands BOA-onderzoek]. Nederlands Tijdschrift voor Geneeskunde1995;139(29):1504-6. TangelderMJ , McDonnelJ , Van BusschbachJJ , BuskensE , AlgraA , LawsonJA , EikelboomBC . Quality of life after infrainguinal bypass grafting surgery. Dutch Bypass Oral Anticoagulants or Aspirin (BOA) Study Group. Journal of Vascular Surgery1999;29(5):913-9. Van HattumES , AlgraA , LawsonJA , EikelboomBC , MollFL , TangelderMJD . Bleeding increases the risk of ischemic events in patients with peripheral arterial disease. Circulation2009;120(16):1569-76. Van HattumES , TangelderMJD , LawsonJA , MollFL , AlgraA . The quality of life in patients after peripheral bypass surgery deteriorates at long-term follow-up. Journal of Vascular Surgery2011;53(3):643-50. ">BOA 2000</a>; <a href="./references#CD000535-bbs2-0013" title="FranksPJ , SianM , KenchingtonGF , AlexanderCE , PowellJT . Aspirin usage and its influence on femoro-popliteal vein graft patency. European Journal of Vascular Surgery1992;6(2):185-8. FranksPJ , SianM , KenchingtonGF , AlexanderCE , PowellJT . Aspirin usage and its influence on femoropopliteal vein graft patency. In: European Society for Vascular Surgery 5th Annual Meeting, 25-27 September 1991; Warsaw, Poland. 1991. McCollumC , AlexanderC , KenchingtonG , FranksPJ , GreenhalghR . Antiplatelet drugs in femoropopliteal vein bypasses: A multicenter trial. Journal of Vascular Surgery1991;13(1):150-62. PowellJT , GreenhalghRM . Smoking and factors influencing the outcome of arterial reconstruction. Annales Chirurgiae et Gynaecologiae1992;81(2):236-41. ">McCollum 1991</a>) and eight previously excluded reports to two included studies (<a href="./references#CD000535-bbs2-0002" title="AlgraA . A randomised trial of oral anticoagulants versus aspirin after infrainguinal bypass surgery. Tijdschrift voor Sociale Gezondheidszorg1999;77(4):11. AriesenMJ , TangelderMJD , LawsonJA , EikelboomBC , GrobbeeDE , AlgraA . Risk of major haemorrhage in patients after infrainguinal venous bypass surgery: Therapeutic consequences? The Dutch BOA (Bypass Oral Anticoagulants or Aspirin) study. European Journal of Vascular and Endovascular Surgery2005;30(2):154-9. Dutch Bypass Oral anticoagulants of Aspirin (BOA) Study Group. Efficacy of oral anticoagulants compared with aspirin after infrainguinal bypass surgery (The Dutch Bypass Oral anticoagulants or Aspirin study): a randomised trial. Lancet2000;355(9201):346-51. EikelboomBC . Prevention of occlusions after infrainguinal bypass surgery with oral anticoagulants or acetylsalicylic acid: A randomised trial. Nederlands Tijdschrift voor Geneeskunde2001;145(22):1060-7. OostenbrinkJB , TangelderMJ , BusschbachJJ , Van HoutBA , BuskensE , AlgraA , et al. Cost effectiveness of oral anticoagulants versus aspirin in patients after infrainguinal bypass grafting surgery. Journal of Vascular Surgery2001;34(2):254-62. SmeetsL , HoGH , TangelderMJ , AlgraA , LawsonJA , EikelboomBC , et al, Dutch BOA Study Group. Outcome after occlusion of infrainguinal bypasses in the Dutch BOA Study: comparison of amputation rate in venous and prosthetic grafts. European Journal of Vascular and Endovascular Surgery2005;30(6):604-9. TangelderMJ , AlgraA , LawsonJA , EikelboomBC . Risk factors for occlusion of infrainguinal bypass grafts. European Journal of Vascular and Endovascular Surgery2000;20(2):118-24. TangelderMJ , AlgraA , LawsonJA , HennekesS , EikelboomBC . Optimal oral anticoagulant intensity to prevent secondary ischemic and hemorrhagic events in patients after infrainguinal bypass graft surgery. Dutch BOA Study Group. Journal of Vascular Surgery2001;33(3):522-7. TangelderMJ , EikelboomBC , LawsonJA , AlgraA . Prevention of occlusion following peripheral bypass surgery using oral anticoagulants or acetylsalicylic acid: a randomized comparison within the Dutch BOA study [Preventi van occlusies na perifere bypass-chirurgie met orale anticoagulantia of acetylsalicylzuur: een gerandomiseerde vergelijking in het Nederlands BOA-onderzoek]. Nederlands Tijdschrift voor Geneeskunde1995;139(29):1504-6. TangelderMJ , McDonnelJ , Van BusschbachJJ , BuskensE , AlgraA , LawsonJA , EikelboomBC . Quality of life after infrainguinal bypass grafting surgery. Dutch Bypass Oral Anticoagulants or Aspirin (BOA) Study Group. Journal of Vascular Surgery1999;29(5):913-9. Van HattumES , AlgraA , LawsonJA , EikelboomBC , MollFL , TangelderMJD . Bleeding increases the risk of ischemic events in patients with peripheral arterial disease. Circulation2009;120(16):1569-76. Van HattumES , TangelderMJD , LawsonJA , MollFL , AlgraA . The quality of life in patients after peripheral bypass surgery deteriorates at long-term follow-up. Journal of Vascular Surgery2011;53(3):643-50. ">BOA 2000</a>; <a href="./references#CD000535-bbs2-0013" title="FranksPJ , SianM , KenchingtonGF , AlexanderCE , PowellJT . Aspirin usage and its influence on femoro-popliteal vein graft patency. European Journal of Vascular Surgery1992;6(2):185-8. FranksPJ , SianM , KenchingtonGF , AlexanderCE , PowellJT . Aspirin usage and its influence on femoropopliteal vein graft patency. In: European Society for Vascular Surgery 5th Annual Meeting, 25-27 September 1991; Warsaw, Poland. 1991. McCollumC , AlexanderC , KenchingtonG , FranksPJ , GreenhalghR . Antiplatelet drugs in femoropopliteal vein bypasses: A multicenter trial. Journal of Vascular Surgery1991;13(1):150-62. PowellJT , GreenhalghRM . Smoking and factors influencing the outcome of arterial reconstruction. Annales Chirurgiae et Gynaecologiae1992;81(2):236-41. ">McCollum 1991</a>). </p> </section> <section id="CD000535-sec-0039"> <h4 class="title">Included studies</h4> <p>For this update there was one additional study included (<a href="./references#CD000535-bbs2-0003" title="Anonymous. Clopidogrel and acetyl salicylic acid in bypass surgery for peripheral arterial disease. clinicaltrials.gov/ct2/show/NCT00174759?term=CASPAR&amp;rank=2 (accessed 5 May 2014). Anonymous. Dual antiplatelet therapy benefits prosthetic but not venous grafts. Vascular News2009;Feb:17. BelchJJ , DormandyJ . Results of the randomized, placebo-controlled clopidogrel and acetylsalicylic acid in bypass surgery for peripheral arterial disease (CASPAR) trial. Journal of Vascular Surgery2010;52(4):825-33. The Caspar Investigators, BelchJ . Effect of adding clopidogrel to aspirin on the success of below knee arterial bypass grafts. A randomised placebo controlled study. In: Vascular Annual Meeting; 2007 Jun; Baltimore, USA. 2007. ">CASPAR 2010</a>) making a total of 16 studies (<a href="./references#CD000535-bbs2-0001" title="BecqueminJP . Effect of ticlopidine on the long-term patency of saphenous-vein bypass grafts in the legs. New England Journal of Medicine1997;337(24):1726-31. ">Becquemin 1997</a>; <a href="./references#CD000535-bbs2-0002" title="AlgraA . A randomised trial of oral anticoagulants versus aspirin after infrainguinal bypass surgery. Tijdschrift voor Sociale Gezondheidszorg1999;77(4):11. AriesenMJ , TangelderMJD , LawsonJA , EikelboomBC , GrobbeeDE , AlgraA . Risk of major haemorrhage in patients after infrainguinal venous bypass surgery: Therapeutic consequences? The Dutch BOA (Bypass Oral Anticoagulants or Aspirin) study. European Journal of Vascular and Endovascular Surgery2005;30(2):154-9. Dutch Bypass Oral anticoagulants of Aspirin (BOA) Study Group. Efficacy of oral anticoagulants compared with aspirin after infrainguinal bypass surgery (The Dutch Bypass Oral anticoagulants or Aspirin study): a randomised trial. Lancet2000;355(9201):346-51. EikelboomBC . Prevention of occlusions after infrainguinal bypass surgery with oral anticoagulants or acetylsalicylic acid: A randomised trial. Nederlands Tijdschrift voor Geneeskunde2001;145(22):1060-7. OostenbrinkJB , TangelderMJ , BusschbachJJ , Van HoutBA , BuskensE , AlgraA , et al. Cost effectiveness of oral anticoagulants versus aspirin in patients after infrainguinal bypass grafting surgery. Journal of Vascular Surgery2001;34(2):254-62. SmeetsL , HoGH , TangelderMJ , AlgraA , LawsonJA , EikelboomBC , et al, Dutch BOA Study Group. Outcome after occlusion of infrainguinal bypasses in the Dutch BOA Study: comparison of amputation rate in venous and prosthetic grafts. European Journal of Vascular and Endovascular Surgery2005;30(6):604-9. TangelderMJ , AlgraA , LawsonJA , EikelboomBC . Risk factors for occlusion of infrainguinal bypass grafts. European Journal of Vascular and Endovascular Surgery2000;20(2):118-24. TangelderMJ , AlgraA , LawsonJA , HennekesS , EikelboomBC . Optimal oral anticoagulant intensity to prevent secondary ischemic and hemorrhagic events in patients after infrainguinal bypass graft surgery. Dutch BOA Study Group. Journal of Vascular Surgery2001;33(3):522-7. TangelderMJ , EikelboomBC , LawsonJA , AlgraA . Prevention of occlusion following peripheral bypass surgery using oral anticoagulants or acetylsalicylic acid: a randomized comparison within the Dutch BOA study [Preventi van occlusies na perifere bypass-chirurgie met orale anticoagulantia of acetylsalicylzuur: een gerandomiseerde vergelijking in het Nederlands BOA-onderzoek]. Nederlands Tijdschrift voor Geneeskunde1995;139(29):1504-6. TangelderMJ , McDonnelJ , Van BusschbachJJ , BuskensE , AlgraA , LawsonJA , EikelboomBC . Quality of life after infrainguinal bypass grafting surgery. Dutch Bypass Oral Anticoagulants or Aspirin (BOA) Study Group. Journal of Vascular Surgery1999;29(5):913-9. Van HattumES , AlgraA , LawsonJA , EikelboomBC , MollFL , TangelderMJD . Bleeding increases the risk of ischemic events in patients with peripheral arterial disease. Circulation2009;120(16):1569-76. Van HattumES , TangelderMJD , LawsonJA , MollFL , AlgraA . The quality of life in patients after peripheral bypass surgery deteriorates at long-term follow-up. Journal of Vascular Surgery2011;53(3):643-50. ">BOA 2000</a>; <a href="./references#CD000535-bbs2-0003" title="Anonymous. Clopidogrel and acetyl salicylic acid in bypass surgery for peripheral arterial disease. clinicaltrials.gov/ct2/show/NCT00174759?term=CASPAR&amp;rank=2 (accessed 5 May 2014). Anonymous. Dual antiplatelet therapy benefits prosthetic but not venous grafts. Vascular News2009;Feb:17. BelchJJ , DormandyJ . Results of the randomized, placebo-controlled clopidogrel and acetylsalicylic acid in bypass surgery for peripheral arterial disease (CASPAR) trial. Journal of Vascular Surgery2010;52(4):825-33. The Caspar Investigators, BelchJ . Effect of adding clopidogrel to aspirin on the success of below knee arterial bypass grafts. A randomised placebo controlled study. In: Vascular Annual Meeting; 2007 Jun; Baltimore, USA. 2007. ">CASPAR 2010</a>; <a href="./references#CD000535-bbs2-0004" title="ClyneCA , ArcherTJ , AtuhaireLK , ChantAD , WebsterJH . Random control trial of a short course of aspirin and dipyridamole (Persantin) for femorodistal grafts. British Journal of Surgery1987;74(4):246-8. ">Clyne 1987</a>; <a href="./references#CD000535-bbs2-0005" title="D'AddatoM , CurtiT , BertiniD , DoniniI , FerreroR , FioraniP , et al. Indobufen vs acetylsalicylic acid plus dipyridamole in long-term patency after femoropopliteal bypass. International Angiology1992;11(2):106-12. ">D'Addato 1992</a>; <a href="./references#CD000535-bbs2-0006" title="DonaldsonDR , SalterMC , KesterRC , RajahSM , HallTJ , SreeharanN , et al. The influence of platelet inhibition on the patency of femoro-popliteal Dacron bypass grafts. Vascular Surgery1985;19(4):224-30. ">Donaldson 1985</a>; <a href="./references#CD000535-bbs2-0007" title="EdmondsonRA , CohenAT , DasSK , WagnerBM , KakkarVV . Low-molecular weight heparin versus aspirin and dipyridamole after femoropopliteal bypass grafting. Lancet1994;344(8927):914-8. ">Edmondson 1994</a>; <a href="./references#CD000535-bbs2-0008" title="GoldmanM , McCollumC . A prospective randomized study to examine the effect of aspirin plus dipyridamole on the patency of prosthetic femoro-popliteal grafts. Vascular Surgery1984;18(4):217-21. ">Goldman 1984</a>; <a href="./references#CD000535-bbs2-0009" title="GreenRM , RoedersheimerRL , DeWeeseJA . Effects of aspirin and dipyridamole on expanded polytetrafluoethylene graft patency. Surgery1982;92(6):1016-26. ">Green 1982</a>; <a href="./references#CD000535-bbs2-0010" title="GrussJD , HiemerW , KroissA , GeisslerC . Experiences with adjuvant prostaglandin therapy in vascular surgery interventions. Vasa-Supplementum1991;33:353-4. ">Gruss 1991</a>; <a href="./references#CD000535-bbs2-0011" title="KohlerTR , KaufmanJL , KacoyanisG , ClowesA , DonaldsonMC , KellyE , et al. Effect of aspirin and dipyridamole on the patency of lower extremity bypass grafts. Surgery1984;96(3):462-6. ">Kohler 1984</a>; <a href="./references#CD000535-bbs2-0012" title="LucasMA . Prevention of post-operative thrombosis in peripheral arteriopathies. Pentoxifylline vs conventional antiaggregants: a six-month randomized follow-up study. Angiology1984;35(7):443-50. ">Lucas 1984</a>; <a href="./references#CD000535-bbs2-0013" title="FranksPJ , SianM , KenchingtonGF , AlexanderCE , PowellJT . Aspirin usage and its influence on femoro-popliteal vein graft patency. European Journal of Vascular Surgery1992;6(2):185-8. FranksPJ , SianM , KenchingtonGF , AlexanderCE , PowellJT . Aspirin usage and its influence on femoropopliteal vein graft patency. In: European Society for Vascular Surgery 5th Annual Meeting, 25-27 September 1991; Warsaw, Poland. 1991. McCollumC , AlexanderC , KenchingtonG , FranksPJ , GreenhalghR . Antiplatelet drugs in femoropopliteal vein bypasses: A multicenter trial. Journal of Vascular Surgery1991;13(1):150-62. PowellJT , GreenhalghRM . Smoking and factors influencing the outcome of arterial reconstruction. Annales Chirurgiae et Gynaecologiae1992;81(2):236-41. ">McCollum 1991</a>; <a href="./references#CD000535-bbs2-0014" title="NoppeneyT , KasprzakP , RaithelD , HircheH . Naftidrofuryl in postoperative treatment after femoropopliteal bypass. Die Medizinische Welt1988;39:1545-50. ">Noppeney 1988</a>; <a href="./references#CD000535-bbs2-0015" title="RaithelD , KasprzakP , Noppeney Th. Relapse prophylaxis after femoropopliteal reconstruction with PTFE-prostheses. Die Medizinische Welt1986;37:664-7. RaithelD . Prevention of reocclusion after prosthetic bypass operations in the femoro-popliteal region: a comparative study of pentoxifylline versus acetylsalicylic acid. Vascular Surgery1987;21(3):208-14. ">Raithel 1987</a>; <a href="./references#CD000535-bbs2-0016" title="SchneiderE , BrunnerU , BollingerA . No English title available [Medikamentose Rezidivprophylaxe nach femoro-poplitealer Arterienrekonstruktion]. Angio1979;2(1):73-7. ">Schneider 1979</a>) which were included in this analysis. See <a href="./references#CD000535-sec-0121" title="">Characteristics of included studies</a> for full details. </p> <p>We conducted comparisons of the following interventions:</p> <p> <ol id="CD000535-list-0002"> <li> <p>Aspirin (ASA) or aspirin and dipyridamole (ASA/DIP) versus placebo or nothing (<a href="./references#CD000535-bbs2-0004" title="ClyneCA , ArcherTJ , AtuhaireLK , ChantAD , WebsterJH . Random control trial of a short course of aspirin and dipyridamole (Persantin) for femorodistal grafts. British Journal of Surgery1987;74(4):246-8. ">Clyne 1987</a>; <a href="./references#CD000535-bbs2-0006" title="DonaldsonDR , SalterMC , KesterRC , RajahSM , HallTJ , SreeharanN , et al. The influence of platelet inhibition on the patency of femoro-popliteal Dacron bypass grafts. Vascular Surgery1985;19(4):224-30. ">Donaldson 1985</a>; <a href="./references#CD000535-bbs2-0008" title="GoldmanM , McCollumC . A prospective randomized study to examine the effect of aspirin plus dipyridamole on the patency of prosthetic femoro-popliteal grafts. Vascular Surgery1984;18(4):217-21. ">Goldman 1984</a>; <a href="./references#CD000535-bbs2-0009" title="GreenRM , RoedersheimerRL , DeWeeseJA . Effects of aspirin and dipyridamole on expanded polytetrafluoethylene graft patency. Surgery1982;92(6):1016-26. ">Green 1982</a>; <a href="./references#CD000535-bbs2-0011" title="KohlerTR , KaufmanJL , KacoyanisG , ClowesA , DonaldsonMC , KellyE , et al. Effect of aspirin and dipyridamole on the patency of lower extremity bypass grafts. Surgery1984;96(3):462-6. ">Kohler 1984</a>; <a href="./references#CD000535-bbs2-0013" title="FranksPJ , SianM , KenchingtonGF , AlexanderCE , PowellJT . Aspirin usage and its influence on femoro-popliteal vein graft patency. European Journal of Vascular Surgery1992;6(2):185-8. FranksPJ , SianM , KenchingtonGF , AlexanderCE , PowellJT . Aspirin usage and its influence on femoropopliteal vein graft patency. In: European Society for Vascular Surgery 5th Annual Meeting, 25-27 September 1991; Warsaw, Poland. 1991. McCollumC , AlexanderC , KenchingtonG , FranksPJ , GreenhalghR . Antiplatelet drugs in femoropopliteal vein bypasses: A multicenter trial. Journal of Vascular Surgery1991;13(1):150-62. PowellJT , GreenhalghRM . Smoking and factors influencing the outcome of arterial reconstruction. Annales Chirurgiae et Gynaecologiae1992;81(2):236-41. ">McCollum 1991</a>) </p> </li> <li> <p>ASA or ASA/DIP versus pentoxifylline (PTX) (<a href="./references#CD000535-bbs2-0012" title="LucasMA . Prevention of post-operative thrombosis in peripheral arteriopathies. Pentoxifylline vs conventional antiaggregants: a six-month randomized follow-up study. Angiology1984;35(7):443-50. ">Lucas 1984</a>; <a href="./references#CD000535-bbs2-0015" title="RaithelD , KasprzakP , Noppeney Th. Relapse prophylaxis after femoropopliteal reconstruction with PTFE-prostheses. Die Medizinische Welt1986;37:664-7. RaithelD . Prevention of reocclusion after prosthetic bypass operations in the femoro-popliteal region: a comparative study of pentoxifylline versus acetylsalicylic acid. Vascular Surgery1987;21(3):208-14. ">Raithel 1987</a>) </p> </li> <li> <p>ASA/DIP versus indobufen (IND), a reversible cyclo‐oxygenase inhibitor (<a href="./references#CD000535-bbs2-0005" title="D'AddatoM , CurtiT , BertiniD , DoniniI , FerreroR , FioraniP , et al. Indobufen vs acetylsalicylic acid plus dipyridamole in long-term patency after femoropopliteal bypass. International Angiology1992;11(2):106-12. ">D'Addato 1992</a>) </p> </li> <li> <p>ASA or ASA/DIP versus vitamin K antagonists (VKA) (<a href="./references#CD000535-bbs2-0002" title="AlgraA . A randomised trial of oral anticoagulants versus aspirin after infrainguinal bypass surgery. Tijdschrift voor Sociale Gezondheidszorg1999;77(4):11. AriesenMJ , TangelderMJD , LawsonJA , EikelboomBC , GrobbeeDE , AlgraA . Risk of major haemorrhage in patients after infrainguinal venous bypass surgery: Therapeutic consequences? The Dutch BOA (Bypass Oral Anticoagulants or Aspirin) study. European Journal of Vascular and Endovascular Surgery2005;30(2):154-9. Dutch Bypass Oral anticoagulants of Aspirin (BOA) Study Group. Efficacy of oral anticoagulants compared with aspirin after infrainguinal bypass surgery (The Dutch Bypass Oral anticoagulants or Aspirin study): a randomised trial. Lancet2000;355(9201):346-51. EikelboomBC . Prevention of occlusions after infrainguinal bypass surgery with oral anticoagulants or acetylsalicylic acid: A randomised trial. Nederlands Tijdschrift voor Geneeskunde2001;145(22):1060-7. OostenbrinkJB , TangelderMJ , BusschbachJJ , Van HoutBA , BuskensE , AlgraA , et al. Cost effectiveness of oral anticoagulants versus aspirin in patients after infrainguinal bypass grafting surgery. Journal of Vascular Surgery2001;34(2):254-62. SmeetsL , HoGH , TangelderMJ , AlgraA , LawsonJA , EikelboomBC , et al, Dutch BOA Study Group. Outcome after occlusion of infrainguinal bypasses in the Dutch BOA Study: comparison of amputation rate in venous and prosthetic grafts. European Journal of Vascular and Endovascular Surgery2005;30(6):604-9. TangelderMJ , AlgraA , LawsonJA , EikelboomBC . Risk factors for occlusion of infrainguinal bypass grafts. European Journal of Vascular and Endovascular Surgery2000;20(2):118-24. TangelderMJ , AlgraA , LawsonJA , HennekesS , EikelboomBC . Optimal oral anticoagulant intensity to prevent secondary ischemic and hemorrhagic events in patients after infrainguinal bypass graft surgery. Dutch BOA Study Group. Journal of Vascular Surgery2001;33(3):522-7. TangelderMJ , EikelboomBC , LawsonJA , AlgraA . Prevention of occlusion following peripheral bypass surgery using oral anticoagulants or acetylsalicylic acid: a randomized comparison within the Dutch BOA study [Preventi van occlusies na perifere bypass-chirurgie met orale anticoagulantia of acetylsalicylzuur: een gerandomiseerde vergelijking in het Nederlands BOA-onderzoek]. Nederlands Tijdschrift voor Geneeskunde1995;139(29):1504-6. TangelderMJ , McDonnelJ , Van BusschbachJJ , BuskensE , AlgraA , LawsonJA , EikelboomBC . Quality of life after infrainguinal bypass grafting surgery. Dutch Bypass Oral Anticoagulants or Aspirin (BOA) Study Group. Journal of Vascular Surgery1999;29(5):913-9. Van HattumES , AlgraA , LawsonJA , EikelboomBC , MollFL , TangelderMJD . Bleeding increases the risk of ischemic events in patients with peripheral arterial disease. Circulation2009;120(16):1569-76. Van HattumES , TangelderMJD , LawsonJA , MollFL , AlgraA . The quality of life in patients after peripheral bypass surgery deteriorates at long-term follow-up. Journal of Vascular Surgery2011;53(3):643-50. ">BOA 2000</a>; <a href="./references#CD000535-bbs2-0016" title="SchneiderE , BrunnerU , BollingerA . No English title available [Medikamentose Rezidivprophylaxe nach femoro-poplitealer Arterienrekonstruktion]. Angio1979;2(1):73-7. ">Schneider 1979</a>) </p> </li> <li> <p>ASA/DIP versus low molecular weight heparin (LMWH) (<a href="./references#CD000535-bbs2-0007" title="EdmondsonRA , CohenAT , DasSK , WagnerBM , KakkarVV . Low-molecular weight heparin versus aspirin and dipyridamole after femoropopliteal bypass grafting. Lancet1994;344(8927):914-8. ">Edmondson 1994</a>) </p> </li> <li> <p>Ticlopidine (TIC) versus placebo (<a href="./references#CD000535-bbs2-0001" title="BecqueminJP . Effect of ticlopidine on the long-term patency of saphenous-vein bypass grafts in the legs. New England Journal of Medicine1997;337(24):1726-31. ">Becquemin 1997</a>) </p> </li> <li> <p>ASA versus prostaglandin E1 (<a href="./references#CD000535-bbs2-0010" title="GrussJD , HiemerW , KroissA , GeisslerC . Experiences with adjuvant prostaglandin therapy in vascular surgery interventions. Vasa-Supplementum1991;33:353-4. ">Gruss 1991</a>) </p> </li> <li> <p>ASA versus naftidrofuryl (<a href="./references#CD000535-bbs2-0014" title="NoppeneyT , KasprzakP , RaithelD , HircheH . Naftidrofuryl in postoperative treatment after femoropopliteal bypass. Die Medizinische Welt1988;39:1545-50. ">Noppeney 1988</a>) </p> </li> <li> <p>Clopidogrel and ASA versus ASA alone (<a href="./references#CD000535-bbs2-0003" title="Anonymous. Clopidogrel and acetyl salicylic acid in bypass surgery for peripheral arterial disease. clinicaltrials.gov/ct2/show/NCT00174759?term=CASPAR&amp;rank=2 (accessed 5 May 2014). Anonymous. Dual antiplatelet therapy benefits prosthetic but not venous grafts. Vascular News2009;Feb:17. BelchJJ , DormandyJ . Results of the randomized, placebo-controlled clopidogrel and acetylsalicylic acid in bypass surgery for peripheral arterial disease (CASPAR) trial. Journal of Vascular Surgery2010;52(4):825-33. The Caspar Investigators, BelchJ . Effect of adding clopidogrel to aspirin on the success of below knee arterial bypass grafts. A randomised placebo controlled study. In: Vascular Annual Meeting; 2007 Jun; Baltimore, USA. 2007. ">CASPAR 2010</a>) </p> </li> </ol> </p> <p>Details of the study designs are shown in the table '<a href="./references#CD000535-sec-0121" title="">Characteristics of included studies</a>' and in <a href="#CD000535-tbl-0001">Table 1</a>. </p> <div class="table" id="CD000535-tbl-0001"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Patient characteristics</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study ID</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>% CLI</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>% below knee</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>% vein</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>% 1‐vessel run‐off</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>dose</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>preoperative start of treatment</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>treatment duration</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>randomisation</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>ABI pre‐op to postop</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000535-bbs2-0001" title="BecqueminJP . Effect of ticlopidine on the long-term patency of saphenous-vein bypass grafts in the legs. New England Journal of Medicine1997;337(24):1726-31. ">Becquemin 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>nd</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>nd</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>TIC 250 mg vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>between the 3rd and 14th post‐op day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>post‐op</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>nd</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000535-bbs2-0002" title="AlgraA . A randomised trial of oral anticoagulants versus aspirin after infrainguinal bypass surgery. Tijdschrift voor Sociale Gezondheidszorg1999;77(4):11. AriesenMJ , TangelderMJD , LawsonJA , EikelboomBC , GrobbeeDE , AlgraA . Risk of major haemorrhage in patients after infrainguinal venous bypass surgery: Therapeutic consequences? The Dutch BOA (Bypass Oral Anticoagulants or Aspirin) study. European Journal of Vascular and Endovascular Surgery2005;30(2):154-9. Dutch Bypass Oral anticoagulants of Aspirin (BOA) Study Group. Efficacy of oral anticoagulants compared with aspirin after infrainguinal bypass surgery (The Dutch Bypass Oral anticoagulants or Aspirin study): a randomised trial. Lancet2000;355(9201):346-51. EikelboomBC . Prevention of occlusions after infrainguinal bypass surgery with oral anticoagulants or acetylsalicylic acid: A randomised trial. Nederlands Tijdschrift voor Geneeskunde2001;145(22):1060-7. OostenbrinkJB , TangelderMJ , BusschbachJJ , Van HoutBA , BuskensE , AlgraA , et al. Cost effectiveness of oral anticoagulants versus aspirin in patients after infrainguinal bypass grafting surgery. Journal of Vascular Surgery2001;34(2):254-62. SmeetsL , HoGH , TangelderMJ , AlgraA , LawsonJA , EikelboomBC , et al, Dutch BOA Study Group. Outcome after occlusion of infrainguinal bypasses in the Dutch BOA Study: comparison of amputation rate in venous and prosthetic grafts. European Journal of Vascular and Endovascular Surgery2005;30(6):604-9. TangelderMJ , AlgraA , LawsonJA , EikelboomBC . Risk factors for occlusion of infrainguinal bypass grafts. European Journal of Vascular and Endovascular Surgery2000;20(2):118-24. TangelderMJ , AlgraA , LawsonJA , HennekesS , EikelboomBC . Optimal oral anticoagulant intensity to prevent secondary ischemic and hemorrhagic events in patients after infrainguinal bypass graft surgery. Dutch BOA Study Group. Journal of Vascular Surgery2001;33(3):522-7. TangelderMJ , EikelboomBC , LawsonJA , AlgraA . Prevention of occlusion following peripheral bypass surgery using oral anticoagulants or acetylsalicylic acid: a randomized comparison within the Dutch BOA study [Preventi van occlusies na perifere bypass-chirurgie met orale anticoagulantia of acetylsalicylzuur: een gerandomiseerde vergelijking in het Nederlands BOA-onderzoek]. Nederlands Tijdschrift voor Geneeskunde1995;139(29):1504-6. TangelderMJ , McDonnelJ , Van BusschbachJJ , BuskensE , AlgraA , LawsonJA , EikelboomBC . Quality of life after infrainguinal bypass grafting surgery. Dutch Bypass Oral Anticoagulants or Aspirin (BOA) Study Group. Journal of Vascular Surgery1999;29(5):913-9. Van HattumES , AlgraA , LawsonJA , EikelboomBC , MollFL , TangelderMJD . Bleeding increases the risk of ischemic events in patients with peripheral arterial disease. Circulation2009;120(16):1569-76. Van HattumES , TangelderMJD , LawsonJA , MollFL , AlgraA . The quality of life in patients after peripheral bypass surgery deteriorates at long-term follow-up. Journal of Vascular Surgery2011;53(3):643-50. ">BOA 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>58.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>nd</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ASA 80 mg vs coumarin INR 3.0 ‐ 4.5 reached in 50%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>within 5 days until 1 month post‐op</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>before surgery</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>nd</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000535-bbs2-0003" title="Anonymous. Clopidogrel and acetyl salicylic acid in bypass surgery for peripheral arterial disease. clinicaltrials.gov/ct2/show/NCT00174759?term=CASPAR&amp;rank=2 (accessed 5 May 2014). Anonymous. Dual antiplatelet therapy benefits prosthetic but not venous grafts. Vascular News2009;Feb:17. BelchJJ , DormandyJ . Results of the randomized, placebo-controlled clopidogrel and acetylsalicylic acid in bypass surgery for peripheral arterial disease (CASPAR) trial. Journal of Vascular Surgery2010;52(4):825-33. The Caspar Investigators, BelchJ . Effect of adding clopidogrel to aspirin on the success of below knee arterial bypass grafts. A randomised placebo controlled study. In: Vascular Annual Meeting; 2007 Jun; Baltimore, USA. 2007. ">CASPAR 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>nd</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ASA 75 ‐ 100 mg plus clopidogrel 75 mg vs ASA 75 ‐ 100 mg plus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 to 4 days post‐op</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>post‐op</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>nd</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000535-bbs2-0004" title="ClyneCA , ArcherTJ , AtuhaireLK , ChantAD , WebsterJH . Random control trial of a short course of aspirin and dipyridamole (Persantin) for femorodistal grafts. British Journal of Surgery1987;74(4):246-8. ">Clyne 1987</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ASA 2 x 300 mg, DIP 2 x 200 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>48 hours pre‐op</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>before surgery</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.38 to 0.78</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000535-bbs2-0005" title="D'AddatoM , CurtiT , BertiniD , DoniniI , FerreroR , FioraniP , et al. Indobufen vs acetylsalicylic acid plus dipyridamole in long-term patency after femoropopliteal bypass. International Angiology1992;11(2):106-12. ">D'Addato 1992</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ASA 900 mg plus DIP 225 mg vs 400 mg IND</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>48 h</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>before surgery</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>nd</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000535-bbs2-0006" title="DonaldsonDR , SalterMC , KesterRC , RajahSM , HallTJ , SreeharanN , et al. The influence of platelet inhibition on the patency of femoro-popliteal Dacron bypass grafts. Vascular Surgery1985;19(4):224-30. ">Donaldson 1985</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ASA 3 x 330 mg plus DIP 75 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Evening prior to surgery</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>before surgery</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.62 to nd</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000535-bbs2-0007" title="EdmondsonRA , CohenAT , DasSK , WagnerBM , KakkarVV . Low-molecular weight heparin versus aspirin and dipyridamole after femoropopliteal bypass grafting. Lancet1994;344(8927):914-8. ">Edmondson 1994</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 x 300 mg ASA plus 3 x 100 mg DIP versus 2500 IU LMWH</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>LMWH 2 hours pre‐op; ASA/DIP 1 week post‐op</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>post‐op</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>nd</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000535-bbs2-0008" title="GoldmanM , McCollumC . A prospective randomized study to examine the effect of aspirin plus dipyridamole on the patency of prosthetic femoro-popliteal grafts. Vascular Surgery1984;18(4):217-21. ">Goldman 1984</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>nd</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ASA 3 x 300 mg plus DIP 3 x 75 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 days ASA/DIP</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>before surgery</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>nd</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000535-bbs2-0009" title="GreenRM , RoedersheimerRL , DeWeeseJA . Effects of aspirin and dipyridamole on expanded polytetrafluoethylene graft patency. Surgery1982;92(6):1016-26. ">Green 1982</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>82</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>nd</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ASA 3 x 325 mg, or ASA 3 x 325 mg plus DIP 3 x 75 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 days ASA/DIP</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>before surgery</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.42 to 1.01</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000535-bbs2-0010" title="GrussJD , HiemerW , KroissA , GeisslerC . Experiences with adjuvant prostaglandin therapy in vascular surgery interventions. Vasa-Supplementum1991;33:353-4. ">Gruss 1991</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>nd</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>nd</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>nd</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 x 0.5 g ASA plus 15,000 IU heparin versus PGE1, 0.2 ng per kg body weight/min plus 15,000 IU heparin </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>post‐op</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>nd</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>nd</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000535-bbs2-0011" title="KohlerTR , KaufmanJL , KacoyanisG , ClowesA , DonaldsonMC , KellyE , et al. Effect of aspirin and dipyridamole on the patency of lower extremity bypass grafts. Surgery1984;96(3):462-6. ">Kohler 1984</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>76</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>nd</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ASA 3 x 325 mg plus DIP 3 x 75 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>first post‐op day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>before surgery</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>nd</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000535-bbs2-0012" title="LucasMA . Prevention of post-operative thrombosis in peripheral arteriopathies. Pentoxifylline vs conventional antiaggregants: a six-month randomized follow-up study. Angiology1984;35(7):443-50. ">Lucas 1984</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>nd</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>nd</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ASA 1050 mg, DIP 150 mg or 1200 mg PTX</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>pre‐op</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>before surgery</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.4</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000535-bbs2-0013" title="FranksPJ , SianM , KenchingtonGF , AlexanderCE , PowellJT . Aspirin usage and its influence on femoro-popliteal vein graft patency. European Journal of Vascular Surgery1992;6(2):185-8. FranksPJ , SianM , KenchingtonGF , AlexanderCE , PowellJT . Aspirin usage and its influence on femoropopliteal vein graft patency. In: European Society for Vascular Surgery 5th Annual Meeting, 25-27 September 1991; Warsaw, Poland. 1991. McCollumC , AlexanderC , KenchingtonG , FranksPJ , GreenhalghR . Antiplatelet drugs in femoropopliteal vein bypasses: A multicenter trial. Journal of Vascular Surgery1991;13(1):150-62. PowellJT , GreenhalghRM . Smoking and factors influencing the outcome of arterial reconstruction. Annales Chirurgiae et Gynaecologiae1992;81(2):236-41. ">McCollum 1991</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>nd; vein &lt; 4 mm:38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ASA 2 x 300 mg plus DIP 2 x 150 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 days ASA/DIP</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>continuing indefinitely</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>before surgery</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.47 to nd</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000535-bbs2-0014" title="NoppeneyT , KasprzakP , RaithelD , HircheH . Naftidrofuryl in postoperative treatment after femoropopliteal bypass. Die Medizinische Welt1988;39:1545-50. ">Noppeney 1988</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>nd</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>nd</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>nd</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>nd</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ASA 1500 mg vs naftidrofuryl 600 mg daily orally</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>day 1 post‐op</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>before surgery</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>nd</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000535-bbs2-0015" title="RaithelD , KasprzakP , Noppeney Th. Relapse prophylaxis after femoropopliteal reconstruction with PTFE-prostheses. Die Medizinische Welt1986;37:664-7. RaithelD . Prevention of reocclusion after prosthetic bypass operations in the femoro-popliteal region: a comparative study of pentoxifylline versus acetylsalicylic acid. Vascular Surgery1987;21(3):208-14. ">Raithel 1987</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>nd</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ASA 1500 mg vs PTX 1200 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>48 h</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>before surgery</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>nd</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000535-bbs2-0016" title="SchneiderE , BrunnerU , BollingerA . No English title available [Medikamentose Rezidivprophylaxe nach femoro-poplitealer Arterienrekonstruktion]. Angio1979;2(1):73-7. ">Schneider 1979</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>nd</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>nd</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>nd</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ASA 1000 mg, or ASA 1000 mg plus DIP 225 mg vs coumarin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>post‐op</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>post‐op</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>nd</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>ASA: Aspirin<br/>CLI: critical limb ischaemia<br/>DIP: dipyridamole<br/>h: hour<br/>IU: international unit<br/>LMWH: low molecular weight heparin<br/>mg: milligram<br/>nd: no data<br/>ng: nanogram<br/>PGE1: prostaglandin E1<br/>PTX: pentoxifylline<br/>TIC: ticlopidine<br/>vs: versus </p> </div> </div> <section id="CD000535-sec-0040"> <h5 class="title">Aspirin (ASA) or aspirin and dipyridamole (ASA/DIP) versus placebo or nothing</h5> <p>In all six trials study medication was started prior to bypass surgery, mostly 48 hours before the operation (<a href="./references#CD000535-bbs2-0004" title="ClyneCA , ArcherTJ , AtuhaireLK , ChantAD , WebsterJH . Random control trial of a short course of aspirin and dipyridamole (Persantin) for femorodistal grafts. British Journal of Surgery1987;74(4):246-8. ">Clyne 1987</a>; <a href="./references#CD000535-bbs2-0006" title="DonaldsonDR , SalterMC , KesterRC , RajahSM , HallTJ , SreeharanN , et al. The influence of platelet inhibition on the patency of femoro-popliteal Dacron bypass grafts. Vascular Surgery1985;19(4):224-30. ">Donaldson 1985</a>; <a href="./references#CD000535-bbs2-0008" title="GoldmanM , McCollumC . A prospective randomized study to examine the effect of aspirin plus dipyridamole on the patency of prosthetic femoro-popliteal grafts. Vascular Surgery1984;18(4):217-21. ">Goldman 1984</a>; <a href="./references#CD000535-bbs2-0009" title="GreenRM , RoedersheimerRL , DeWeeseJA . Effects of aspirin and dipyridamole on expanded polytetrafluoethylene graft patency. Surgery1982;92(6):1016-26. ">Green 1982</a>; <a href="./references#CD000535-bbs2-0011" title="KohlerTR , KaufmanJL , KacoyanisG , ClowesA , DonaldsonMC , KellyE , et al. Effect of aspirin and dipyridamole on the patency of lower extremity bypass grafts. Surgery1984;96(3):462-6. ">Kohler 1984</a>; <a href="./references#CD000535-bbs2-0013" title="FranksPJ , SianM , KenchingtonGF , AlexanderCE , PowellJT . Aspirin usage and its influence on femoro-popliteal vein graft patency. European Journal of Vascular Surgery1992;6(2):185-8. FranksPJ , SianM , KenchingtonGF , AlexanderCE , PowellJT . Aspirin usage and its influence on femoropopliteal vein graft patency. In: European Society for Vascular Surgery 5th Annual Meeting, 25-27 September 1991; Warsaw, Poland. 1991. McCollumC , AlexanderC , KenchingtonG , FranksPJ , GreenhalghR . Antiplatelet drugs in femoropopliteal vein bypasses: A multicenter trial. Journal of Vascular Surgery1991;13(1):150-62. PowellJT , GreenhalghRM . Smoking and factors influencing the outcome of arterial reconstruction. Annales Chirurgiae et Gynaecologiae1992;81(2):236-41. ">McCollum 1991</a>). Doses ranged from 300 mg to 325 mg ASA and 75 mg DIP, given two and three times daily. Participants were randomised before surgery. Duration of treatment was six weeks in the <a href="./references#CD000535-bbs2-0004" title="ClyneCA , ArcherTJ , AtuhaireLK , ChantAD , WebsterJH . Random control trial of a short course of aspirin and dipyridamole (Persantin) for femorodistal grafts. British Journal of Surgery1987;74(4):246-8. ">Clyne 1987</a> trial but at least 12 to 24 months in the other trials. The percentage of participants with critical leg ischaemia (CLI) ranged from 60% to 80%, with the exception of <a href="./references#CD000535-bbs2-0006" title="DonaldsonDR , SalterMC , KesterRC , RajahSM , HallTJ , SreeharanN , et al. The influence of platelet inhibition on the patency of femoro-popliteal Dacron bypass grafts. Vascular Surgery1985;19(4):224-30. ">Donaldson 1985</a> which only included participants with disabling intermittent claudication. </p> </section> <section id="CD000535-sec-0041"> <h5 class="title">Aspirin (ASA) or aspirin and dipyridamole (ASA/DIP) versus pentoxifylline (PTX)</h5> <p>Two studies were included, comparing 1000 mg or 1500 mg ASA to 1200 mg PTX daily (<a href="./references#CD000535-bbs2-0012" title="LucasMA . Prevention of post-operative thrombosis in peripheral arteriopathies. Pentoxifylline vs conventional antiaggregants: a six-month randomized follow-up study. Angiology1984;35(7):443-50. ">Lucas 1984</a>; <a href="./references#CD000535-bbs2-0015" title="RaithelD , KasprzakP , Noppeney Th. Relapse prophylaxis after femoropopliteal reconstruction with PTFE-prostheses. Die Medizinische Welt1986;37:664-7. RaithelD . Prevention of reocclusion after prosthetic bypass operations in the femoro-popliteal region: a comparative study of pentoxifylline versus acetylsalicylic acid. Vascular Surgery1987;21(3):208-14. ">Raithel 1987</a>). Participant characteristics and graft type were similar in both trials. While <a href="./references#CD000535-bbs2-0015" title="RaithelD , KasprzakP , Noppeney Th. Relapse prophylaxis after femoropopliteal reconstruction with PTFE-prostheses. Die Medizinische Welt1986;37:664-7. RaithelD . Prevention of reocclusion after prosthetic bypass operations in the femoro-popliteal region: a comparative study of pentoxifylline versus acetylsalicylic acid. Vascular Surgery1987;21(3):208-14. ">Raithel 1987</a>'s participants all received prosthetic grafts, <a href="./references#CD000535-bbs2-0012" title="LucasMA . Prevention of post-operative thrombosis in peripheral arteriopathies. Pentoxifylline vs conventional antiaggregants: a six-month randomized follow-up study. Angiology1984;35(7):443-50. ">Lucas 1984</a> also included participants with venous grafts. More than 90% of <a href="./references#CD000535-bbs2-0015" title="RaithelD , KasprzakP , Noppeney Th. Relapse prophylaxis after femoropopliteal reconstruction with PTFE-prostheses. Die Medizinische Welt1986;37:664-7. RaithelD . Prevention of reocclusion after prosthetic bypass operations in the femoro-popliteal region: a comparative study of pentoxifylline versus acetylsalicylic acid. Vascular Surgery1987;21(3):208-14. ">Raithel 1987</a>'s participants had CLI compared to only 55% in the <a href="./references#CD000535-bbs2-0012" title="LucasMA . Prevention of post-operative thrombosis in peripheral arteriopathies. Pentoxifylline vs conventional antiaggregants: a six-month randomized follow-up study. Angiology1984;35(7):443-50. ">Lucas 1984</a> trial. </p> </section> <section id="CD000535-sec-0042"> <h5 class="title">Aspirin and dipyridamole (ASA/DIP) versus indobufen (IND)</h5> <p>We found only one multicentre double‐blind randomised clinical trial including participants operated on for a prosthetic polytetrafluoroethylene (PTFE) femoropopliteal graft for inclusion (<a href="./references#CD000535-bbs2-0005" title="D'AddatoM , CurtiT , BertiniD , DoniniI , FerreroR , FioraniP , et al. Indobufen vs acetylsalicylic acid plus dipyridamole in long-term patency after femoropopliteal bypass. International Angiology1992;11(2):106-12. ">D'Addato 1992</a>). </p> </section> <section id="CD000535-sec-0043"> <h5 class="title">Aspirin and dipyridamole (ASA/DIP) versus vitamin K antagonists (VKA)</h5> <p>We include two trials in this category (<a href="./references#CD000535-bbs2-0002" title="AlgraA . A randomised trial of oral anticoagulants versus aspirin after infrainguinal bypass surgery. Tijdschrift voor Sociale Gezondheidszorg1999;77(4):11. AriesenMJ , TangelderMJD , LawsonJA , EikelboomBC , GrobbeeDE , AlgraA . Risk of major haemorrhage in patients after infrainguinal venous bypass surgery: Therapeutic consequences? The Dutch BOA (Bypass Oral Anticoagulants or Aspirin) study. European Journal of Vascular and Endovascular Surgery2005;30(2):154-9. Dutch Bypass Oral anticoagulants of Aspirin (BOA) Study Group. Efficacy of oral anticoagulants compared with aspirin after infrainguinal bypass surgery (The Dutch Bypass Oral anticoagulants or Aspirin study): a randomised trial. Lancet2000;355(9201):346-51. EikelboomBC . Prevention of occlusions after infrainguinal bypass surgery with oral anticoagulants or acetylsalicylic acid: A randomised trial. Nederlands Tijdschrift voor Geneeskunde2001;145(22):1060-7. OostenbrinkJB , TangelderMJ , BusschbachJJ , Van HoutBA , BuskensE , AlgraA , et al. Cost effectiveness of oral anticoagulants versus aspirin in patients after infrainguinal bypass grafting surgery. Journal of Vascular Surgery2001;34(2):254-62. SmeetsL , HoGH , TangelderMJ , AlgraA , LawsonJA , EikelboomBC , et al, Dutch BOA Study Group. Outcome after occlusion of infrainguinal bypasses in the Dutch BOA Study: comparison of amputation rate in venous and prosthetic grafts. European Journal of Vascular and Endovascular Surgery2005;30(6):604-9. TangelderMJ , AlgraA , LawsonJA , EikelboomBC . Risk factors for occlusion of infrainguinal bypass grafts. European Journal of Vascular and Endovascular Surgery2000;20(2):118-24. TangelderMJ , AlgraA , LawsonJA , HennekesS , EikelboomBC . Optimal oral anticoagulant intensity to prevent secondary ischemic and hemorrhagic events in patients after infrainguinal bypass graft surgery. Dutch BOA Study Group. Journal of Vascular Surgery2001;33(3):522-7. TangelderMJ , EikelboomBC , LawsonJA , AlgraA . Prevention of occlusion following peripheral bypass surgery using oral anticoagulants or acetylsalicylic acid: a randomized comparison within the Dutch BOA study [Preventi van occlusies na perifere bypass-chirurgie met orale anticoagulantia of acetylsalicylzuur: een gerandomiseerde vergelijking in het Nederlands BOA-onderzoek]. Nederlands Tijdschrift voor Geneeskunde1995;139(29):1504-6. TangelderMJ , McDonnelJ , Van BusschbachJJ , BuskensE , AlgraA , LawsonJA , EikelboomBC . Quality of life after infrainguinal bypass grafting surgery. Dutch Bypass Oral Anticoagulants or Aspirin (BOA) Study Group. Journal of Vascular Surgery1999;29(5):913-9. Van HattumES , AlgraA , LawsonJA , EikelboomBC , MollFL , TangelderMJD . Bleeding increases the risk of ischemic events in patients with peripheral arterial disease. Circulation2009;120(16):1569-76. Van HattumES , TangelderMJD , LawsonJA , MollFL , AlgraA . The quality of life in patients after peripheral bypass surgery deteriorates at long-term follow-up. Journal of Vascular Surgery2011;53(3):643-50. ">BOA 2000</a>; <a href="./references#CD000535-bbs2-0016" title="SchneiderE , BrunnerU , BollingerA . No English title available [Medikamentose Rezidivprophylaxe nach femoro-poplitealer Arterienrekonstruktion]. Angio1979;2(1):73-7. ">Schneider 1979</a>), comparing ASA or ASA and DIP with VKA. The Dutch <a href="./references#CD000535-bbs2-0002" title="AlgraA . A randomised trial of oral anticoagulants versus aspirin after infrainguinal bypass surgery. Tijdschrift voor Sociale Gezondheidszorg1999;77(4):11. AriesenMJ , TangelderMJD , LawsonJA , EikelboomBC , GrobbeeDE , AlgraA . Risk of major haemorrhage in patients after infrainguinal venous bypass surgery: Therapeutic consequences? The Dutch BOA (Bypass Oral Anticoagulants or Aspirin) study. European Journal of Vascular and Endovascular Surgery2005;30(2):154-9. Dutch Bypass Oral anticoagulants of Aspirin (BOA) Study Group. Efficacy of oral anticoagulants compared with aspirin after infrainguinal bypass surgery (The Dutch Bypass Oral anticoagulants or Aspirin study): a randomised trial. Lancet2000;355(9201):346-51. EikelboomBC . Prevention of occlusions after infrainguinal bypass surgery with oral anticoagulants or acetylsalicylic acid: A randomised trial. Nederlands Tijdschrift voor Geneeskunde2001;145(22):1060-7. OostenbrinkJB , TangelderMJ , BusschbachJJ , Van HoutBA , BuskensE , AlgraA , et al. Cost effectiveness of oral anticoagulants versus aspirin in patients after infrainguinal bypass grafting surgery. Journal of Vascular Surgery2001;34(2):254-62. SmeetsL , HoGH , TangelderMJ , AlgraA , LawsonJA , EikelboomBC , et al, Dutch BOA Study Group. Outcome after occlusion of infrainguinal bypasses in the Dutch BOA Study: comparison of amputation rate in venous and prosthetic grafts. European Journal of Vascular and Endovascular Surgery2005;30(6):604-9. TangelderMJ , AlgraA , LawsonJA , EikelboomBC . Risk factors for occlusion of infrainguinal bypass grafts. European Journal of Vascular and Endovascular Surgery2000;20(2):118-24. TangelderMJ , AlgraA , LawsonJA , HennekesS , EikelboomBC . Optimal oral anticoagulant intensity to prevent secondary ischemic and hemorrhagic events in patients after infrainguinal bypass graft surgery. Dutch BOA Study Group. Journal of Vascular Surgery2001;33(3):522-7. TangelderMJ , EikelboomBC , LawsonJA , AlgraA . Prevention of occlusion following peripheral bypass surgery using oral anticoagulants or acetylsalicylic acid: a randomized comparison within the Dutch BOA study [Preventi van occlusies na perifere bypass-chirurgie met orale anticoagulantia of acetylsalicylzuur: een gerandomiseerde vergelijking in het Nederlands BOA-onderzoek]. Nederlands Tijdschrift voor Geneeskunde1995;139(29):1504-6. TangelderMJ , McDonnelJ , Van BusschbachJJ , BuskensE , AlgraA , LawsonJA , EikelboomBC . Quality of life after infrainguinal bypass grafting surgery. Dutch Bypass Oral Anticoagulants or Aspirin (BOA) Study Group. Journal of Vascular Surgery1999;29(5):913-9. Van HattumES , AlgraA , LawsonJA , EikelboomBC , MollFL , TangelderMJD . Bleeding increases the risk of ischemic events in patients with peripheral arterial disease. Circulation2009;120(16):1569-76. Van HattumES , TangelderMJD , LawsonJA , MollFL , AlgraA . The quality of life in patients after peripheral bypass surgery deteriorates at long-term follow-up. Journal of Vascular Surgery2011;53(3):643-50. ">BOA 2000</a> trial included a much higher number of participants than the <a href="./references#CD000535-bbs2-0016" title="SchneiderE , BrunnerU , BollingerA . No English title available [Medikamentose Rezidivprophylaxe nach femoro-poplitealer Arterienrekonstruktion]. Angio1979;2(1):73-7. ">Schneider 1979</a> trial; prosthetic grafts were included in the <a href="./references#CD000535-bbs2-0002" title="AlgraA . A randomised trial of oral anticoagulants versus aspirin after infrainguinal bypass surgery. Tijdschrift voor Sociale Gezondheidszorg1999;77(4):11. AriesenMJ , TangelderMJD , LawsonJA , EikelboomBC , GrobbeeDE , AlgraA . Risk of major haemorrhage in patients after infrainguinal venous bypass surgery: Therapeutic consequences? The Dutch BOA (Bypass Oral Anticoagulants or Aspirin) study. European Journal of Vascular and Endovascular Surgery2005;30(2):154-9. Dutch Bypass Oral anticoagulants of Aspirin (BOA) Study Group. Efficacy of oral anticoagulants compared with aspirin after infrainguinal bypass surgery (The Dutch Bypass Oral anticoagulants or Aspirin study): a randomised trial. Lancet2000;355(9201):346-51. EikelboomBC . Prevention of occlusions after infrainguinal bypass surgery with oral anticoagulants or acetylsalicylic acid: A randomised trial. Nederlands Tijdschrift voor Geneeskunde2001;145(22):1060-7. OostenbrinkJB , TangelderMJ , BusschbachJJ , Van HoutBA , BuskensE , AlgraA , et al. Cost effectiveness of oral anticoagulants versus aspirin in patients after infrainguinal bypass grafting surgery. Journal of Vascular Surgery2001;34(2):254-62. SmeetsL , HoGH , TangelderMJ , AlgraA , LawsonJA , EikelboomBC , et al, Dutch BOA Study Group. Outcome after occlusion of infrainguinal bypasses in the Dutch BOA Study: comparison of amputation rate in venous and prosthetic grafts. European Journal of Vascular and Endovascular Surgery2005;30(6):604-9. TangelderMJ , AlgraA , LawsonJA , EikelboomBC . Risk factors for occlusion of infrainguinal bypass grafts. European Journal of Vascular and Endovascular Surgery2000;20(2):118-24. TangelderMJ , AlgraA , LawsonJA , HennekesS , EikelboomBC . Optimal oral anticoagulant intensity to prevent secondary ischemic and hemorrhagic events in patients after infrainguinal bypass graft surgery. Dutch BOA Study Group. Journal of Vascular Surgery2001;33(3):522-7. TangelderMJ , EikelboomBC , LawsonJA , AlgraA . Prevention of occlusion following peripheral bypass surgery using oral anticoagulants or acetylsalicylic acid: a randomized comparison within the Dutch BOA study [Preventi van occlusies na perifere bypass-chirurgie met orale anticoagulantia of acetylsalicylzuur: een gerandomiseerde vergelijking in het Nederlands BOA-onderzoek]. Nederlands Tijdschrift voor Geneeskunde1995;139(29):1504-6. TangelderMJ , McDonnelJ , Van BusschbachJJ , BuskensE , AlgraA , LawsonJA , EikelboomBC . Quality of life after infrainguinal bypass grafting surgery. Dutch Bypass Oral Anticoagulants or Aspirin (BOA) Study Group. Journal of Vascular Surgery1999;29(5):913-9. Van HattumES , AlgraA , LawsonJA , EikelboomBC , MollFL , TangelderMJD . Bleeding increases the risk of ischemic events in patients with peripheral arterial disease. Circulation2009;120(16):1569-76. Van HattumES , TangelderMJD , LawsonJA , MollFL , AlgraA . The quality of life in patients after peripheral bypass surgery deteriorates at long-term follow-up. Journal of Vascular Surgery2011;53(3):643-50. ">BOA 2000</a> trial. It should be noted that participants receiving ASA in the <a href="./references#CD000535-bbs2-0002" title="AlgraA . A randomised trial of oral anticoagulants versus aspirin after infrainguinal bypass surgery. Tijdschrift voor Sociale Gezondheidszorg1999;77(4):11. AriesenMJ , TangelderMJD , LawsonJA , EikelboomBC , GrobbeeDE , AlgraA . Risk of major haemorrhage in patients after infrainguinal venous bypass surgery: Therapeutic consequences? The Dutch BOA (Bypass Oral Anticoagulants or Aspirin) study. European Journal of Vascular and Endovascular Surgery2005;30(2):154-9. Dutch Bypass Oral anticoagulants of Aspirin (BOA) Study Group. Efficacy of oral anticoagulants compared with aspirin after infrainguinal bypass surgery (The Dutch Bypass Oral anticoagulants or Aspirin study): a randomised trial. Lancet2000;355(9201):346-51. EikelboomBC . Prevention of occlusions after infrainguinal bypass surgery with oral anticoagulants or acetylsalicylic acid: A randomised trial. Nederlands Tijdschrift voor Geneeskunde2001;145(22):1060-7. OostenbrinkJB , TangelderMJ , BusschbachJJ , Van HoutBA , BuskensE , AlgraA , et al. Cost effectiveness of oral anticoagulants versus aspirin in patients after infrainguinal bypass grafting surgery. Journal of Vascular Surgery2001;34(2):254-62. SmeetsL , HoGH , TangelderMJ , AlgraA , LawsonJA , EikelboomBC , et al, Dutch BOA Study Group. Outcome after occlusion of infrainguinal bypasses in the Dutch BOA Study: comparison of amputation rate in venous and prosthetic grafts. European Journal of Vascular and Endovascular Surgery2005;30(6):604-9. TangelderMJ , AlgraA , LawsonJA , EikelboomBC . Risk factors for occlusion of infrainguinal bypass grafts. European Journal of Vascular and Endovascular Surgery2000;20(2):118-24. TangelderMJ , AlgraA , LawsonJA , HennekesS , EikelboomBC . Optimal oral anticoagulant intensity to prevent secondary ischemic and hemorrhagic events in patients after infrainguinal bypass graft surgery. Dutch BOA Study Group. Journal of Vascular Surgery2001;33(3):522-7. TangelderMJ , EikelboomBC , LawsonJA , AlgraA . Prevention of occlusion following peripheral bypass surgery using oral anticoagulants or acetylsalicylic acid: a randomized comparison within the Dutch BOA study [Preventi van occlusies na perifere bypass-chirurgie met orale anticoagulantia of acetylsalicylzuur: een gerandomiseerde vergelijking in het Nederlands BOA-onderzoek]. Nederlands Tijdschrift voor Geneeskunde1995;139(29):1504-6. TangelderMJ , McDonnelJ , Van BusschbachJJ , BuskensE , AlgraA , LawsonJA , EikelboomBC . Quality of life after infrainguinal bypass grafting surgery. Dutch Bypass Oral Anticoagulants or Aspirin (BOA) Study Group. Journal of Vascular Surgery1999;29(5):913-9. Van HattumES , AlgraA , LawsonJA , EikelboomBC , MollFL , TangelderMJD . Bleeding increases the risk of ischemic events in patients with peripheral arterial disease. Circulation2009;120(16):1569-76. Van HattumES , TangelderMJD , LawsonJA , MollFL , AlgraA . The quality of life in patients after peripheral bypass surgery deteriorates at long-term follow-up. Journal of Vascular Surgery2011;53(3):643-50. ">BOA 2000</a> trial were treated with a dose of only 80 mg, while all other trials included in this review compared doses of 600 mg to 1500 mg daily, sometimes with additional DIP. </p> </section> <section id="CD000535-sec-0044"> <h5 class="title">Aspirin and dipyridamole (ASA/DIP) versus low molecular weight heparin (LMWH)</h5> <p>We include one open, randomised clinical trial for comparison of LMWH (Fragmin) and ASA and DIP (<a href="./references#CD000535-bbs2-0007" title="EdmondsonRA , CohenAT , DasSK , WagnerBM , KakkarVV . Low-molecular weight heparin versus aspirin and dipyridamole after femoropopliteal bypass grafting. Lancet1994;344(8927):914-8. ">Edmondson 1994</a>). Participants were assessed for their clinical outcomes on the seventh postoperative day. </p> </section> <section id="CD000535-sec-0045"> <h5 class="title">Ticlopidine (TIC) versus nothing</h5> <p>Only one double‐blind trial (<a href="./references#CD000535-bbs2-0001" title="BecqueminJP . Effect of ticlopidine on the long-term patency of saphenous-vein bypass grafts in the legs. New England Journal of Medicine1997;337(24):1726-31. ">Becquemin 1997</a>) could be included for analysis, which randomised 243 participants after surgery. All participants received autologous saphenous vein grafts. </p> </section> <section id="CD000535-sec-0046"> <h5 class="title">Aspirin versus prostaglandin E1 (PGE1)</h5> <p>One open, randomised clinical trial compared ASA to PGE1 on a background of 15,000 IU of heparin for early graft occlusion, within three days postoperatively, in 100 participants who all received autologous saphenous vein grafts (<a href="./references#CD000535-bbs2-0010" title="GrussJD , HiemerW , KroissA , GeisslerC . Experiences with adjuvant prostaglandin therapy in vascular surgery interventions. Vasa-Supplementum1991;33:353-4. ">Gruss 1991</a>). </p> </section> <section id="CD000535-sec-0047"> <h5 class="title">Aspirin versus naftidrofuryl</h5> <p>We could consider only one trial in the analysis that compared ASA to naftidrofuryl (<a href="./references#CD000535-bbs2-0014" title="NoppeneyT , KasprzakP , RaithelD , HircheH . Naftidrofuryl in postoperative treatment after femoropopliteal bypass. Die Medizinische Welt1988;39:1545-50. ">Noppeney 1988</a>). This study, which commenced on postoperative day one, randomised 99 participants who all had prosthetic PTFE grafts. </p> </section> <section id="CD000535-sec-0048"> <h5 class="title">Clopidogrel and ASA (Clopidogrel/ASA) versus ASA alone</h5> <p>A single trial evaluated the comparison between clopidogrel with ASA versus ASA alone (<a href="./references#CD000535-bbs2-0003" title="Anonymous. Clopidogrel and acetyl salicylic acid in bypass surgery for peripheral arterial disease. clinicaltrials.gov/ct2/show/NCT00174759?term=CASPAR&amp;rank=2 (accessed 5 May 2014). Anonymous. Dual antiplatelet therapy benefits prosthetic but not venous grafts. Vascular News2009;Feb:17. BelchJJ , DormandyJ . Results of the randomized, placebo-controlled clopidogrel and acetylsalicylic acid in bypass surgery for peripheral arterial disease (CASPAR) trial. Journal of Vascular Surgery2010;52(4):825-33. The Caspar Investigators, BelchJ . Effect of adding clopidogrel to aspirin on the success of below knee arterial bypass grafts. A randomised placebo controlled study. In: Vascular Annual Meeting; 2007 Jun; Baltimore, USA. 2007. ">CASPAR 2010</a>), which was a large trial of 851 randomised, receiving a mixture of venous and prosthetic grafts. </p> </section> </section> <section id="CD000535-sec-0049"> <h4 class="title">Excluded studies</h4> <p>For this update we excluded an additional three studies (<a href="./references#CD000535-bbs2-0018" title="BurdessA , NimmoA , GardenOJ , MurieJA , DawsonAR , FoxKA , et al. Dual antiplatelet therapy in surgery for critical limb ischaemia. The Vascular Society of Great Britain &amp; Ireland Yearbook 20082008:47. BurdessA , NimmoAF , GardenOJ , MurieJA , DawsonAR , FoxKA , et al. Randomized controlled trial of dual antiplatelet therapy in patients undergoing surgery for critical limb ischemia. Annals of Surgery2010;252(1):37-42. ">Burdess 2010</a>; <a href="./references#CD000535-bbs2-0021" title="EUCTR2007-003746-15-DE. Prospective randomized open study on the comparison of fondaparinux with the low-molecular-weight heparin enoxaparin in patients undergoing femoro-distal venous bypass operation. www.clinicaltrialsregister.eu/ctr-search/trial/2007-003746-15/DE2008. ">EUCTR2007 2008</a>; <a href="./references#CD000535-bbs2-0029" title="MonacoM , Di TommasoL , PinnaGB , LilloS , SchiavoneV , StassanoP . Combination therapy with warfarin plus clopidogrel improves outcomes in femoropopliteal bypass surgery patients. Journal of Vascular Surgery2012;56(1):96-105. ">Monaco 2012</a>), making a total of 20 excluded studies (<a href="./references#CD000535-bbs2-0017" title="BöhmigHJ , ZeidlerG , SchwierzTH , LoyE . Orthograde vein bypass procedure for inguinal arterial reconstructions - 20 years experience [20 Jahre orthograder venen-bypass für infrainguinale arterielle rekonstruktion]. Chirurg1995;66(2):120-6. ">Böhmig 1995</a>; <a href="./references#CD000535-bbs2-0018" title="BurdessA , NimmoA , GardenOJ , MurieJA , DawsonAR , FoxKA , et al. Dual antiplatelet therapy in surgery for critical limb ischaemia. The Vascular Society of Great Britain &amp; Ireland Yearbook 20082008:47. BurdessA , NimmoAF , GardenOJ , MurieJA , DawsonAR , FoxKA , et al. Randomized controlled trial of dual antiplatelet therapy in patients undergoing surgery for critical limb ischemia. Annals of Surgery2010;252(1):37-42. ">Burdess 2010</a>; <a href="./references#CD000535-bbs2-0019" title="DeWeeseJA , RobCG . Autogenous venous bypass grafts five years later. Annals of Surgery1971;174(3):346-56. ">DeWeese 1971</a>; <a href="./references#CD000535-bbs2-0020" title="EhresmannU , AlemanyJ , LoewD . Use of acetylsalicylic acid in the prevention of re-occlusion following revascularization interventions. Results of a double blind long term study [Prophylaxe von rezidivverschlüssen nach revaskularisationseingriffen mit acetylsalicylsäure]. Medizinische Welt1977;28(26):1157-62. ">Ehersmann 1977</a>; <a href="./references#CD000535-bbs2-0021" title="EUCTR2007-003746-15-DE. Prospective randomized open study on the comparison of fondaparinux with the low-molecular-weight heparin enoxaparin in patients undergoing femoro-distal venous bypass operation. www.clinicaltrialsregister.eu/ctr-search/trial/2007-003746-15/DE2008. ">EUCTR2007 2008</a>; <a href="./references#CD000535-bbs2-0022" title="GorterJW , OostenbrinkJB , TangelderMJ , Stroke Pi, Reversible Ischemia Trial (SPIRIT) Study Group, Dutch BypassO , Anticoagulants or Aspirin Study (BOA). Costs of outpatient anticoagulant treatment in patients with cerebral and peripheral arterial occlusive disease. Thrombosis and Haemostasis2001;85(1):52-6. ">Gorter 2001</a>; <a href="./references#CD000535-bbs2-0023" title="HarjolaPT , MeuralaH , FrickMH . Prevention of early reocclusion by dipyridamole and ASA in arterial reconstructive surgery. Journal of Cardiovascular Surgery1981;22(2):141-4. ">Harjola 1981</a>; <a href="./references#CD000535-bbs2-0024" title="JivegardL , DrottC , GelinJ , GrothO , HensaterM , JensenN , et al. Effects of three months of low molecular weight heparin (Dalteparin) treatment after bypass surgery for lower limb ischemia - A randomised placebo-controlled double blind multicentre trial. European Journal of Vascular and Endovascular Surgery2005;29(2):190-8. ">Jivegard 2005</a>; <a href="./references#CD000535-bbs2-0025" title="JohnsonWC , WillifordWO , Department of Veterans Affairs Cooperative Study # 362. Benefits, morbidity, and mortality associated with long-term administration of oral anticoagulant therapy to patients with peripheral arterial bypass procedures: a prospective randomized study. Journal of Vascular Surgery2002;35(3):413-21. ">Johnson 2002</a>; <a href="./references#CD000535-bbs2-0026" title="JohnsonWC , WillifordWO , CorsonJD , Padberg FT Jr. Hemorrhagic complications during long-term postoperative warfarin administration in patients undergoing lower extremity arterial bypass surgery. Vascular2004;12(6):362-8. ">Johnson 2004</a>; <a href="./references#CD000535-bbs2-0027" title="KibbeMR , HassettAL , McSherryF , ConnerP , BontempoFA , WillifordW , et al. Can screening for genetic markers improve peripheral artery bypass patency?Journal of Vascular Surgery2002;36(6):1198-206. ">Kibbe 2002</a>; <a href="./references#CD000535-bbs2-0028" title="LassilaR , LepäntaloM , LindforsO . The effect of acetylicsalicylic acid on the outcome after lower limb arterial surgery with special reference to cigarette smoking. World Journal of Surgery1991;15(3):378-82. ">Lassila 1991</a>; <a href="./references#CD000535-bbs2-0029" title="MonacoM , Di TommasoL , PinnaGB , LilloS , SchiavoneV , StassanoP . Combination therapy with warfarin plus clopidogrel improves outcomes in femoropopliteal bypass surgery patients. Journal of Vascular Surgery2012;56(1):96-105. ">Monaco 2012</a>; <a href="./references#CD000535-bbs2-0030" title="NevelsteenA , MortelmansL , Van de CruysA , MerckxE , VerhaegheR . Effect of ticlopidine on blood loss, platelet turnover and platelet deposition on prosthetic surfaces in patients undergoing aorto-femoral bypass grafting. Thrombosis Research1991;64(3):363-9. ">Nevelsteen 1991</a>; <a href="./references#CD000535-bbs2-0031" title="RaithelD , NoppeneyT , KasprzakP . Medikamentöse Therapie nach femoro.poplitealem Kunststoffbypass - naftidrofuryl versus ASS. In: Vasa-Supplementum. Vol. 20. 1987:223-Abstract No 78. ">Raithel 1987b</a>; <a href="./references#CD000535-bbs2-0032" title="ReichleFA , RankinKP , TysonRR , FinestoneAJ , ShumanC . Long-term results of 474 arterial reconstructions for severely ischemic limbs: A fourteen year follow-up. Surgery1979;85(1):93-100. ">Reichle 1979</a>; <a href="./references#CD000535-bbs2-0033" title="RosenthalD , MittenthalMH , RubenDM , JonesDH , EstesJW , StantonPE , et al. The effects of aspirin, dipyridamole and warfarin in femorodistal reconstruction: long-term results. American Surgeon1987;53(9):477-81. ">Rosenthal 1987</a>; <a href="./references#CD000535-bbs2-0034" title="SatianiB . A prospective randomized trial of aspirin in femoral popliteal and tibial bypass grafts. Angiology1985;36(9):608-16. ">Satiani 1985</a>; <a href="./references#CD000535-bbs2-0035" title="ShionoyaS , SakuraiT , UeyamaT , KusakawaM , SakaguchiS , TsuchiokaH , et al. Effect of ticlopidine on graft patency following arterial reconstructive surgery in the lower extremity: a multicenter three-year prospective study. Vascular Surgery1990;24(8):541-7. ">Shionoya 1990</a>; <a href="./references#CD000535-bbs2-0036" title="SmoutJD , MikhailidisDP , ShentonBK , StansbyG . Combination antiplatelet therapy in patients with peripheral vascular bypass grafts. Clinical and Applied Thrombosis/Hemostasis2004;10(1):9-18. ">Smout 2004</a>).The reasons for exclusion varied and include, among others: lack of a control group, not a randomised controlled trial, a heterogeneous cohort of participants, intervention not within the scope of the review, and too little information to determine inclusion. </p> <p>See <a href="./references#CD000535-sec-0122" title="">Characteristics of excluded studies</a> for full descriptions of excluded studies. </p> </section> </section> <section id="CD000535-sec-0050"> <h3 class="title">Risk of bias in included studies</h3> <p>See <a href="#CD000535-fig-0002">Figure 2</a>and <a href="#CD000535-fig-0003">Figure 3</a> for 'Risk of bias' evaluation. </p> <div class="figure" id="CD000535-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD000535-fig-0002" src="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/image_n/nCD000535-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD000535-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD000535-fig-0003" src="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/image_n/nCD000535-FIG-03.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD000535-sec-0051"> <h4 class="title">Allocation</h4> <p>Random sequence generation methods were adequately described in six studies (<a href="./references#CD000535-bbs2-0001" title="BecqueminJP . Effect of ticlopidine on the long-term patency of saphenous-vein bypass grafts in the legs. New England Journal of Medicine1997;337(24):1726-31. ">Becquemin 1997</a>; <a href="./references#CD000535-bbs2-0002" title="AlgraA . A randomised trial of oral anticoagulants versus aspirin after infrainguinal bypass surgery. Tijdschrift voor Sociale Gezondheidszorg1999;77(4):11. AriesenMJ , TangelderMJD , LawsonJA , EikelboomBC , GrobbeeDE , AlgraA . Risk of major haemorrhage in patients after infrainguinal venous bypass surgery: Therapeutic consequences? The Dutch BOA (Bypass Oral Anticoagulants or Aspirin) study. European Journal of Vascular and Endovascular Surgery2005;30(2):154-9. Dutch Bypass Oral anticoagulants of Aspirin (BOA) Study Group. Efficacy of oral anticoagulants compared with aspirin after infrainguinal bypass surgery (The Dutch Bypass Oral anticoagulants or Aspirin study): a randomised trial. Lancet2000;355(9201):346-51. EikelboomBC . Prevention of occlusions after infrainguinal bypass surgery with oral anticoagulants or acetylsalicylic acid: A randomised trial. Nederlands Tijdschrift voor Geneeskunde2001;145(22):1060-7. OostenbrinkJB , TangelderMJ , BusschbachJJ , Van HoutBA , BuskensE , AlgraA , et al. Cost effectiveness of oral anticoagulants versus aspirin in patients after infrainguinal bypass grafting surgery. Journal of Vascular Surgery2001;34(2):254-62. SmeetsL , HoGH , TangelderMJ , AlgraA , LawsonJA , EikelboomBC , et al, Dutch BOA Study Group. Outcome after occlusion of infrainguinal bypasses in the Dutch BOA Study: comparison of amputation rate in venous and prosthetic grafts. European Journal of Vascular and Endovascular Surgery2005;30(6):604-9. TangelderMJ , AlgraA , LawsonJA , EikelboomBC . Risk factors for occlusion of infrainguinal bypass grafts. European Journal of Vascular and Endovascular Surgery2000;20(2):118-24. TangelderMJ , AlgraA , LawsonJA , HennekesS , EikelboomBC . Optimal oral anticoagulant intensity to prevent secondary ischemic and hemorrhagic events in patients after infrainguinal bypass graft surgery. Dutch BOA Study Group. Journal of Vascular Surgery2001;33(3):522-7. TangelderMJ , EikelboomBC , LawsonJA , AlgraA . Prevention of occlusion following peripheral bypass surgery using oral anticoagulants or acetylsalicylic acid: a randomized comparison within the Dutch BOA study [Preventi van occlusies na perifere bypass-chirurgie met orale anticoagulantia of acetylsalicylzuur: een gerandomiseerde vergelijking in het Nederlands BOA-onderzoek]. Nederlands Tijdschrift voor Geneeskunde1995;139(29):1504-6. TangelderMJ , McDonnelJ , Van BusschbachJJ , BuskensE , AlgraA , LawsonJA , EikelboomBC . Quality of life after infrainguinal bypass grafting surgery. Dutch Bypass Oral Anticoagulants or Aspirin (BOA) Study Group. Journal of Vascular Surgery1999;29(5):913-9. Van HattumES , AlgraA , LawsonJA , EikelboomBC , MollFL , TangelderMJD . Bleeding increases the risk of ischemic events in patients with peripheral arterial disease. Circulation2009;120(16):1569-76. Van HattumES , TangelderMJD , LawsonJA , MollFL , AlgraA . The quality of life in patients after peripheral bypass surgery deteriorates at long-term follow-up. Journal of Vascular Surgery2011;53(3):643-50. ">BOA 2000</a>; <a href="./references#CD000535-bbs2-0003" title="Anonymous. Clopidogrel and acetyl salicylic acid in bypass surgery for peripheral arterial disease. clinicaltrials.gov/ct2/show/NCT00174759?term=CASPAR&amp;rank=2 (accessed 5 May 2014). Anonymous. Dual antiplatelet therapy benefits prosthetic but not venous grafts. Vascular News2009;Feb:17. BelchJJ , DormandyJ . Results of the randomized, placebo-controlled clopidogrel and acetylsalicylic acid in bypass surgery for peripheral arterial disease (CASPAR) trial. Journal of Vascular Surgery2010;52(4):825-33. The Caspar Investigators, BelchJ . Effect of adding clopidogrel to aspirin on the success of below knee arterial bypass grafts. A randomised placebo controlled study. In: Vascular Annual Meeting; 2007 Jun; Baltimore, USA. 2007. ">CASPAR 2010</a>; <a href="./references#CD000535-bbs2-0007" title="EdmondsonRA , CohenAT , DasSK , WagnerBM , KakkarVV . Low-molecular weight heparin versus aspirin and dipyridamole after femoropopliteal bypass grafting. Lancet1994;344(8927):914-8. ">Edmondson 1994</a>; <a href="./references#CD000535-bbs2-0011" title="KohlerTR , KaufmanJL , KacoyanisG , ClowesA , DonaldsonMC , KellyE , et al. Effect of aspirin and dipyridamole on the patency of lower extremity bypass grafts. Surgery1984;96(3):462-6. ">Kohler 1984</a>; <a href="./references#CD000535-bbs2-0012" title="LucasMA . Prevention of post-operative thrombosis in peripheral arteriopathies. Pentoxifylline vs conventional antiaggregants: a six-month randomized follow-up study. Angiology1984;35(7):443-50. ">Lucas 1984</a>). The remaining 10 studies did not sufficiently describe how they generated their random sequence, leading to a rating of 'unclear' (<a href="./references#CD000535-bbs2-0004" title="ClyneCA , ArcherTJ , AtuhaireLK , ChantAD , WebsterJH . Random control trial of a short course of aspirin and dipyridamole (Persantin) for femorodistal grafts. British Journal of Surgery1987;74(4):246-8. ">Clyne 1987</a>; <a href="./references#CD000535-bbs2-0005" title="D'AddatoM , CurtiT , BertiniD , DoniniI , FerreroR , FioraniP , et al. Indobufen vs acetylsalicylic acid plus dipyridamole in long-term patency after femoropopliteal bypass. International Angiology1992;11(2):106-12. ">D'Addato 1992</a>; <a href="./references#CD000535-bbs2-0006" title="DonaldsonDR , SalterMC , KesterRC , RajahSM , HallTJ , SreeharanN , et al. The influence of platelet inhibition on the patency of femoro-popliteal Dacron bypass grafts. Vascular Surgery1985;19(4):224-30. ">Donaldson 1985</a>; <a href="./references#CD000535-bbs2-0008" title="GoldmanM , McCollumC . A prospective randomized study to examine the effect of aspirin plus dipyridamole on the patency of prosthetic femoro-popliteal grafts. Vascular Surgery1984;18(4):217-21. ">Goldman 1984</a>; <a href="./references#CD000535-bbs2-0009" title="GreenRM , RoedersheimerRL , DeWeeseJA . Effects of aspirin and dipyridamole on expanded polytetrafluoethylene graft patency. Surgery1982;92(6):1016-26. ">Green 1982</a>; <a href="./references#CD000535-bbs2-0010" title="GrussJD , HiemerW , KroissA , GeisslerC . Experiences with adjuvant prostaglandin therapy in vascular surgery interventions. Vasa-Supplementum1991;33:353-4. ">Gruss 1991</a>; <a href="./references#CD000535-bbs2-0013" title="FranksPJ , SianM , KenchingtonGF , AlexanderCE , PowellJT . Aspirin usage and its influence on femoro-popliteal vein graft patency. European Journal of Vascular Surgery1992;6(2):185-8. FranksPJ , SianM , KenchingtonGF , AlexanderCE , PowellJT . Aspirin usage and its influence on femoropopliteal vein graft patency. In: European Society for Vascular Surgery 5th Annual Meeting, 25-27 September 1991; Warsaw, Poland. 1991. McCollumC , AlexanderC , KenchingtonG , FranksPJ , GreenhalghR . Antiplatelet drugs in femoropopliteal vein bypasses: A multicenter trial. Journal of Vascular Surgery1991;13(1):150-62. PowellJT , GreenhalghRM . Smoking and factors influencing the outcome of arterial reconstruction. Annales Chirurgiae et Gynaecologiae1992;81(2):236-41. ">McCollum 1991</a>; <a href="./references#CD000535-bbs2-0014" title="NoppeneyT , KasprzakP , RaithelD , HircheH . Naftidrofuryl in postoperative treatment after femoropopliteal bypass. Die Medizinische Welt1988;39:1545-50. ">Noppeney 1988</a>; <a href="./references#CD000535-bbs2-0015" title="RaithelD , KasprzakP , Noppeney Th. Relapse prophylaxis after femoropopliteal reconstruction with PTFE-prostheses. Die Medizinische Welt1986;37:664-7. RaithelD . Prevention of reocclusion after prosthetic bypass operations in the femoro-popliteal region: a comparative study of pentoxifylline versus acetylsalicylic acid. Vascular Surgery1987;21(3):208-14. ">Raithel 1987</a>; <a href="./references#CD000535-bbs2-0016" title="SchneiderE , BrunnerU , BollingerA . No English title available [Medikamentose Rezidivprophylaxe nach femoro-poplitealer Arterienrekonstruktion]. Angio1979;2(1):73-7. ">Schneider 1979</a>). </p> <p>Six studies described allocation concealment methods that were low‐risk (<a href="./references#CD000535-bbs2-0002" title="AlgraA . A randomised trial of oral anticoagulants versus aspirin after infrainguinal bypass surgery. Tijdschrift voor Sociale Gezondheidszorg1999;77(4):11. AriesenMJ , TangelderMJD , LawsonJA , EikelboomBC , GrobbeeDE , AlgraA . Risk of major haemorrhage in patients after infrainguinal venous bypass surgery: Therapeutic consequences? The Dutch BOA (Bypass Oral Anticoagulants or Aspirin) study. European Journal of Vascular and Endovascular Surgery2005;30(2):154-9. Dutch Bypass Oral anticoagulants of Aspirin (BOA) Study Group. Efficacy of oral anticoagulants compared with aspirin after infrainguinal bypass surgery (The Dutch Bypass Oral anticoagulants or Aspirin study): a randomised trial. Lancet2000;355(9201):346-51. EikelboomBC . Prevention of occlusions after infrainguinal bypass surgery with oral anticoagulants or acetylsalicylic acid: A randomised trial. Nederlands Tijdschrift voor Geneeskunde2001;145(22):1060-7. OostenbrinkJB , TangelderMJ , BusschbachJJ , Van HoutBA , BuskensE , AlgraA , et al. Cost effectiveness of oral anticoagulants versus aspirin in patients after infrainguinal bypass grafting surgery. Journal of Vascular Surgery2001;34(2):254-62. SmeetsL , HoGH , TangelderMJ , AlgraA , LawsonJA , EikelboomBC , et al, Dutch BOA Study Group. Outcome after occlusion of infrainguinal bypasses in the Dutch BOA Study: comparison of amputation rate in venous and prosthetic grafts. European Journal of Vascular and Endovascular Surgery2005;30(6):604-9. TangelderMJ , AlgraA , LawsonJA , EikelboomBC . Risk factors for occlusion of infrainguinal bypass grafts. European Journal of Vascular and Endovascular Surgery2000;20(2):118-24. TangelderMJ , AlgraA , LawsonJA , HennekesS , EikelboomBC . Optimal oral anticoagulant intensity to prevent secondary ischemic and hemorrhagic events in patients after infrainguinal bypass graft surgery. Dutch BOA Study Group. Journal of Vascular Surgery2001;33(3):522-7. TangelderMJ , EikelboomBC , LawsonJA , AlgraA . Prevention of occlusion following peripheral bypass surgery using oral anticoagulants or acetylsalicylic acid: a randomized comparison within the Dutch BOA study [Preventi van occlusies na perifere bypass-chirurgie met orale anticoagulantia of acetylsalicylzuur: een gerandomiseerde vergelijking in het Nederlands BOA-onderzoek]. Nederlands Tijdschrift voor Geneeskunde1995;139(29):1504-6. TangelderMJ , McDonnelJ , Van BusschbachJJ , BuskensE , AlgraA , LawsonJA , EikelboomBC . Quality of life after infrainguinal bypass grafting surgery. Dutch Bypass Oral Anticoagulants or Aspirin (BOA) Study Group. Journal of Vascular Surgery1999;29(5):913-9. Van HattumES , AlgraA , LawsonJA , EikelboomBC , MollFL , TangelderMJD . Bleeding increases the risk of ischemic events in patients with peripheral arterial disease. Circulation2009;120(16):1569-76. Van HattumES , TangelderMJD , LawsonJA , MollFL , AlgraA . The quality of life in patients after peripheral bypass surgery deteriorates at long-term follow-up. Journal of Vascular Surgery2011;53(3):643-50. ">BOA 2000</a>; <a href="./references#CD000535-bbs2-0003" title="Anonymous. Clopidogrel and acetyl salicylic acid in bypass surgery for peripheral arterial disease. clinicaltrials.gov/ct2/show/NCT00174759?term=CASPAR&amp;rank=2 (accessed 5 May 2014). Anonymous. Dual antiplatelet therapy benefits prosthetic but not venous grafts. Vascular News2009;Feb:17. BelchJJ , DormandyJ . Results of the randomized, placebo-controlled clopidogrel and acetylsalicylic acid in bypass surgery for peripheral arterial disease (CASPAR) trial. Journal of Vascular Surgery2010;52(4):825-33. The Caspar Investigators, BelchJ . Effect of adding clopidogrel to aspirin on the success of below knee arterial bypass grafts. A randomised placebo controlled study. In: Vascular Annual Meeting; 2007 Jun; Baltimore, USA. 2007. ">CASPAR 2010</a>; <a href="./references#CD000535-bbs2-0007" title="EdmondsonRA , CohenAT , DasSK , WagnerBM , KakkarVV . Low-molecular weight heparin versus aspirin and dipyridamole after femoropopliteal bypass grafting. Lancet1994;344(8927):914-8. ">Edmondson 1994</a>; <a href="./references#CD000535-bbs2-0009" title="GreenRM , RoedersheimerRL , DeWeeseJA . Effects of aspirin and dipyridamole on expanded polytetrafluoethylene graft patency. Surgery1982;92(6):1016-26. ">Green 1982</a>; <a href="./references#CD000535-bbs2-0012" title="LucasMA . Prevention of post-operative thrombosis in peripheral arteriopathies. Pentoxifylline vs conventional antiaggregants: a six-month randomized follow-up study. Angiology1984;35(7):443-50. ">Lucas 1984</a>; <a href="./references#CD000535-bbs2-0013" title="FranksPJ , SianM , KenchingtonGF , AlexanderCE , PowellJT . Aspirin usage and its influence on femoro-popliteal vein graft patency. European Journal of Vascular Surgery1992;6(2):185-8. FranksPJ , SianM , KenchingtonGF , AlexanderCE , PowellJT . Aspirin usage and its influence on femoropopliteal vein graft patency. In: European Society for Vascular Surgery 5th Annual Meeting, 25-27 September 1991; Warsaw, Poland. 1991. McCollumC , AlexanderC , KenchingtonG , FranksPJ , GreenhalghR . Antiplatelet drugs in femoropopliteal vein bypasses: A multicenter trial. Journal of Vascular Surgery1991;13(1):150-62. PowellJT , GreenhalghRM . Smoking and factors influencing the outcome of arterial reconstruction. Annales Chirurgiae et Gynaecologiae1992;81(2):236-41. ">McCollum 1991</a>), while the remaining 10 studies did not describe their methods adequately (<a href="./references#CD000535-bbs2-0001" title="BecqueminJP . Effect of ticlopidine on the long-term patency of saphenous-vein bypass grafts in the legs. New England Journal of Medicine1997;337(24):1726-31. ">Becquemin 1997</a>; <a href="./references#CD000535-bbs2-0004" title="ClyneCA , ArcherTJ , AtuhaireLK , ChantAD , WebsterJH . Random control trial of a short course of aspirin and dipyridamole (Persantin) for femorodistal grafts. British Journal of Surgery1987;74(4):246-8. ">Clyne 1987</a>; <a href="./references#CD000535-bbs2-0005" title="D'AddatoM , CurtiT , BertiniD , DoniniI , FerreroR , FioraniP , et al. Indobufen vs acetylsalicylic acid plus dipyridamole in long-term patency after femoropopliteal bypass. International Angiology1992;11(2):106-12. ">D'Addato 1992</a>; <a href="./references#CD000535-bbs2-0006" title="DonaldsonDR , SalterMC , KesterRC , RajahSM , HallTJ , SreeharanN , et al. The influence of platelet inhibition on the patency of femoro-popliteal Dacron bypass grafts. Vascular Surgery1985;19(4):224-30. ">Donaldson 1985</a>; <a href="./references#CD000535-bbs2-0008" title="GoldmanM , McCollumC . A prospective randomized study to examine the effect of aspirin plus dipyridamole on the patency of prosthetic femoro-popliteal grafts. Vascular Surgery1984;18(4):217-21. ">Goldman 1984</a>; <a href="./references#CD000535-bbs2-0010" title="GrussJD , HiemerW , KroissA , GeisslerC . Experiences with adjuvant prostaglandin therapy in vascular surgery interventions. Vasa-Supplementum1991;33:353-4. ">Gruss 1991</a>; <a href="./references#CD000535-bbs2-0011" title="KohlerTR , KaufmanJL , KacoyanisG , ClowesA , DonaldsonMC , KellyE , et al. Effect of aspirin and dipyridamole on the patency of lower extremity bypass grafts. Surgery1984;96(3):462-6. ">Kohler 1984</a>; <a href="./references#CD000535-bbs2-0014" title="NoppeneyT , KasprzakP , RaithelD , HircheH . Naftidrofuryl in postoperative treatment after femoropopliteal bypass. Die Medizinische Welt1988;39:1545-50. ">Noppeney 1988</a>; <a href="./references#CD000535-bbs2-0015" title="RaithelD , KasprzakP , Noppeney Th. Relapse prophylaxis after femoropopliteal reconstruction with PTFE-prostheses. Die Medizinische Welt1986;37:664-7. RaithelD . Prevention of reocclusion after prosthetic bypass operations in the femoro-popliteal region: a comparative study of pentoxifylline versus acetylsalicylic acid. Vascular Surgery1987;21(3):208-14. ">Raithel 1987</a>; <a href="./references#CD000535-bbs2-0016" title="SchneiderE , BrunnerU , BollingerA . No English title available [Medikamentose Rezidivprophylaxe nach femoro-poplitealer Arterienrekonstruktion]. Angio1979;2(1):73-7. ">Schneider 1979</a>). </p> </section> <section id="CD000535-sec-0052"> <h4 class="title">Blinding</h4> <p>Blinding of participants and personnel was adequate in seven studies (<a href="./references#CD000535-bbs2-0001" title="BecqueminJP . Effect of ticlopidine on the long-term patency of saphenous-vein bypass grafts in the legs. New England Journal of Medicine1997;337(24):1726-31. ">Becquemin 1997</a>; <a href="./references#CD000535-bbs2-0003" title="Anonymous. Clopidogrel and acetyl salicylic acid in bypass surgery for peripheral arterial disease. clinicaltrials.gov/ct2/show/NCT00174759?term=CASPAR&amp;rank=2 (accessed 5 May 2014). Anonymous. Dual antiplatelet therapy benefits prosthetic but not venous grafts. Vascular News2009;Feb:17. BelchJJ , DormandyJ . Results of the randomized, placebo-controlled clopidogrel and acetylsalicylic acid in bypass surgery for peripheral arterial disease (CASPAR) trial. Journal of Vascular Surgery2010;52(4):825-33. The Caspar Investigators, BelchJ . Effect of adding clopidogrel to aspirin on the success of below knee arterial bypass grafts. A randomised placebo controlled study. In: Vascular Annual Meeting; 2007 Jun; Baltimore, USA. 2007. ">CASPAR 2010</a>; <a href="./references#CD000535-bbs2-0006" title="DonaldsonDR , SalterMC , KesterRC , RajahSM , HallTJ , SreeharanN , et al. The influence of platelet inhibition on the patency of femoro-popliteal Dacron bypass grafts. Vascular Surgery1985;19(4):224-30. ">Donaldson 1985</a>; <a href="./references#CD000535-bbs2-0008" title="GoldmanM , McCollumC . A prospective randomized study to examine the effect of aspirin plus dipyridamole on the patency of prosthetic femoro-popliteal grafts. Vascular Surgery1984;18(4):217-21. ">Goldman 1984</a>; <a href="./references#CD000535-bbs2-0009" title="GreenRM , RoedersheimerRL , DeWeeseJA . Effects of aspirin and dipyridamole on expanded polytetrafluoethylene graft patency. Surgery1982;92(6):1016-26. ">Green 1982</a>; <a href="./references#CD000535-bbs2-0011" title="KohlerTR , KaufmanJL , KacoyanisG , ClowesA , DonaldsonMC , KellyE , et al. Effect of aspirin and dipyridamole on the patency of lower extremity bypass grafts. Surgery1984;96(3):462-6. ">Kohler 1984</a>; <a href="./references#CD000535-bbs2-0013" title="FranksPJ , SianM , KenchingtonGF , AlexanderCE , PowellJT . Aspirin usage and its influence on femoro-popliteal vein graft patency. European Journal of Vascular Surgery1992;6(2):185-8. FranksPJ , SianM , KenchingtonGF , AlexanderCE , PowellJT . Aspirin usage and its influence on femoropopliteal vein graft patency. In: European Society for Vascular Surgery 5th Annual Meeting, 25-27 September 1991; Warsaw, Poland. 1991. McCollumC , AlexanderC , KenchingtonG , FranksPJ , GreenhalghR . Antiplatelet drugs in femoropopliteal vein bypasses: A multicenter trial. Journal of Vascular Surgery1991;13(1):150-62. PowellJT , GreenhalghRM . Smoking and factors influencing the outcome of arterial reconstruction. Annales Chirurgiae et Gynaecologiae1992;81(2):236-41. ">McCollum 1991</a>). Six studies were unblinded, leading to a high risk of performance bias (<a href="./references#CD000535-bbs2-0002" title="AlgraA . A randomised trial of oral anticoagulants versus aspirin after infrainguinal bypass surgery. Tijdschrift voor Sociale Gezondheidszorg1999;77(4):11. AriesenMJ , TangelderMJD , LawsonJA , EikelboomBC , GrobbeeDE , AlgraA . Risk of major haemorrhage in patients after infrainguinal venous bypass surgery: Therapeutic consequences? The Dutch BOA (Bypass Oral Anticoagulants or Aspirin) study. European Journal of Vascular and Endovascular Surgery2005;30(2):154-9. Dutch Bypass Oral anticoagulants of Aspirin (BOA) Study Group. Efficacy of oral anticoagulants compared with aspirin after infrainguinal bypass surgery (The Dutch Bypass Oral anticoagulants or Aspirin study): a randomised trial. Lancet2000;355(9201):346-51. EikelboomBC . Prevention of occlusions after infrainguinal bypass surgery with oral anticoagulants or acetylsalicylic acid: A randomised trial. Nederlands Tijdschrift voor Geneeskunde2001;145(22):1060-7. OostenbrinkJB , TangelderMJ , BusschbachJJ , Van HoutBA , BuskensE , AlgraA , et al. Cost effectiveness of oral anticoagulants versus aspirin in patients after infrainguinal bypass grafting surgery. Journal of Vascular Surgery2001;34(2):254-62. SmeetsL , HoGH , TangelderMJ , AlgraA , LawsonJA , EikelboomBC , et al, Dutch BOA Study Group. Outcome after occlusion of infrainguinal bypasses in the Dutch BOA Study: comparison of amputation rate in venous and prosthetic grafts. European Journal of Vascular and Endovascular Surgery2005;30(6):604-9. TangelderMJ , AlgraA , LawsonJA , EikelboomBC . Risk factors for occlusion of infrainguinal bypass grafts. European Journal of Vascular and Endovascular Surgery2000;20(2):118-24. TangelderMJ , AlgraA , LawsonJA , HennekesS , EikelboomBC . Optimal oral anticoagulant intensity to prevent secondary ischemic and hemorrhagic events in patients after infrainguinal bypass graft surgery. Dutch BOA Study Group. Journal of Vascular Surgery2001;33(3):522-7. TangelderMJ , EikelboomBC , LawsonJA , AlgraA . Prevention of occlusion following peripheral bypass surgery using oral anticoagulants or acetylsalicylic acid: a randomized comparison within the Dutch BOA study [Preventi van occlusies na perifere bypass-chirurgie met orale anticoagulantia of acetylsalicylzuur: een gerandomiseerde vergelijking in het Nederlands BOA-onderzoek]. Nederlands Tijdschrift voor Geneeskunde1995;139(29):1504-6. TangelderMJ , McDonnelJ , Van BusschbachJJ , BuskensE , AlgraA , LawsonJA , EikelboomBC . Quality of life after infrainguinal bypass grafting surgery. Dutch Bypass Oral Anticoagulants or Aspirin (BOA) Study Group. Journal of Vascular Surgery1999;29(5):913-9. Van HattumES , AlgraA , LawsonJA , EikelboomBC , MollFL , TangelderMJD . Bleeding increases the risk of ischemic events in patients with peripheral arterial disease. Circulation2009;120(16):1569-76. Van HattumES , TangelderMJD , LawsonJA , MollFL , AlgraA . The quality of life in patients after peripheral bypass surgery deteriorates at long-term follow-up. Journal of Vascular Surgery2011;53(3):643-50. ">BOA 2000</a>; <a href="./references#CD000535-bbs2-0004" title="ClyneCA , ArcherTJ , AtuhaireLK , ChantAD , WebsterJH . Random control trial of a short course of aspirin and dipyridamole (Persantin) for femorodistal grafts. British Journal of Surgery1987;74(4):246-8. ">Clyne 1987</a>; <a href="./references#CD000535-bbs2-0007" title="EdmondsonRA , CohenAT , DasSK , WagnerBM , KakkarVV . Low-molecular weight heparin versus aspirin and dipyridamole after femoropopliteal bypass grafting. Lancet1994;344(8927):914-8. ">Edmondson 1994</a>; <a href="./references#CD000535-bbs2-0010" title="GrussJD , HiemerW , KroissA , GeisslerC . Experiences with adjuvant prostaglandin therapy in vascular surgery interventions. Vasa-Supplementum1991;33:353-4. ">Gruss 1991</a>; <a href="./references#CD000535-bbs2-0014" title="NoppeneyT , KasprzakP , RaithelD , HircheH . Naftidrofuryl in postoperative treatment after femoropopliteal bypass. Die Medizinische Welt1988;39:1545-50. ">Noppeney 1988</a>; <a href="./references#CD000535-bbs2-0015" title="RaithelD , KasprzakP , Noppeney Th. Relapse prophylaxis after femoropopliteal reconstruction with PTFE-prostheses. Die Medizinische Welt1986;37:664-7. RaithelD . Prevention of reocclusion after prosthetic bypass operations in the femoro-popliteal region: a comparative study of pentoxifylline versus acetylsalicylic acid. Vascular Surgery1987;21(3):208-14. ">Raithel 1987</a>). The remaining three studies mentioned blinding but did not adequately describe their methods (<a href="./references#CD000535-bbs2-0005" title="D'AddatoM , CurtiT , BertiniD , DoniniI , FerreroR , FioraniP , et al. Indobufen vs acetylsalicylic acid plus dipyridamole in long-term patency after femoropopliteal bypass. International Angiology1992;11(2):106-12. ">D'Addato 1992</a>; <a href="./references#CD000535-bbs2-0012" title="LucasMA . Prevention of post-operative thrombosis in peripheral arteriopathies. Pentoxifylline vs conventional antiaggregants: a six-month randomized follow-up study. Angiology1984;35(7):443-50. ">Lucas 1984</a>; <a href="./references#CD000535-bbs2-0016" title="SchneiderE , BrunnerU , BollingerA . No English title available [Medikamentose Rezidivprophylaxe nach femoro-poplitealer Arterienrekonstruktion]. Angio1979;2(1):73-7. ">Schneider 1979</a>), and are rated at unclear risk. </p> <p>Blinding of outcome assessors was only described in two studies (<a href="./references#CD000535-bbs2-0001" title="BecqueminJP . Effect of ticlopidine on the long-term patency of saphenous-vein bypass grafts in the legs. New England Journal of Medicine1997;337(24):1726-31. ">Becquemin 1997</a>; <a href="./references#CD000535-bbs2-0003" title="Anonymous. Clopidogrel and acetyl salicylic acid in bypass surgery for peripheral arterial disease. clinicaltrials.gov/ct2/show/NCT00174759?term=CASPAR&amp;rank=2 (accessed 5 May 2014). Anonymous. Dual antiplatelet therapy benefits prosthetic but not venous grafts. Vascular News2009;Feb:17. BelchJJ , DormandyJ . Results of the randomized, placebo-controlled clopidogrel and acetylsalicylic acid in bypass surgery for peripheral arterial disease (CASPAR) trial. Journal of Vascular Surgery2010;52(4):825-33. The Caspar Investigators, BelchJ . Effect of adding clopidogrel to aspirin on the success of below knee arterial bypass grafts. A randomised placebo controlled study. In: Vascular Annual Meeting; 2007 Jun; Baltimore, USA. 2007. ">CASPAR 2010</a>), while the remaining were at unclear risk of detection bias, with no description of assessor blinding. </p> </section> <section id="CD000535-sec-0053"> <h4 class="title">Incomplete outcome data</h4> <p>The majority of studies had no issues with attrition bias, but five studies were at unclear risk, with <a href="./references#CD000535-bbs2-0006" title="DonaldsonDR , SalterMC , KesterRC , RajahSM , HallTJ , SreeharanN , et al. The influence of platelet inhibition on the patency of femoro-popliteal Dacron bypass grafts. Vascular Surgery1985;19(4):224-30. ">Donaldson 1985</a> having a higher rate of drop‐outs in the intervention arm, <a href="./references#CD000535-bbs2-0010" title="GrussJD , HiemerW , KroissA , GeisslerC . Experiences with adjuvant prostaglandin therapy in vascular surgery interventions. Vasa-Supplementum1991;33:353-4. ">Gruss 1991</a> not reporting drop‐outs or withdrawals, <a href="./references#CD000535-bbs2-0011" title="KohlerTR , KaufmanJL , KacoyanisG , ClowesA , DonaldsonMC , KellyE , et al. Effect of aspirin and dipyridamole on the patency of lower extremity bypass grafts. Surgery1984;96(3):462-6. ">Kohler 1984</a> inconsistently reporting drop‐outs between treatment groups, <a href="./references#CD000535-bbs2-0015" title="RaithelD , KasprzakP , Noppeney Th. Relapse prophylaxis after femoropopliteal reconstruction with PTFE-prostheses. Die Medizinische Welt1986;37:664-7. RaithelD . Prevention of reocclusion after prosthetic bypass operations in the femoro-popliteal region: a comparative study of pentoxifylline versus acetylsalicylic acid. Vascular Surgery1987;21(3):208-14. ">Raithel 1987</a> only reporting participants available for follow‐up but not the number initially randomised, and <a href="./references#CD000535-bbs2-0016" title="SchneiderE , BrunnerU , BollingerA . No English title available [Medikamentose Rezidivprophylaxe nach femoro-poplitealer Arterienrekonstruktion]. Angio1979;2(1):73-7. ">Schneider 1979</a> not having enough information for us to adequately assess whether attrition bias was a problem. </p> </section> <section id="CD000535-sec-0054"> <h4 class="title">Selective reporting</h4> <p>Selective reporting was a concern in three studies, which we evaluated as 'unclear' (<a href="./references#CD000535-bbs2-0009" title="GreenRM , RoedersheimerRL , DeWeeseJA . Effects of aspirin and dipyridamole on expanded polytetrafluoethylene graft patency. Surgery1982;92(6):1016-26. ">Green 1982</a>; <a href="./references#CD000535-bbs2-0010" title="GrussJD , HiemerW , KroissA , GeisslerC . Experiences with adjuvant prostaglandin therapy in vascular surgery interventions. Vasa-Supplementum1991;33:353-4. ">Gruss 1991</a>; <a href="./references#CD000535-bbs2-0016" title="SchneiderE , BrunnerU , BollingerA . No English title available [Medikamentose Rezidivprophylaxe nach femoro-poplitealer Arterienrekonstruktion]. Angio1979;2(1):73-7. ">Schneider 1979</a>). For <a href="./references#CD000535-bbs2-0009" title="GreenRM , RoedersheimerRL , DeWeeseJA . Effects of aspirin and dipyridamole on expanded polytetrafluoethylene graft patency. Surgery1982;92(6):1016-26. ">Green 1982</a> adverse events were not clearly reported, and for both <a href="./references#CD000535-bbs2-0010" title="GrussJD , HiemerW , KroissA , GeisslerC . Experiences with adjuvant prostaglandin therapy in vascular surgery interventions. Vasa-Supplementum1991;33:353-4. ">Gruss 1991</a> and <a href="./references#CD000535-bbs2-0016" title="SchneiderE , BrunnerU , BollingerA . No English title available [Medikamentose Rezidivprophylaxe nach femoro-poplitealer Arterienrekonstruktion]. Angio1979;2(1):73-7. ">Schneider 1979</a> there was not enough information in the text to determine the risk of reporting bias. All remaining studies were at low risk of reporting bias. </p> </section> <section id="CD000535-sec-0055"> <h4 class="title">Other potential sources of bias</h4> <p>Other bias was a concern in five studies (<a href="./references#CD000535-bbs2-0004" title="ClyneCA , ArcherTJ , AtuhaireLK , ChantAD , WebsterJH . Random control trial of a short course of aspirin and dipyridamole (Persantin) for femorodistal grafts. British Journal of Surgery1987;74(4):246-8. ">Clyne 1987</a>; <a href="./references#CD000535-bbs2-0006" title="DonaldsonDR , SalterMC , KesterRC , RajahSM , HallTJ , SreeharanN , et al. The influence of platelet inhibition on the patency of femoro-popliteal Dacron bypass grafts. Vascular Surgery1985;19(4):224-30. ">Donaldson 1985</a>; <a href="./references#CD000535-bbs2-0008" title="GoldmanM , McCollumC . A prospective randomized study to examine the effect of aspirin plus dipyridamole on the patency of prosthetic femoro-popliteal grafts. Vascular Surgery1984;18(4):217-21. ">Goldman 1984</a>; <a href="./references#CD000535-bbs2-0013" title="FranksPJ , SianM , KenchingtonGF , AlexanderCE , PowellJT . Aspirin usage and its influence on femoro-popliteal vein graft patency. European Journal of Vascular Surgery1992;6(2):185-8. FranksPJ , SianM , KenchingtonGF , AlexanderCE , PowellJT . Aspirin usage and its influence on femoropopliteal vein graft patency. In: European Society for Vascular Surgery 5th Annual Meeting, 25-27 September 1991; Warsaw, Poland. 1991. McCollumC , AlexanderC , KenchingtonG , FranksPJ , GreenhalghR . Antiplatelet drugs in femoropopliteal vein bypasses: A multicenter trial. Journal of Vascular Surgery1991;13(1):150-62. PowellJT , GreenhalghRM . Smoking and factors influencing the outcome of arterial reconstruction. Annales Chirurgiae et Gynaecologiae1992;81(2):236-41. ">McCollum 1991</a>; <a href="./references#CD000535-bbs2-0015" title="RaithelD , KasprzakP , Noppeney Th. Relapse prophylaxis after femoropopliteal reconstruction with PTFE-prostheses. Die Medizinische Welt1986;37:664-7. RaithelD . Prevention of reocclusion after prosthetic bypass operations in the femoro-popliteal region: a comparative study of pentoxifylline versus acetylsalicylic acid. Vascular Surgery1987;21(3):208-14. ">Raithel 1987</a>), with the rest at low risk of other bias. For <a href="./references#CD000535-bbs2-0004" title="ClyneCA , ArcherTJ , AtuhaireLK , ChantAD , WebsterJH . Random control trial of a short course of aspirin and dipyridamole (Persantin) for femorodistal grafts. British Journal of Surgery1987;74(4):246-8. ">Clyne 1987</a> and <a href="./references#CD000535-bbs2-0006" title="DonaldsonDR , SalterMC , KesterRC , RajahSM , HallTJ , SreeharanN , et al. The influence of platelet inhibition on the patency of femoro-popliteal Dacron bypass grafts. Vascular Surgery1985;19(4):224-30. ">Donaldson 1985</a> all the data were presented by number of bypasses and not by the number of participants. <a href="./references#CD000535-bbs2-0008" title="GoldmanM , McCollumC . A prospective randomized study to examine the effect of aspirin plus dipyridamole on the patency of prosthetic femoro-popliteal grafts. Vascular Surgery1984;18(4):217-21. ">Goldman 1984</a>, <a href="./references#CD000535-bbs2-0013" title="FranksPJ , SianM , KenchingtonGF , AlexanderCE , PowellJT . Aspirin usage and its influence on femoro-popliteal vein graft patency. European Journal of Vascular Surgery1992;6(2):185-8. FranksPJ , SianM , KenchingtonGF , AlexanderCE , PowellJT . Aspirin usage and its influence on femoropopliteal vein graft patency. In: European Society for Vascular Surgery 5th Annual Meeting, 25-27 September 1991; Warsaw, Poland. 1991. McCollumC , AlexanderC , KenchingtonG , FranksPJ , GreenhalghR . Antiplatelet drugs in femoropopliteal vein bypasses: A multicenter trial. Journal of Vascular Surgery1991;13(1):150-62. PowellJT , GreenhalghRM . Smoking and factors influencing the outcome of arterial reconstruction. Annales Chirurgiae et Gynaecologiae1992;81(2):236-41. ">McCollum 1991</a>, and <a href="./references#CD000535-bbs2-0015" title="RaithelD , KasprzakP , Noppeney Th. Relapse prophylaxis after femoropopliteal reconstruction with PTFE-prostheses. Die Medizinische Welt1986;37:664-7. RaithelD . Prevention of reocclusion after prosthetic bypass operations in the femoro-popliteal region: a comparative study of pentoxifylline versus acetylsalicylic acid. Vascular Surgery1987;21(3):208-14. ">Raithel 1987</a> had differences in the treatment groups at baseline, and <a href="./references#CD000535-bbs2-0013" title="FranksPJ , SianM , KenchingtonGF , AlexanderCE , PowellJT . Aspirin usage and its influence on femoro-popliteal vein graft patency. European Journal of Vascular Surgery1992;6(2):185-8. FranksPJ , SianM , KenchingtonGF , AlexanderCE , PowellJT . Aspirin usage and its influence on femoropopliteal vein graft patency. In: European Society for Vascular Surgery 5th Annual Meeting, 25-27 September 1991; Warsaw, Poland. 1991. McCollumC , AlexanderC , KenchingtonG , FranksPJ , GreenhalghR . Antiplatelet drugs in femoropopliteal vein bypasses: A multicenter trial. Journal of Vascular Surgery1991;13(1):150-62. PowellJT , GreenhalghRM . Smoking and factors influencing the outcome of arterial reconstruction. Annales Chirurgiae et Gynaecologiae1992;81(2):236-41. ">McCollum 1991</a> may be at risk of being underpowered, as the study power calculation required a study population of 800 participants to detect a 10% reduction in occlusion rate, but only 549 participants were randomised. </p> </section> </section> <section id="CD000535-sec-0056"> <h3 class="title" id="CD000535-sec-0056">Effects of interventions</h3> <p>For the outcome 'primary patency' the numbers recorded for analyses were actually the number of grafts that occluded during the specified time period as reported by the trialists. We used these numbers due to the properties of odds ratios (ORs), and we found this method more straightforward to interpret. Both patency and occlusion are used to describe the treatment outcomes within the included studies and within this review, which should be kept in mind when interpreting the presented data. </p> <p>Analysis for secondary graft patency, side effects of treatment and complications, limb amputation, cardiovascular events and mortality are only described when sufficient data were available. Otherwise, these outcomes are not mentioned. </p> <p>None of the included studies reported on assisted primary patency, objective assessment of lower limb blood flow or participant quality of life. </p> <p>None of the meta‐analyses included 10 or more studies, so we could not construct funnel plots to evaluate possible publication bias. </p> <section id="CD000535-sec-0057"> <h4 class="title">Aspirin (ASA) or aspirin and dipyridamole (ASA/DIP) versus nothing or placebo</h4> <section id="CD000535-sec-0058"> <h5 class="title">Primary graft patency</h5> <p>The effect of ASA or ASA/DIP on infrainguinal bypass patency was assessed in six trials (<a href="./references#CD000535-bbs2-0004" title="ClyneCA , ArcherTJ , AtuhaireLK , ChantAD , WebsterJH . Random control trial of a short course of aspirin and dipyridamole (Persantin) for femorodistal grafts. British Journal of Surgery1987;74(4):246-8. ">Clyne 1987</a>; <a href="./references#CD000535-bbs2-0006" title="DonaldsonDR , SalterMC , KesterRC , RajahSM , HallTJ , SreeharanN , et al. The influence of platelet inhibition on the patency of femoro-popliteal Dacron bypass grafts. Vascular Surgery1985;19(4):224-30. ">Donaldson 1985</a>; <a href="./references#CD000535-bbs2-0008" title="GoldmanM , McCollumC . A prospective randomized study to examine the effect of aspirin plus dipyridamole on the patency of prosthetic femoro-popliteal grafts. Vascular Surgery1984;18(4):217-21. ">Goldman 1984</a>; <a href="./references#CD000535-bbs2-0009" title="GreenRM , RoedersheimerRL , DeWeeseJA . Effects of aspirin and dipyridamole on expanded polytetrafluoethylene graft patency. Surgery1982;92(6):1016-26. ">Green 1982</a>; <a href="./references#CD000535-bbs2-0011" title="KohlerTR , KaufmanJL , KacoyanisG , ClowesA , DonaldsonMC , KellyE , et al. Effect of aspirin and dipyridamole on the patency of lower extremity bypass grafts. Surgery1984;96(3):462-6. ">Kohler 1984</a>; <a href="./references#CD000535-bbs2-0013" title="FranksPJ , SianM , KenchingtonGF , AlexanderCE , PowellJT . Aspirin usage and its influence on femoro-popliteal vein graft patency. European Journal of Vascular Surgery1992;6(2):185-8. FranksPJ , SianM , KenchingtonGF , AlexanderCE , PowellJT . Aspirin usage and its influence on femoropopliteal vein graft patency. In: European Society for Vascular Surgery 5th Annual Meeting, 25-27 September 1991; Warsaw, Poland. 1991. McCollumC , AlexanderC , KenchingtonG , FranksPJ , GreenhalghR . Antiplatelet drugs in femoropopliteal vein bypasses: A multicenter trial. Journal of Vascular Surgery1991;13(1):150-62. PowellJT , GreenhalghRM . Smoking and factors influencing the outcome of arterial reconstruction. Annales Chirurgiae et Gynaecologiae1992;81(2):236-41. ">McCollum 1991</a>). The OR from the random‐effects model for primary occlusion at 12 months for all grafts was 0.42 (95% confidence interval (CI) 0.22 to 0.83; P = 0.01, I² = 72%, participants = 952), showing a positive effect of ASA on infrainguinal grafts at one year (<a href="./references#CD000535-fig-0004" title="">Analysis 1.1</a>).<br/>Three of these studies had unit of analysis issues, with multiple grafts or re‐randomisation of participants (<a href="./references#CD000535-bbs2-0004" title="ClyneCA , ArcherTJ , AtuhaireLK , ChantAD , WebsterJH . Random control trial of a short course of aspirin and dipyridamole (Persantin) for femorodistal grafts. British Journal of Surgery1987;74(4):246-8. ">Clyne 1987</a>; <a href="./references#CD000535-bbs2-0006" title="DonaldsonDR , SalterMC , KesterRC , RajahSM , HallTJ , SreeharanN , et al. The influence of platelet inhibition on the patency of femoro-popliteal Dacron bypass grafts. Vascular Surgery1985;19(4):224-30. ">Donaldson 1985</a>; <a href="./references#CD000535-bbs2-0011" title="KohlerTR , KaufmanJL , KacoyanisG , ClowesA , DonaldsonMC , KellyE , et al. Effect of aspirin and dipyridamole on the patency of lower extremity bypass grafts. Surgery1984;96(3):462-6. ">Kohler 1984</a>). The association becomes attenuated when these studies are excluded (OR 0.36, 95% CI 0.13 to 0.99; P = 0.05, participants = 651). </p> <p>When we performed the analysis for venous grafts alone, there was no difference in primary graft patency between the treatment groups at one, three and six months (OR 0.76, 95% CI 0.26 to 2.25, P = 0.62; OR 0.85, 95% CI 0.54 to 1.35, P = 0.50; and OR 0.88, 95% CI 0.59 to 1.31; P = 0.53, respectively, participants = 642 for all) (all fixed‐effect analyses) (<a href="./references#CD000535-fig-0009" title="">Analysis 2.1</a>; <a href="./references#CD000535-fig-0010" title="">Analysis 2.2</a>; <a href="./references#CD000535-fig-0011" title="">Analysis 2.3</a>). At 12 months post‐operation there was a possible increase in occlusion in the control group (OR 0.69, 95% CI 0.48 to 0.99; P = 0.05, participants = 642) (fixed‐effect), but this was not seen at 24 months in the random‐effects model analysis, (OR 1.03; 95% CI 0.32 to 3.28; P = 0.96, I² = 79%, participants = 620) (<a href="./references#CD000535-fig-0012" title="">Analysis 2.4</a>; <a href="./references#CD000535-fig-0013" title="">Analysis 2.5</a>). </p> <p>Analysis for prosthetic grafts, however, showed a much stronger positive effect of ASA on primary patency as calculated from four studies (<a href="./references#CD000535-bbs2-0004" title="ClyneCA , ArcherTJ , AtuhaireLK , ChantAD , WebsterJH . Random control trial of a short course of aspirin and dipyridamole (Persantin) for femorodistal grafts. British Journal of Surgery1987;74(4):246-8. ">Clyne 1987</a>; <a href="./references#CD000535-bbs2-0006" title="DonaldsonDR , SalterMC , KesterRC , RajahSM , HallTJ , SreeharanN , et al. The influence of platelet inhibition on the patency of femoro-popliteal Dacron bypass grafts. Vascular Surgery1985;19(4):224-30. ">Donaldson 1985</a>; <a href="./references#CD000535-bbs2-0008" title="GoldmanM , McCollumC . A prospective randomized study to examine the effect of aspirin plus dipyridamole on the patency of prosthetic femoro-popliteal grafts. Vascular Surgery1984;18(4):217-21. ">Goldman 1984</a>; <a href="./references#CD000535-bbs2-0009" title="GreenRM , RoedersheimerRL , DeWeeseJA . Effects of aspirin and dipyridamole on expanded polytetrafluoethylene graft patency. Surgery1982;92(6):1016-26. ">Green 1982</a>): ORs of 0.14 (95% CI 0.04 to 0.51; P = 0.003, participants = 157) at one month; 0.31 (95% CI 0.14 to 0.66; P = 0.003, participants = 222) at three months; 0.21 (95% CI 0.11 to 0.41; P &lt; 0.00001, participants = 222) at six months; and 0.19 (95% CI 0.10 to 0.36, participants = 222) at 12 months (<a href="./references#CD000535-fig-0014" title="">Analysis 2.6</a>; <a href="./references#CD000535-fig-0015" title="">Analysis 2.7</a>; <a href="./references#CD000535-fig-0016" title="">Analysis 2.8</a>; <a href="./references#CD000535-fig-0018" title="">Analysis 2.10</a>). Primary patency at nine months was only evaluated in a single study, with an OR of 0.17 (95% CI 0.04 to 0.67, participants = 65) (<a href="./references#CD000535-fig-0017" title="">Analysis 2.9</a>). </p> <p>Removal of the trials associated with unit of analysis issues meant that we could not conduct data analysis for venous grafts at one, three, six,12, and 24 months as only one study remained. For prosthetic grafts, the OR was 0.25 (95% CI 0.05 to 1.30; P = 0.10, participants = 102) at one month; 0.30 (95% CI 0.09 to 1.01; P = 0.05, participants = 102) at three months; 0.31 (95% CI 0.13 to 0.74; P = 0.008, participants = 102) at six months; and 0.23 (95% CI 0.10 to 0.54; P = 0.0008, participants = 102) at 12 months, all fixed‐effect models. For all comparisons the overall effect was reduced, and for months one and three the association no longer favoured ASA or ASA/DIP<b>.</b> </p> </section> <section id="CD000535-sec-0059"> <h5 class="title">Secondary graft patency</h5> <p><a href="./references#CD000535-bbs2-0013" title="FranksPJ , SianM , KenchingtonGF , AlexanderCE , PowellJT . Aspirin usage and its influence on femoro-popliteal vein graft patency. European Journal of Vascular Surgery1992;6(2):185-8. FranksPJ , SianM , KenchingtonGF , AlexanderCE , PowellJT . Aspirin usage and its influence on femoropopliteal vein graft patency. In: European Society for Vascular Surgery 5th Annual Meeting, 25-27 September 1991; Warsaw, Poland. 1991. McCollumC , AlexanderC , KenchingtonG , FranksPJ , GreenhalghR . Antiplatelet drugs in femoropopliteal vein bypasses: A multicenter trial. Journal of Vascular Surgery1991;13(1):150-62. PowellJT , GreenhalghRM . Smoking and factors influencing the outcome of arterial reconstruction. Annales Chirurgiae et Gynaecologiae1992;81(2):236-41. ">McCollum 1991</a> reported on secondary patency of the failed grafts, but the time frame of the reported cases is unclear. The study reported that of the 172 failed grafts (86 in each treatment group), eight in the ASA/DIP group and four in the placebo group were restored by re‐operation but it is unclear if all failed grafts were re‐operated. <a href="./references#CD000535-bbs2-0013" title="FranksPJ , SianM , KenchingtonGF , AlexanderCE , PowellJT . Aspirin usage and its influence on femoro-popliteal vein graft patency. European Journal of Vascular Surgery1992;6(2):185-8. FranksPJ , SianM , KenchingtonGF , AlexanderCE , PowellJT . Aspirin usage and its influence on femoropopliteal vein graft patency. In: European Society for Vascular Surgery 5th Annual Meeting, 25-27 September 1991; Warsaw, Poland. 1991. McCollumC , AlexanderC , KenchingtonG , FranksPJ , GreenhalghR . Antiplatelet drugs in femoropopliteal vein bypasses: A multicenter trial. Journal of Vascular Surgery1991;13(1):150-62. PowellJT , GreenhalghRM . Smoking and factors influencing the outcome of arterial reconstruction. Annales Chirurgiae et Gynaecologiae1992;81(2):236-41. ">McCollum 1991</a> also reported that the cumulative secondary patency rate for the ASA/DIP group was 80% at one year, 73% at two years and 63% at three years, and 74%, 64% and 61% respectively for the placebo group. Because the number of participants that were included to derive these values was unclear, we cannot use them in meta‐analysis. </p> </section> <section id="CD000535-sec-0060"> <h5 class="title">Side effects of treatment and complications</h5> <p>Side effects were reported in five studies (<a href="./references#CD000535-bbs2-0004" title="ClyneCA , ArcherTJ , AtuhaireLK , ChantAD , WebsterJH . Random control trial of a short course of aspirin and dipyridamole (Persantin) for femorodistal grafts. British Journal of Surgery1987;74(4):246-8. ">Clyne 1987</a>; <a href="./references#CD000535-bbs2-0006" title="DonaldsonDR , SalterMC , KesterRC , RajahSM , HallTJ , SreeharanN , et al. The influence of platelet inhibition on the patency of femoro-popliteal Dacron bypass grafts. Vascular Surgery1985;19(4):224-30. ">Donaldson 1985</a>; <a href="./references#CD000535-bbs2-0009" title="GreenRM , RoedersheimerRL , DeWeeseJA . Effects of aspirin and dipyridamole on expanded polytetrafluoethylene graft patency. Surgery1982;92(6):1016-26. ">Green 1982</a>; <a href="./references#CD000535-bbs2-0011" title="KohlerTR , KaufmanJL , KacoyanisG , ClowesA , DonaldsonMC , KellyE , et al. Effect of aspirin and dipyridamole on the patency of lower extremity bypass grafts. Surgery1984;96(3):462-6. ">Kohler 1984</a>; <a href="./references#CD000535-bbs2-0013" title="FranksPJ , SianM , KenchingtonGF , AlexanderCE , PowellJT . Aspirin usage and its influence on femoro-popliteal vein graft patency. European Journal of Vascular Surgery1992;6(2):185-8. FranksPJ , SianM , KenchingtonGF , AlexanderCE , PowellJT . Aspirin usage and its influence on femoropopliteal vein graft patency. In: European Society for Vascular Surgery 5th Annual Meeting, 25-27 September 1991; Warsaw, Poland. 1991. McCollumC , AlexanderC , KenchingtonG , FranksPJ , GreenhalghR . Antiplatelet drugs in femoropopliteal vein bypasses: A multicenter trial. Journal of Vascular Surgery1991;13(1):150-62. PowellJT , GreenhalghRM . Smoking and factors influencing the outcome of arterial reconstruction. Annales Chirurgiae et Gynaecologiae1992;81(2):236-41. ">McCollum 1991</a>) and the fixed‐effect model found an OR of 1.55 (95% CI 1.00 to 2.41; P = 0.05, participants = 913) for general side effects (<a href="./references#CD000535-fig-0005" title="">Analysis 1.2</a>). However, when <a href="./references#CD000535-bbs2-0004" title="ClyneCA , ArcherTJ , AtuhaireLK , ChantAD , WebsterJH . Random control trial of a short course of aspirin and dipyridamole (Persantin) for femorodistal grafts. British Journal of Surgery1987;74(4):246-8. ">Clyne 1987</a>, <a href="./references#CD000535-bbs2-0006" title="DonaldsonDR , SalterMC , KesterRC , RajahSM , HallTJ , SreeharanN , et al. The influence of platelet inhibition on the patency of femoro-popliteal Dacron bypass grafts. Vascular Surgery1985;19(4):224-30. ">Donaldson 1985</a> and <a href="./references#CD000535-bbs2-0011" title="KohlerTR , KaufmanJL , KacoyanisG , ClowesA , DonaldsonMC , KellyE , et al. Effect of aspirin and dipyridamole on the patency of lower extremity bypass grafts. Surgery1984;96(3):462-6. ">Kohler 1984</a> were removed due to unit of analysis issues the association was attenuated with an OR of 1.34 (95% CI 0.83 to 2.16; P = 0.23, participants = 598). Six studies evaluated side effects specific to the gastrointestinal tract (<a href="./references#CD000535-bbs2-0004" title="ClyneCA , ArcherTJ , AtuhaireLK , ChantAD , WebsterJH . Random control trial of a short course of aspirin and dipyridamole (Persantin) for femorodistal grafts. British Journal of Surgery1987;74(4):246-8. ">Clyne 1987</a>; <a href="./references#CD000535-bbs2-0006" title="DonaldsonDR , SalterMC , KesterRC , RajahSM , HallTJ , SreeharanN , et al. The influence of platelet inhibition on the patency of femoro-popliteal Dacron bypass grafts. Vascular Surgery1985;19(4):224-30. ">Donaldson 1985</a>; <a href="./references#CD000535-bbs2-0008" title="GoldmanM , McCollumC . A prospective randomized study to examine the effect of aspirin plus dipyridamole on the patency of prosthetic femoro-popliteal grafts. Vascular Surgery1984;18(4):217-21. ">Goldman 1984</a>; <a href="./references#CD000535-bbs2-0009" title="GreenRM , RoedersheimerRL , DeWeeseJA . Effects of aspirin and dipyridamole on expanded polytetrafluoethylene graft patency. Surgery1982;92(6):1016-26. ">Green 1982</a>; <a href="./references#CD000535-bbs2-0011" title="KohlerTR , KaufmanJL , KacoyanisG , ClowesA , DonaldsonMC , KellyE , et al. Effect of aspirin and dipyridamole on the patency of lower extremity bypass grafts. Surgery1984;96(3):462-6. ">Kohler 1984</a>; <a href="./references#CD000535-bbs2-0013" title="FranksPJ , SianM , KenchingtonGF , AlexanderCE , PowellJT . Aspirin usage and its influence on femoro-popliteal vein graft patency. European Journal of Vascular Surgery1992;6(2):185-8. FranksPJ , SianM , KenchingtonGF , AlexanderCE , PowellJT . Aspirin usage and its influence on femoropopliteal vein graft patency. In: European Society for Vascular Surgery 5th Annual Meeting, 25-27 September 1991; Warsaw, Poland. 1991. McCollumC , AlexanderC , KenchingtonG , FranksPJ , GreenhalghR . Antiplatelet drugs in femoropopliteal vein bypasses: A multicenter trial. Journal of Vascular Surgery1991;13(1):150-62. PowellJT , GreenhalghRM . Smoking and factors influencing the outcome of arterial reconstruction. Annales Chirurgiae et Gynaecologiae1992;81(2):236-41. ">McCollum 1991</a>), and found no differences between the two treatment groups (OR 1.44, 95% CI 0.92 to 2.24; P = 0.11, participants = 952) in the fixed‐effect model. When <a href="./references#CD000535-bbs2-0004" title="ClyneCA , ArcherTJ , AtuhaireLK , ChantAD , WebsterJH . Random control trial of a short course of aspirin and dipyridamole (Persantin) for femorodistal grafts. British Journal of Surgery1987;74(4):246-8. ">Clyne 1987</a><a href="./references#CD000535-bbs2-0006" title="DonaldsonDR , SalterMC , KesterRC , RajahSM , HallTJ , SreeharanN , et al. The influence of platelet inhibition on the patency of femoro-popliteal Dacron bypass grafts. Vascular Surgery1985;19(4):224-30. ">Donaldson 1985</a> and <a href="./references#CD000535-bbs2-0011" title="KohlerTR , KaufmanJL , KacoyanisG , ClowesA , DonaldsonMC , KellyE , et al. Effect of aspirin and dipyridamole on the patency of lower extremity bypass grafts. Surgery1984;96(3):462-6. ">Kohler 1984</a> were removed due to unit of analysis issues there was very little change in the outcome (OR 1.38, 95% CI 0.87 to 2.21; P = 0.17, participants = 651). </p> <p>Major bleeding was similar between the treatment groups for two trials (<a href="./references#CD000535-bbs2-0009" title="GreenRM , RoedersheimerRL , DeWeeseJA . Effects of aspirin and dipyridamole on expanded polytetrafluoethylene graft patency. Surgery1982;92(6):1016-26. ">Green 1982</a>; <a href="./references#CD000535-bbs2-0013" title="FranksPJ , SianM , KenchingtonGF , AlexanderCE , PowellJT . Aspirin usage and its influence on femoro-popliteal vein graft patency. European Journal of Vascular Surgery1992;6(2):185-8. FranksPJ , SianM , KenchingtonGF , AlexanderCE , PowellJT . Aspirin usage and its influence on femoropopliteal vein graft patency. In: European Society for Vascular Surgery 5th Annual Meeting, 25-27 September 1991; Warsaw, Poland. 1991. McCollumC , AlexanderC , KenchingtonG , FranksPJ , GreenhalghR . Antiplatelet drugs in femoropopliteal vein bypasses: A multicenter trial. Journal of Vascular Surgery1991;13(1):150-62. PowellJT , GreenhalghRM . Smoking and factors influencing the outcome of arterial reconstruction. Annales Chirurgiae et Gynaecologiae1992;81(2):236-41. ">McCollum 1991</a>) (OR 1.88, 95% CI 0.85 to 4.16; P = 0.12, participants = 598) in the fixed‐effect model. Minor bleeding was only evaluated in one study (<a href="./references#CD000535-bbs2-0004" title="ClyneCA , ArcherTJ , AtuhaireLK , ChantAD , WebsterJH . Random control trial of a short course of aspirin and dipyridamole (Persantin) for femorodistal grafts. British Journal of Surgery1987;74(4):246-8. ">Clyne 1987</a>), with an OR of 0.73 (95% CI 0.31 to 1.70, participants = 148). Wound or graft infection was only evaluated in <a href="./references#CD000535-bbs2-0013" title="FranksPJ , SianM , KenchingtonGF , AlexanderCE , PowellJT . Aspirin usage and its influence on femoro-popliteal vein graft patency. European Journal of Vascular Surgery1992;6(2):185-8. FranksPJ , SianM , KenchingtonGF , AlexanderCE , PowellJT . Aspirin usage and its influence on femoropopliteal vein graft patency. In: European Society for Vascular Surgery 5th Annual Meeting, 25-27 September 1991; Warsaw, Poland. 1991. McCollumC , AlexanderC , KenchingtonG , FranksPJ , GreenhalghR . Antiplatelet drugs in femoropopliteal vein bypasses: A multicenter trial. Journal of Vascular Surgery1991;13(1):150-62. PowellJT , GreenhalghRM . Smoking and factors influencing the outcome of arterial reconstruction. Annales Chirurgiae et Gynaecologiae1992;81(2):236-41. ">McCollum 1991</a>, with similar events in both treatment groups (OR 1.07, 95% CI 0.67 to 1.71, participants = 549). </p> </section> <section id="CD000535-sec-0061"> <h5 class="title">Limb amputation</h5> <p><a href="./references#CD000535-bbs2-0004" title="ClyneCA , ArcherTJ , AtuhaireLK , ChantAD , WebsterJH . Random control trial of a short course of aspirin and dipyridamole (Persantin) for femorodistal grafts. British Journal of Surgery1987;74(4):246-8. ">Clyne 1987</a> reported amputations with an OR of 0.55 (95% CI 0.21 to 1.44, grafts = 148), but it should be noted this was one of the studies with multiple grafts in some of the participants (148 grafts in 140 participants) (<a href="./references#CD000535-fig-0006" title="">Analysis 1.3</a>). </p> </section> <section id="CD000535-sec-0062"> <h5 class="title">Cardiovascular events and mortality</h5> <p>Analysis of cardiovascular events was performed in four trials (<a href="./references#CD000535-bbs2-0004" title="ClyneCA , ArcherTJ , AtuhaireLK , ChantAD , WebsterJH . Random control trial of a short course of aspirin and dipyridamole (Persantin) for femorodistal grafts. British Journal of Surgery1987;74(4):246-8. ">Clyne 1987</a>; <a href="./references#CD000535-bbs2-0006" title="DonaldsonDR , SalterMC , KesterRC , RajahSM , HallTJ , SreeharanN , et al. The influence of platelet inhibition on the patency of femoro-popliteal Dacron bypass grafts. Vascular Surgery1985;19(4):224-30. ">Donaldson 1985</a>; <a href="./references#CD000535-bbs2-0009" title="GreenRM , RoedersheimerRL , DeWeeseJA . Effects of aspirin and dipyridamole on expanded polytetrafluoethylene graft patency. Surgery1982;92(6):1016-26. ">Green 1982</a>; <a href="./references#CD000535-bbs2-0013" title="FranksPJ , SianM , KenchingtonGF , AlexanderCE , PowellJT . Aspirin usage and its influence on femoro-popliteal vein graft patency. European Journal of Vascular Surgery1992;6(2):185-8. FranksPJ , SianM , KenchingtonGF , AlexanderCE , PowellJT . Aspirin usage and its influence on femoropopliteal vein graft patency. In: European Society for Vascular Surgery 5th Annual Meeting, 25-27 September 1991; Warsaw, Poland. 1991. McCollumC , AlexanderC , KenchingtonG , FranksPJ , GreenhalghR . Antiplatelet drugs in femoropopliteal vein bypasses: A multicenter trial. Journal of Vascular Surgery1991;13(1):150-62. PowellJT , GreenhalghRM . Smoking and factors influencing the outcome of arterial reconstruction. Annales Chirurgiae et Gynaecologiae1992;81(2):236-41. ">McCollum 1991</a>) and the random‐effects model found an OR of 1.27 (95% CI 0.43 to 3.80; P = 0.66, I² = 52%, participants = 811) (<a href="./references#CD000535-fig-0007" title="">Analysis 1.4</a>). When <a href="./references#CD000535-bbs2-0004" title="ClyneCA , ArcherTJ , AtuhaireLK , ChantAD , WebsterJH . Random control trial of a short course of aspirin and dipyridamole (Persantin) for femorodistal grafts. British Journal of Surgery1987;74(4):246-8. ">Clyne 1987</a> and <a href="./references#CD000535-bbs2-0006" title="DonaldsonDR , SalterMC , KesterRC , RajahSM , HallTJ , SreeharanN , et al. The influence of platelet inhibition on the patency of femoro-popliteal Dacron bypass grafts. Vascular Surgery1985;19(4):224-30. ">Donaldson 1985</a> were removed for unit of analysis issues, the association was statistically significant, in favour of ASA or ASA/DIP (OR 0.58, 95% CI 0.37 to 0.91; P = 0.02, participants = 598), although it should be noted that <a href="./references#CD000535-bbs2-0013" title="FranksPJ , SianM , KenchingtonGF , AlexanderCE , PowellJT . Aspirin usage and its influence on femoro-popliteal vein graft patency. European Journal of Vascular Surgery1992;6(2):185-8. FranksPJ , SianM , KenchingtonGF , AlexanderCE , PowellJT . Aspirin usage and its influence on femoropopliteal vein graft patency. In: European Society for Vascular Surgery 5th Annual Meeting, 25-27 September 1991; Warsaw, Poland. 1991. McCollumC , AlexanderC , KenchingtonG , FranksPJ , GreenhalghR . Antiplatelet drugs in femoropopliteal vein bypasses: A multicenter trial. Journal of Vascular Surgery1991;13(1):150-62. PowellJT , GreenhalghRM . Smoking and factors influencing the outcome of arterial reconstruction. Annales Chirurgiae et Gynaecologiae1992;81(2):236-41. ">McCollum 1991</a> then comprises 96% of the analysis. </p> <p>The OR for postoperative death for the fixed‐effect model, as evaluated in four studies (<a href="./references#CD000535-bbs2-0004" title="ClyneCA , ArcherTJ , AtuhaireLK , ChantAD , WebsterJH . Random control trial of a short course of aspirin and dipyridamole (Persantin) for femorodistal grafts. British Journal of Surgery1987;74(4):246-8. ">Clyne 1987</a>; <a href="./references#CD000535-bbs2-0008" title="GoldmanM , McCollumC . A prospective randomized study to examine the effect of aspirin plus dipyridamole on the patency of prosthetic femoro-popliteal grafts. Vascular Surgery1984;18(4):217-21. ">Goldman 1984</a>; <a href="./references#CD000535-bbs2-0009" title="GreenRM , RoedersheimerRL , DeWeeseJA . Effects of aspirin and dipyridamole on expanded polytetrafluoethylene graft patency. Surgery1982;92(6):1016-26. ">Green 1982</a>; <a href="./references#CD000535-bbs2-0013" title="FranksPJ , SianM , KenchingtonGF , AlexanderCE , PowellJT . Aspirin usage and its influence on femoro-popliteal vein graft patency. European Journal of Vascular Surgery1992;6(2):185-8. FranksPJ , SianM , KenchingtonGF , AlexanderCE , PowellJT . Aspirin usage and its influence on femoropopliteal vein graft patency. In: European Society for Vascular Surgery 5th Annual Meeting, 25-27 September 1991; Warsaw, Poland. 1991. McCollumC , AlexanderC , KenchingtonG , FranksPJ , GreenhalghR . Antiplatelet drugs in femoropopliteal vein bypasses: A multicenter trial. Journal of Vascular Surgery1991;13(1):150-62. PowellJT , GreenhalghRM . Smoking and factors influencing the outcome of arterial reconstruction. Annales Chirurgiae et Gynaecologiae1992;81(2):236-41. ">McCollum 1991</a>) was 0.84 (95% CI 0.56 to 1.26; P = 0.41, participants = 799) (<a href="./references#CD000535-fig-0008" title="">Analysis 1.5</a>). When <a href="./references#CD000535-bbs2-0004" title="ClyneCA , ArcherTJ , AtuhaireLK , ChantAD , WebsterJH . Random control trial of a short course of aspirin and dipyridamole (Persantin) for femorodistal grafts. British Journal of Surgery1987;74(4):246-8. ">Clyne 1987</a> was removed for sensitivity analysis due to unit of analysis issues the resulting OR was 0.77 (95% CI 0.49 to 1.21; P = 0.26, participants = 651). Again <a href="./references#CD000535-bbs2-0013" title="FranksPJ , SianM , KenchingtonGF , AlexanderCE , PowellJT . Aspirin usage and its influence on femoro-popliteal vein graft patency. European Journal of Vascular Surgery1992;6(2):185-8. FranksPJ , SianM , KenchingtonGF , AlexanderCE , PowellJT . Aspirin usage and its influence on femoropopliteal vein graft patency. In: European Society for Vascular Surgery 5th Annual Meeting, 25-27 September 1991; Warsaw, Poland. 1991. McCollumC , AlexanderC , KenchingtonG , FranksPJ , GreenhalghR . Antiplatelet drugs in femoropopliteal vein bypasses: A multicenter trial. Journal of Vascular Surgery1991;13(1):150-62. PowellJT , GreenhalghRM . Smoking and factors influencing the outcome of arterial reconstruction. Annales Chirurgiae et Gynaecologiae1992;81(2):236-41. ">McCollum 1991</a> accounted for a large majority of the weight. </p> </section> </section> <section id="CD000535-sec-0063"> <h4 class="title">Aspirin (ASA) or aspirin and dipyridamole (ASA/DIP) versus pentoxifylline (PTX)</h4> <section id="CD000535-sec-0064"> <h5 class="title">Primary graft patency</h5> <p>The effect of PTX on graft patency when compared to ASA or ASA/DIP treatment could only be evaluated in a formal analysis from two RCTs (<a href="./references#CD000535-bbs2-0012" title="LucasMA . Prevention of post-operative thrombosis in peripheral arteriopathies. Pentoxifylline vs conventional antiaggregants: a six-month randomized follow-up study. Angiology1984;35(7):443-50. ">Lucas 1984</a>; <a href="./references#CD000535-bbs2-0015" title="RaithelD , KasprzakP , Noppeney Th. Relapse prophylaxis after femoropopliteal reconstruction with PTFE-prostheses. Die Medizinische Welt1986;37:664-7. RaithelD . Prevention of reocclusion after prosthetic bypass operations in the femoro-popliteal region: a comparative study of pentoxifylline versus acetylsalicylic acid. Vascular Surgery1987;21(3):208-14. ">Raithel 1987</a>) at six months post‐operation. The fixed‐effect model had an OR of 1.32 (95% CI 0.56 to 3.11; P = 0.52, participants = 151) showing no difference between the treatment groups (<a href="./references#CD000535-fig-0021" title="">Analysis 3.3</a>). This analysis should be considered with caution as <a href="./references#CD000535-bbs2-0012" title="LucasMA . Prevention of post-operative thrombosis in peripheral arteriopathies. Pentoxifylline vs conventional antiaggregants: a six-month randomized follow-up study. Angiology1984;35(7):443-50. ">Lucas 1984</a> involved multiple grafts and there appeared to be substantial heterogeneity among the sample population. At other time points, only <a href="./references#CD000535-bbs2-0015" title="RaithelD , KasprzakP , Noppeney Th. Relapse prophylaxis after femoropopliteal reconstruction with PTFE-prostheses. Die Medizinische Welt1986;37:664-7. RaithelD . Prevention of reocclusion after prosthetic bypass operations in the femoro-popliteal region: a comparative study of pentoxifylline versus acetylsalicylic acid. Vascular Surgery1987;21(3):208-14. ">Raithel 1987</a> provided raw data and showed a similar effect of both drugs on graft patency: OR 2.04 (95% CI 0.18 to 23.07, participants = 118) at one month; OR 1.00 (95% CI 0.27 to 3.65, participants = 118) at three months; and OR 0.91 (95% CI 0.38 to 2.15, participants = 118) at 12 months (<a href="./references#CD000535-fig-0019" title="">Analysis 3.1</a>; <a href="./references#CD000535-fig-0020" title="">Analysis 3.2</a>; <a href="./references#CD000535-fig-0022" title="">Analysis 3.4</a>). </p> </section> <section id="CD000535-sec-0065"> <h5 class="title">Side effects of treatment and complications</h5> <p><a href="./references#CD000535-bbs2-0015" title="RaithelD , KasprzakP , Noppeney Th. Relapse prophylaxis after femoropopliteal reconstruction with PTFE-prostheses. Die Medizinische Welt1986;37:664-7. RaithelD . Prevention of reocclusion after prosthetic bypass operations in the femoro-popliteal region: a comparative study of pentoxifylline versus acetylsalicylic acid. Vascular Surgery1987;21(3):208-14. ">Raithel 1987</a> reported on side effects that included gastric intolerance, gastric haemorrhage and vertigo, with ORs of 18.04 (95% CI 5.07 to 64.17), 3.11 (95% CI 0.31 to 30.77) and 0.48 (95% CI 0.08 to 2.74) respectively, all with 118 participants (<a href="./references#CD000535-fig-0023" title="">Analysis 3.5</a>). It should be noted that side effects were extrapolated from graphs and therefore may not be completely accurate. </p> </section> <section id="CD000535-sec-0066"> <h5 class="title">Limb amputation</h5> <p>Amputation was also only evaluated in the <a href="./references#CD000535-bbs2-0015" title="RaithelD , KasprzakP , Noppeney Th. Relapse prophylaxis after femoropopliteal reconstruction with PTFE-prostheses. Die Medizinische Welt1986;37:664-7. RaithelD . Prevention of reocclusion after prosthetic bypass operations in the femoro-popliteal region: a comparative study of pentoxifylline versus acetylsalicylic acid. Vascular Surgery1987;21(3):208-14. ">Raithel 1987</a> study, with an OR of 0.38 (95% CI 0.07 to 2.04, participants = 118) (<a href="./references#CD000535-fig-0024" title="">Analysis 3.6</a>). </p> </section> <section id="CD000535-sec-0067"> <h5 class="title">Cardiovascular events and mortality</h5> <p>Reported only in <a href="./references#CD000535-bbs2-0015" title="RaithelD , KasprzakP , Noppeney Th. Relapse prophylaxis after femoropopliteal reconstruction with PTFE-prostheses. Die Medizinische Welt1986;37:664-7. RaithelD . Prevention of reocclusion after prosthetic bypass operations in the femoro-popliteal region: a comparative study of pentoxifylline versus acetylsalicylic acid. Vascular Surgery1987;21(3):208-14. ">Raithel 1987</a>, there were six deaths in the ASA group and three in the PTX group, with an OR of 2.11 (95% CI 0.50 to 8.88, participants = 118) (<a href="./references#CD000535-fig-0025" title="">Analysis 3.7</a>). The authors reported that eight of the deaths were from myocardial infarction and one from cardiac failure, but they did not detail which treatment groups they came from. </p> </section> </section> <section id="CD000535-sec-0068"> <h4 class="title">Aspirin and dipyridamole (ASA/DIP) versus indobufen (IND)</h4> <section id="CD000535-sec-0069"> <h5 class="title">Primary graft patency</h5> <p>The one eligible RCT (<a href="./references#CD000535-bbs2-0005" title="D'AddatoM , CurtiT , BertiniD , DoniniI , FerreroR , FioraniP , et al. Indobufen vs acetylsalicylic acid plus dipyridamole in long-term patency after femoropopliteal bypass. International Angiology1992;11(2):106-12. ">D'Addato 1992</a>) compared ASA/DIP to IND in receiving infrainguinal prosthetic PTFE grafts. The study had an OR of 1.67 (95% CI 0.51 to 5.44, participants = 113) for primary patency at three months, OR 1.60 (95% CI 0.60 to 4.27, participants = 113) at six months, OR 1.26 (95% CI 0.56 to 2.85, participants = 113) at nine months and OR 1.34 (95% CI 0.61 to 2.93, participants = 113) at 12 months (<a href="./references#CD000535-fig-0026" title="">Analysis 4.1</a>; <a href="./references#CD000535-fig-0027" title="">Analysis 4.2</a>; <a href="./references#CD000535-fig-0028" title="">Analysis 4.3</a>; <a href="./references#CD000535-fig-0029" title="">Analysis 4.4</a>). </p> </section> </section> <section id="CD000535-sec-0070"> <h4 class="title">Aspirin and dipyridamole (ASA/DIP) versus vitamin K antagonists (VKA)</h4> <section id="CD000535-sec-0071"> <h5 class="title">Primary graft patency</h5> <p>This was reported in two trials (<a href="./references#CD000535-bbs2-0002" title="AlgraA . A randomised trial of oral anticoagulants versus aspirin after infrainguinal bypass surgery. Tijdschrift voor Sociale Gezondheidszorg1999;77(4):11. AriesenMJ , TangelderMJD , LawsonJA , EikelboomBC , GrobbeeDE , AlgraA . Risk of major haemorrhage in patients after infrainguinal venous bypass surgery: Therapeutic consequences? The Dutch BOA (Bypass Oral Anticoagulants or Aspirin) study. European Journal of Vascular and Endovascular Surgery2005;30(2):154-9. Dutch Bypass Oral anticoagulants of Aspirin (BOA) Study Group. Efficacy of oral anticoagulants compared with aspirin after infrainguinal bypass surgery (The Dutch Bypass Oral anticoagulants or Aspirin study): a randomised trial. Lancet2000;355(9201):346-51. EikelboomBC . Prevention of occlusions after infrainguinal bypass surgery with oral anticoagulants or acetylsalicylic acid: A randomised trial. Nederlands Tijdschrift voor Geneeskunde2001;145(22):1060-7. OostenbrinkJB , TangelderMJ , BusschbachJJ , Van HoutBA , BuskensE , AlgraA , et al. Cost effectiveness of oral anticoagulants versus aspirin in patients after infrainguinal bypass grafting surgery. Journal of Vascular Surgery2001;34(2):254-62. SmeetsL , HoGH , TangelderMJ , AlgraA , LawsonJA , EikelboomBC , et al, Dutch BOA Study Group. Outcome after occlusion of infrainguinal bypasses in the Dutch BOA Study: comparison of amputation rate in venous and prosthetic grafts. European Journal of Vascular and Endovascular Surgery2005;30(6):604-9. TangelderMJ , AlgraA , LawsonJA , EikelboomBC . Risk factors for occlusion of infrainguinal bypass grafts. European Journal of Vascular and Endovascular Surgery2000;20(2):118-24. TangelderMJ , AlgraA , LawsonJA , HennekesS , EikelboomBC . Optimal oral anticoagulant intensity to prevent secondary ischemic and hemorrhagic events in patients after infrainguinal bypass graft surgery. Dutch BOA Study Group. Journal of Vascular Surgery2001;33(3):522-7. TangelderMJ , EikelboomBC , LawsonJA , AlgraA . Prevention of occlusion following peripheral bypass surgery using oral anticoagulants or acetylsalicylic acid: a randomized comparison within the Dutch BOA study [Preventi van occlusies na perifere bypass-chirurgie met orale anticoagulantia of acetylsalicylzuur: een gerandomiseerde vergelijking in het Nederlands BOA-onderzoek]. Nederlands Tijdschrift voor Geneeskunde1995;139(29):1504-6. TangelderMJ , McDonnelJ , Van BusschbachJJ , BuskensE , AlgraA , LawsonJA , EikelboomBC . Quality of life after infrainguinal bypass grafting surgery. Dutch Bypass Oral Anticoagulants or Aspirin (BOA) Study Group. Journal of Vascular Surgery1999;29(5):913-9. Van HattumES , AlgraA , LawsonJA , EikelboomBC , MollFL , TangelderMJD . Bleeding increases the risk of ischemic events in patients with peripheral arterial disease. Circulation2009;120(16):1569-76. Van HattumES , TangelderMJD , LawsonJA , MollFL , AlgraA . The quality of life in patients after peripheral bypass surgery deteriorates at long-term follow-up. Journal of Vascular Surgery2011;53(3):643-50. ">BOA 2000</a>; <a href="./references#CD000535-bbs2-0016" title="SchneiderE , BrunnerU , BollingerA . No English title available [Medikamentose Rezidivprophylaxe nach femoro-poplitealer Arterienrekonstruktion]. Angio1979;2(1):73-7. ">Schneider 1979</a>). Primary graft patency for all grafts showed no difference for coumarin versus aspirin, irrespective of time point: OR 0.88 (95% CI 0.68 to 1.14; P = 0.34, I² = 0%) at three months, OR 0.72 (95% CI 0.27 to 1.96; P = 0.52, I² = 61%) at six months, OR 0.68 (95% CI 0.27 to 1.69; P = 0.40, I² = 67%) at 12 months; and OR 0.64 (95% CI 0.25 to 1.63; P = 0.36, I² = 74%) at 24 months, with 2781 participants included in each outcome (<a href="./references#CD000535-fig-0030" title="">Analysis 5.1</a>; <a href="./references#CD000535-fig-0031" title="">Analysis 5.2</a>; <a href="./references#CD000535-fig-0032" title="">Analysis 5.3</a>; <a href="./references#CD000535-fig-0033" title="">Analysis 5.4</a>). We used a fixed‐effect model at three months, and random‐effects models for months six, 12 and 24, due to high heterogeneity. </p> </section> <section id="CD000535-sec-0072"> <h5 class="title">Side effects of treatment and complications</h5> <p>In the <a href="./references#CD000535-bbs2-0002" title="AlgraA . A randomised trial of oral anticoagulants versus aspirin after infrainguinal bypass surgery. Tijdschrift voor Sociale Gezondheidszorg1999;77(4):11. AriesenMJ , TangelderMJD , LawsonJA , EikelboomBC , GrobbeeDE , AlgraA . Risk of major haemorrhage in patients after infrainguinal venous bypass surgery: Therapeutic consequences? The Dutch BOA (Bypass Oral Anticoagulants or Aspirin) study. European Journal of Vascular and Endovascular Surgery2005;30(2):154-9. Dutch Bypass Oral anticoagulants of Aspirin (BOA) Study Group. Efficacy of oral anticoagulants compared with aspirin after infrainguinal bypass surgery (The Dutch Bypass Oral anticoagulants or Aspirin study): a randomised trial. Lancet2000;355(9201):346-51. EikelboomBC . Prevention of occlusions after infrainguinal bypass surgery with oral anticoagulants or acetylsalicylic acid: A randomised trial. Nederlands Tijdschrift voor Geneeskunde2001;145(22):1060-7. OostenbrinkJB , TangelderMJ , BusschbachJJ , Van HoutBA , BuskensE , AlgraA , et al. Cost effectiveness of oral anticoagulants versus aspirin in patients after infrainguinal bypass grafting surgery. Journal of Vascular Surgery2001;34(2):254-62. SmeetsL , HoGH , TangelderMJ , AlgraA , LawsonJA , EikelboomBC , et al, Dutch BOA Study Group. Outcome after occlusion of infrainguinal bypasses in the Dutch BOA Study: comparison of amputation rate in venous and prosthetic grafts. European Journal of Vascular and Endovascular Surgery2005;30(6):604-9. TangelderMJ , AlgraA , LawsonJA , EikelboomBC . Risk factors for occlusion of infrainguinal bypass grafts. European Journal of Vascular and Endovascular Surgery2000;20(2):118-24. TangelderMJ , AlgraA , LawsonJA , HennekesS , EikelboomBC . Optimal oral anticoagulant intensity to prevent secondary ischemic and hemorrhagic events in patients after infrainguinal bypass graft surgery. Dutch BOA Study Group. Journal of Vascular Surgery2001;33(3):522-7. TangelderMJ , EikelboomBC , LawsonJA , AlgraA . Prevention of occlusion following peripheral bypass surgery using oral anticoagulants or acetylsalicylic acid: a randomized comparison within the Dutch BOA study [Preventi van occlusies na perifere bypass-chirurgie met orale anticoagulantia of acetylsalicylzuur: een gerandomiseerde vergelijking in het Nederlands BOA-onderzoek]. Nederlands Tijdschrift voor Geneeskunde1995;139(29):1504-6. TangelderMJ , McDonnelJ , Van BusschbachJJ , BuskensE , AlgraA , LawsonJA , EikelboomBC . Quality of life after infrainguinal bypass grafting surgery. Dutch Bypass Oral Anticoagulants or Aspirin (BOA) Study Group. Journal of Vascular Surgery1999;29(5):913-9. Van HattumES , AlgraA , LawsonJA , EikelboomBC , MollFL , TangelderMJD . Bleeding increases the risk of ischemic events in patients with peripheral arterial disease. Circulation2009;120(16):1569-76. Van HattumES , TangelderMJD , LawsonJA , MollFL , AlgraA . The quality of life in patients after peripheral bypass surgery deteriorates at long-term follow-up. Journal of Vascular Surgery2011;53(3):643-50. ">BOA 2000</a> trial, haemorrhage necessitating hospital admission was reported for 119 (9%) participants in the coumarin group and 59 (4.5%) in the aspirin group. A total of 16 (1.2%) participants died from fatal bleeding in the coumarin group and 12 (0.9%) participants in the aspirin group. In <a href="./references#CD000535-bbs2-0016" title="SchneiderE , BrunnerU , BollingerA . No English title available [Medikamentose Rezidivprophylaxe nach femoro-poplitealer Arterienrekonstruktion]. Angio1979;2(1):73-7. ">Schneider 1979</a> the adverse effects reported were: two participants (0.6%) who stopped coumarin treatment because of bleeding complications and 13 participants (21%) who stopped aspirin for differing reasons. </p> </section> <section id="CD000535-sec-0073"> <h5 class="title">Limb amputation</h5> <p>The two trials (<a href="./references#CD000535-bbs2-0002" title="AlgraA . A randomised trial of oral anticoagulants versus aspirin after infrainguinal bypass surgery. Tijdschrift voor Sociale Gezondheidszorg1999;77(4):11. AriesenMJ , TangelderMJD , LawsonJA , EikelboomBC , GrobbeeDE , AlgraA . Risk of major haemorrhage in patients after infrainguinal venous bypass surgery: Therapeutic consequences? The Dutch BOA (Bypass Oral Anticoagulants or Aspirin) study. European Journal of Vascular and Endovascular Surgery2005;30(2):154-9. Dutch Bypass Oral anticoagulants of Aspirin (BOA) Study Group. Efficacy of oral anticoagulants compared with aspirin after infrainguinal bypass surgery (The Dutch Bypass Oral anticoagulants or Aspirin study): a randomised trial. Lancet2000;355(9201):346-51. EikelboomBC . Prevention of occlusions after infrainguinal bypass surgery with oral anticoagulants or acetylsalicylic acid: A randomised trial. Nederlands Tijdschrift voor Geneeskunde2001;145(22):1060-7. OostenbrinkJB , TangelderMJ , BusschbachJJ , Van HoutBA , BuskensE , AlgraA , et al. Cost effectiveness of oral anticoagulants versus aspirin in patients after infrainguinal bypass grafting surgery. Journal of Vascular Surgery2001;34(2):254-62. SmeetsL , HoGH , TangelderMJ , AlgraA , LawsonJA , EikelboomBC , et al, Dutch BOA Study Group. Outcome after occlusion of infrainguinal bypasses in the Dutch BOA Study: comparison of amputation rate in venous and prosthetic grafts. European Journal of Vascular and Endovascular Surgery2005;30(6):604-9. TangelderMJ , AlgraA , LawsonJA , EikelboomBC . Risk factors for occlusion of infrainguinal bypass grafts. European Journal of Vascular and Endovascular Surgery2000;20(2):118-24. TangelderMJ , AlgraA , LawsonJA , HennekesS , EikelboomBC . Optimal oral anticoagulant intensity to prevent secondary ischemic and hemorrhagic events in patients after infrainguinal bypass graft surgery. Dutch BOA Study Group. Journal of Vascular Surgery2001;33(3):522-7. TangelderMJ , EikelboomBC , LawsonJA , AlgraA . Prevention of occlusion following peripheral bypass surgery using oral anticoagulants or acetylsalicylic acid: a randomized comparison within the Dutch BOA study [Preventi van occlusies na perifere bypass-chirurgie met orale anticoagulantia of acetylsalicylzuur: een gerandomiseerde vergelijking in het Nederlands BOA-onderzoek]. Nederlands Tijdschrift voor Geneeskunde1995;139(29):1504-6. TangelderMJ , McDonnelJ , Van BusschbachJJ , BuskensE , AlgraA , LawsonJA , EikelboomBC . Quality of life after infrainguinal bypass grafting surgery. Dutch Bypass Oral Anticoagulants or Aspirin (BOA) Study Group. Journal of Vascular Surgery1999;29(5):913-9. Van HattumES , AlgraA , LawsonJA , EikelboomBC , MollFL , TangelderMJD . Bleeding increases the risk of ischemic events in patients with peripheral arterial disease. Circulation2009;120(16):1569-76. Van HattumES , TangelderMJD , LawsonJA , MollFL , AlgraA . The quality of life in patients after peripheral bypass surgery deteriorates at long-term follow-up. Journal of Vascular Surgery2011;53(3):643-50. ">BOA 2000</a>; <a href="./references#CD000535-bbs2-0016" title="SchneiderE , BrunnerU , BollingerA . No English title available [Medikamentose Rezidivprophylaxe nach femoro-poplitealer Arterienrekonstruktion]. Angio1979;2(1):73-7. ">Schneider 1979</a>), did not report data on limb salvage or survival that was suitable for formal meta‐analysis. However, in <a href="./references#CD000535-bbs2-0002" title="AlgraA . A randomised trial of oral anticoagulants versus aspirin after infrainguinal bypass surgery. Tijdschrift voor Sociale Gezondheidszorg1999;77(4):11. AriesenMJ , TangelderMJD , LawsonJA , EikelboomBC , GrobbeeDE , AlgraA . Risk of major haemorrhage in patients after infrainguinal venous bypass surgery: Therapeutic consequences? The Dutch BOA (Bypass Oral Anticoagulants or Aspirin) study. European Journal of Vascular and Endovascular Surgery2005;30(2):154-9. Dutch Bypass Oral anticoagulants of Aspirin (BOA) Study Group. Efficacy of oral anticoagulants compared with aspirin after infrainguinal bypass surgery (The Dutch Bypass Oral anticoagulants or Aspirin study): a randomised trial. Lancet2000;355(9201):346-51. EikelboomBC . Prevention of occlusions after infrainguinal bypass surgery with oral anticoagulants or acetylsalicylic acid: A randomised trial. Nederlands Tijdschrift voor Geneeskunde2001;145(22):1060-7. OostenbrinkJB , TangelderMJ , BusschbachJJ , Van HoutBA , BuskensE , AlgraA , et al. Cost effectiveness of oral anticoagulants versus aspirin in patients after infrainguinal bypass grafting surgery. Journal of Vascular Surgery2001;34(2):254-62. SmeetsL , HoGH , TangelderMJ , AlgraA , LawsonJA , EikelboomBC , et al, Dutch BOA Study Group. Outcome after occlusion of infrainguinal bypasses in the Dutch BOA Study: comparison of amputation rate in venous and prosthetic grafts. European Journal of Vascular and Endovascular Surgery2005;30(6):604-9. TangelderMJ , AlgraA , LawsonJA , EikelboomBC . Risk factors for occlusion of infrainguinal bypass grafts. European Journal of Vascular and Endovascular Surgery2000;20(2):118-24. TangelderMJ , AlgraA , LawsonJA , HennekesS , EikelboomBC . Optimal oral anticoagulant intensity to prevent secondary ischemic and hemorrhagic events in patients after infrainguinal bypass graft surgery. Dutch BOA Study Group. Journal of Vascular Surgery2001;33(3):522-7. TangelderMJ , EikelboomBC , LawsonJA , AlgraA . Prevention of occlusion following peripheral bypass surgery using oral anticoagulants or acetylsalicylic acid: a randomized comparison within the Dutch BOA study [Preventi van occlusies na perifere bypass-chirurgie met orale anticoagulantia of acetylsalicylzuur: een gerandomiseerde vergelijking in het Nederlands BOA-onderzoek]. Nederlands Tijdschrift voor Geneeskunde1995;139(29):1504-6. TangelderMJ , McDonnelJ , Van BusschbachJJ , BuskensE , AlgraA , LawsonJA , EikelboomBC . Quality of life after infrainguinal bypass grafting surgery. Dutch Bypass Oral Anticoagulants or Aspirin (BOA) Study Group. Journal of Vascular Surgery1999;29(5):913-9. Van HattumES , AlgraA , LawsonJA , EikelboomBC , MollFL , TangelderMJD . Bleeding increases the risk of ischemic events in patients with peripheral arterial disease. Circulation2009;120(16):1569-76. Van HattumES , TangelderMJD , LawsonJA , MollFL , AlgraA . The quality of life in patients after peripheral bypass surgery deteriorates at long-term follow-up. Journal of Vascular Surgery2011;53(3):643-50. ">BOA 2000</a> limb amputation had to be performed in a similar number of participants in each treatment group, with an OR of 0.99 (95% CI 0.75 to 1.30, participants = 2690) (<a href="./references#CD000535-fig-0034" title="">Analysis 5.5</a>). </p> </section> <section id="CD000535-sec-0074"> <h5 class="title">Cardiovascular events and mortality</h5> <p>Only <a href="./references#CD000535-bbs2-0002" title="AlgraA . A randomised trial of oral anticoagulants versus aspirin after infrainguinal bypass surgery. Tijdschrift voor Sociale Gezondheidszorg1999;77(4):11. AriesenMJ , TangelderMJD , LawsonJA , EikelboomBC , GrobbeeDE , AlgraA . Risk of major haemorrhage in patients after infrainguinal venous bypass surgery: Therapeutic consequences? The Dutch BOA (Bypass Oral Anticoagulants or Aspirin) study. European Journal of Vascular and Endovascular Surgery2005;30(2):154-9. Dutch Bypass Oral anticoagulants of Aspirin (BOA) Study Group. Efficacy of oral anticoagulants compared with aspirin after infrainguinal bypass surgery (The Dutch Bypass Oral anticoagulants or Aspirin study): a randomised trial. Lancet2000;355(9201):346-51. EikelboomBC . Prevention of occlusions after infrainguinal bypass surgery with oral anticoagulants or acetylsalicylic acid: A randomised trial. Nederlands Tijdschrift voor Geneeskunde2001;145(22):1060-7. OostenbrinkJB , TangelderMJ , BusschbachJJ , Van HoutBA , BuskensE , AlgraA , et al. Cost effectiveness of oral anticoagulants versus aspirin in patients after infrainguinal bypass grafting surgery. Journal of Vascular Surgery2001;34(2):254-62. SmeetsL , HoGH , TangelderMJ , AlgraA , LawsonJA , EikelboomBC , et al, Dutch BOA Study Group. Outcome after occlusion of infrainguinal bypasses in the Dutch BOA Study: comparison of amputation rate in venous and prosthetic grafts. European Journal of Vascular and Endovascular Surgery2005;30(6):604-9. TangelderMJ , AlgraA , LawsonJA , EikelboomBC . Risk factors for occlusion of infrainguinal bypass grafts. European Journal of Vascular and Endovascular Surgery2000;20(2):118-24. TangelderMJ , AlgraA , LawsonJA , HennekesS , EikelboomBC . Optimal oral anticoagulant intensity to prevent secondary ischemic and hemorrhagic events in patients after infrainguinal bypass graft surgery. Dutch BOA Study Group. Journal of Vascular Surgery2001;33(3):522-7. TangelderMJ , EikelboomBC , LawsonJA , AlgraA . Prevention of occlusion following peripheral bypass surgery using oral anticoagulants or acetylsalicylic acid: a randomized comparison within the Dutch BOA study [Preventi van occlusies na perifere bypass-chirurgie met orale anticoagulantia of acetylsalicylzuur: een gerandomiseerde vergelijking in het Nederlands BOA-onderzoek]. Nederlands Tijdschrift voor Geneeskunde1995;139(29):1504-6. TangelderMJ , McDonnelJ , Van BusschbachJJ , BuskensE , AlgraA , LawsonJA , EikelboomBC . Quality of life after infrainguinal bypass grafting surgery. Dutch Bypass Oral Anticoagulants or Aspirin (BOA) Study Group. Journal of Vascular Surgery1999;29(5):913-9. Van HattumES , AlgraA , LawsonJA , EikelboomBC , MollFL , TangelderMJD . Bleeding increases the risk of ischemic events in patients with peripheral arterial disease. Circulation2009;120(16):1569-76. Van HattumES , TangelderMJD , LawsonJA , MollFL , AlgraA . The quality of life in patients after peripheral bypass surgery deteriorates at long-term follow-up. Journal of Vascular Surgery2011;53(3):643-50. ">BOA 2000</a> reported on cardiovascular events and mortality for this treatment comparison. Myocardial infarction and stroke were similar for both treatment groups, with slightly higher occurrences in the ASA/DIP group: OR 1.45 (95% CI 0.90 to 2.34) and OR 1.34 (95% CI 0.86 to 2.09) respectively; participants = 2690 (<a href="./references#CD000535-fig-0035" title="">Analysis 5.6</a>). Death from all causes, after two years, was similar in both treatment groups, with an OR of 1.02 (95% CI 0.83 to 1.26, participants = 2690) (<a href="./references#CD000535-fig-0036" title="">Analysis 5.7</a>). </p> </section> </section> <section id="CD000535-sec-0075"> <h4 class="title">Aspirin and dipyridamole (ASA/DIP) versus low molecular weight heparin (LMWH)</h4> <section id="CD000535-sec-0076"> <h5 class="title">Primary graft patency</h5> <p>In <a href="./references#CD000535-bbs2-0007" title="EdmondsonRA , CohenAT , DasSK , WagnerBM , KakkarVV . Low-molecular weight heparin versus aspirin and dipyridamole after femoropopliteal bypass grafting. Lancet1994;344(8927):914-8. ">Edmondson 1994</a> primary patency was measured at six and 12 months with little difference between the treatment groups: OR 1.69 (95% CI 0.78 to 3.65, participants = 200), and OR 1.19 (95% CI 0.66 to 2.15, participants = 200), respectively (<a href="./references#CD000535-fig-0037" title="">Analysis 6.1</a>; <a href="./references#CD000535-fig-0038" title="">Analysis 6.2</a>). </p> </section> <section id="CD000535-sec-0077"> <h5 class="title">Side effects of treatment and complications</h5> <p>No major bleedings or adverse events occurred.</p> </section> <section id="CD000535-sec-0078"> <h5 class="title">Cardiovascular events and mortality</h5> <p>There were more deaths in the LMWH treatment group compared to the ASA/DIP group: OR 0.18 (95% CI 0.04 to 0.86, participants = 200) (<a href="./references#CD000535-fig-0039" title="">Analysis 6.3</a>). </p> </section> </section> <section id="CD000535-sec-0079"> <h4 class="title">Ticlopidine (TIC) versus nothing</h4> <section id="CD000535-sec-0080"> <h5 class="title">Primary graft patency</h5> <p>Intention‐to‐treat analysis of one trial (<a href="./references#CD000535-bbs2-0001" title="BecqueminJP . Effect of ticlopidine on the long-term patency of saphenous-vein bypass grafts in the legs. New England Journal of Medicine1997;337(24):1726-31. ">Becquemin 1997</a>) involving participants undergoing bypass with venous grafts showed no difference in primary patency at one month between the treatment groups: OR 3.00 (95% CI 0.12 to 74.37, participants = 243), with a wide confidence interval as only one event occurred by this time point (<a href="./references#CD000535-fig-0040" title="">Analysis 7.1</a>). However, primary patency at six, 12 and 24 months showed increased patency in the TIC treatment group: OR 0.26 (95% CI 0.11 to 0.63, participants = 243) at six months; OR 0.38 (95% CI 0.19 to 0.75, participants = 243) at 12 months; and OR 0.37 (95% CI 0.21 to 0.67, participants = 243) at 24 months (<a href="./references#CD000535-fig-0041" title="">Analysis 7.2</a>; <a href="./references#CD000535-fig-0042" title="">Analysis 7.3</a>; <a href="./references#CD000535-fig-0043" title="">Analysis 7.4</a>). </p> </section> </section> <section id="CD000535-sec-0081"> <h4 class="title">Aspirin versus prostaglandin E1 (PGE1)</h4> <section id="CD000535-sec-0082"> <h5 class="title">Primary graft patency</h5> <p>One study (<a href="./references#CD000535-bbs2-0010" title="GrussJD , HiemerW , KroissA , GeisslerC . Experiences with adjuvant prostaglandin therapy in vascular surgery interventions. Vasa-Supplementum1991;33:353-4. ">Gruss 1991</a>) reported on the drug comparison of aspirin to PGE1 in participants receiving autologous venous grafts. Early occlusion, within the first three postoperative days, had few events, with an OR of 3.91 (95% CI 0.77 to 19.83, participants = 100) (<a href="./references#CD000535-fig-0044" title="">Analysis 8.1</a>). Longer‐term patency was not reported. </p> </section> </section> <section id="CD000535-sec-0083"> <h4 class="title">Aspirin versus naftidrofuryl</h4> <section id="CD000535-sec-0084"> <h5 class="title">Primary graft patency</h5> <p>One study (<a href="./references#CD000535-bbs2-0014" title="NoppeneyT , KasprzakP , RaithelD , HircheH . Naftidrofuryl in postoperative treatment after femoropopliteal bypass. Die Medizinische Welt1988;39:1545-50. ">Noppeney 1988</a>) reported graft occlusion in seven of the 50 participants administered naftidrofuryl compared to 10 of the 49 given ASA, with an OR of 1.58 (95% CI 0.55 to 4.54, participants = 99) (<a href="./references#CD000535-fig-0045" title="">Analysis 9.1</a>). </p> </section> <section id="CD000535-sec-0085"> <h5 class="title">Side effects of treatment and complications</h5> <p>More general side effects were experienced by the ASA group compared to naftidrofuryl: OR 13.86 (95% CI 3.80 to 50.60, participants = 99). Gastrointestinal side effects were also more common in the aspirin group: OR 28.45 (95% CI 3.61 to 223.97, participants = 99). Only two participants reported vertigo, both in the naftidrofuryl treatment group: OR 0.20 (95% CI 0.01 to 4.19, participants = 99). Stomach bleeding was reported in five participants, all in the aspirin treatment group: OR 12.48 (95% CI 0.67 to 232.14, participants = 99) (<a href="./references#CD000535-fig-0046" title="">Analysis 9.2</a>). </p> </section> <section id="CD000535-sec-0086"> <h5 class="title">Cardiovascular events and mortality</h5> <p>Deaths occurred in both treatment groups, with an OR of 2.73 (95% CI 0.50 to 14.78, participants = 99) (<a href="./references#CD000535-fig-0047" title="">Analysis 9.3</a>). </p> </section> </section> <section id="CD000535-sec-0087"> <h4 class="title">Clopidogrel and ASA (clopidogrel/ASA) versus ASA alone</h4> <p><a href="./references#CD000535-bbs2-0003" title="Anonymous. Clopidogrel and acetyl salicylic acid in bypass surgery for peripheral arterial disease. clinicaltrials.gov/ct2/show/NCT00174759?term=CASPAR&amp;rank=2 (accessed 5 May 2014). Anonymous. Dual antiplatelet therapy benefits prosthetic but not venous grafts. Vascular News2009;Feb:17. BelchJJ , DormandyJ . Results of the randomized, placebo-controlled clopidogrel and acetylsalicylic acid in bypass surgery for peripheral arterial disease (CASPAR) trial. Journal of Vascular Surgery2010;52(4):825-33. The Caspar Investigators, BelchJ . Effect of adding clopidogrel to aspirin on the success of below knee arterial bypass grafts. A randomised placebo controlled study. In: Vascular Annual Meeting; 2007 Jun; Baltimore, USA. 2007. ">CASPAR 2010</a> was the only study to compare clopidogrel/ASA to ASA alone. Outcomes were reported at 24 months as a whole population and split by subgroups based on whether participants received venous or prosthetic grafts. </p> <section id="CD000535-sec-0088"> <h5 class="title">Primary graft patency</h5> <p>Primary graft patency for all participants was similar between both treatment groups, OR 0.95 (95% CI 0.69 to 1.31, participants = 851) <a href="./references#CD000535-fig-0048" title="">Analysis 10.1</a>. There were more cases of occlusion in the clopidogrel/ASA group, compared to ASA alone, when only venous grafts were included: OR 1.47 (95% CI 0.93 to 2.31, participants = 598), but higher occlusion rates in the ASA alone group for prosthetic grafts: OR 0.53 (95% CI 0.32 to 0.88, participants = 253) (<a href="./references#CD000535-fig-0052" title="">Analysis 11.1</a>; <a href="./references#CD000535-fig-0053" title="">Analysis 11.2</a>). </p> </section> <section id="CD000535-sec-0089"> <h5 class="title">Side effects of treatment and complications</h5> <p>Total cases of bleeding were fewer in the ASA alone group: OR 2.65 (95% CI 1.69 to 4.15, participants = 851), as were mild bleeding: OR 2.34 (95% CI 1.37 to 4.00, participants = 851) and moderate bleeding: OR 4.13 (95% CI 1.37 to 12.45, participants = 851). Cases of severe bleeding and fatal bleeding were few, and similar between the treatment groups: OR 1.82 (95% CI 0.61 to 5.48, participants = 851) and OR 2.01 (95% CI 0.18 to 22.24, participants = 851), respectively (<a href="./references#CD000535-fig-0049" title="">Analysis 10.2</a>). </p> <p>When we evaluated graft subgroups, there was still less mild bleeding in the ASA alone group for venous grafts: OR 2.46 (95% CI 1.33 to 4.53, participants = 598), but the occurrence of mild bleeding events was more similar between the treatment groups for prosthetic grafts: OR 1.86 (95% CI 0.67 to 5.21, participants = 253). The same trend was seen for moderate bleeding: venous grafts: OR 5.75 (95% CI 1.26 to 26.17, participants = 598) and prosthetic grafts: OR 2.50 (95% CI 0.48 to 13.13, participants = 253). Severe bleeding was similar between treatment groups for both venous and prosthetic grafts: OR 2.75 (95% CI 0.72 to 10.47, participants = 598) and OR 0.48 (95% CI 0.04 to 5.41, participants = 253), respectively (<a href="./references#CD000535-fig-0054" title="">Analysis 11.3</a>). </p> </section> <section id="CD000535-sec-0090"> <h5 class="title">Limb amputation</h5> <p>For all grafts, amputations were similar between groups, with slightly higher occurrence in the ASA alone group: OR 0.67 (95% CI 0.41 to 1.08, participants = 851) (<a href="./references#CD000535-fig-0050" title="">Analysis 10.3</a>). Amputation occurrence was also similar between treatment groups for venous grafts: OR 0.91 (95% CI 0.48 to 1.73, participants = 598), but more occurred in the ASA alone group for prosthetic grafts: OR 0.44 (95% CI 0.21 to 0.91, participants = 253) (<a href="./references#CD000535-fig-0055" title="">Analysis 11.4</a>). </p> </section> <section id="CD000535-sec-0091"> <h5 class="title">Cardiovascular events and mortality</h5> <p>For all graft types, death was similar between both treatment groups: OR 1.44 (95% CI 0.76 to 2.72, participants = 851), which was also the case for both venous and prosthetic grafts: OR 1.43 (95% CI 0.69 to 2.97, participants = 598), and OR 1.49 (95% CI 0.41 to 5.40, participants = 253), respectively (<a href="./references#CD000535-fig-0051" title="">Analysis 10.4</a>; <a href="./references#CD000535-fig-0056" title="">Analysis 11.5</a>). </p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD000535-sec-0092" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD000535-sec-0092"></div> <section id="CD000535-sec-0093"> <h3 class="title" id="CD000535-sec-0093">Summary of main results</h3> <section id="CD000535-sec-0094"> <h4 class="title">Antiplatelet therapy effect on bypass patency</h4> <p>In the present meta‐analysis we evaluated the effect of postoperatively administered antiplatelet treatment in people with peripheral arterial disease (PAD) receiving infrainguinal bypasses. It was shown that antiplatelet treatment with aspirin (ASA) or a combination of ASA and dipyridamole (ASA/DIP) has an overall positive effect on primary patency 12 months after the procedure. Interestingly, the size of the effect differed between participants receiving prosthetic grafts and those receiving venous grafts. When we limited the analysis to the subgroups receiving prosthetic (polytetrafluoroethylene (PTFE) or Dacron) grafts, the effect was statistically significant at all time points. In contrast, there was no evidence to support an effect of ASA or ASA/DIP in participants receiving venous graft bypasses. The evidence for secondary patency is too limited to draw any conclusions at this time. It should be noted that we did not perform a formal test for interaction to statistically demonstrate a differential effect of antiplatelet agents by graft type. </p> <p>There was no difference in primary patency for the comparison between ASA/DIP versus pentoxifylline (PTX) at one, three, six and 12 months. However, for most of the time points we evaluated only a single study. For the comparisons between ASA and DIP versus indobufen (prosthetic grafts only), ASA or ASA/DIP versus vitamin K antagonists (VKA), as well as ASA/DIP versus low molecular weight heparin (LMWH), there were no differences between the treatment groups in primary patency at any time point. The analyses of indobufen and LMWH only had single study reporting and VKA included only two studies. </p> <p>A single study evaluated ticlopidine versus placebo in participants receiving venous graphs only. Primary patency was significantly improved at six, 12 and 24 months after the procedure, but not in the first month post‐procedure. Thus, ticlopidine seems to be the only antiplatelet agent achieving a favourable effect on venous graft patency. ASA versus prostaglandin E1, also only with venous grafts, was reported in a single study, with few outcome events and no difference between the treatment groups for early occlusions. Comparing ASA with naftidrofuryl in a single study, there was no difference in primary patency at 12 months. </p> <p>Clopidogrel with ASA versus ASA alone was reported in a single study, with no difference in primary patency at 24 months for all participants, as well as no difference for venous grafts. Prosthetic grafts showed improvement in patency at 24 months for the clopidogrel with ASA group. </p> </section> <section id="CD000535-sec-0095"> <h4 class="title">Side effects and limb amputations</h4> <p>For the comparison of ASA or ASA/DIP versus placebo or nothing, there were no differences between the treatment groups for any of the evaluated side effects, complications or amputations. Comparing ASA or ASA/DIP to PTX there was a possible increase in gastric intolerance, but no differences for gastric haemorrhage, vertigo or amputations. There were also no differences in amputation comparing ASA or ASA/DIP to VKA. Both general and gastrointestinal side effects were increased in the ASA group, compared with naftidrofuryl, but vertigo and stomach bleeding were similar between the two groups. Comparing clopidogrel/ASA with ASA alone, there were increased total, mild and moderate bleeding events in the one study that evaluated this treatment comparison, in all participants, but no difference for severe or fatal bleeding events. In venous grafts within this study, there was an increase in mild and moderate events, but no difference in severe bleeding events, and there was no difference in any of the bleeding categories for prosthetic grafts. Within this comparison, amputations were similar between treatment groups for all participants, including venous grafts, but there was a slight decrease in amputations in the clopidogrel/ASA group. </p> </section> <section id="CD000535-sec-0096"> <h4 class="title">Cardiovascular events and mortality</h4> <p>For the comparisons of ASA or ASA/DIP versus placebo or nothing and ASA or ASA/DIP versus VKA there were no differences between the treatment groups for cardiovascular events or mortality. There was also no difference in mortality when comparing ASA or ASA/DIP versus PTX, ASA versus naftidrofuryl, or clopidogrel/ASA versus ASA alone; cardiovascular events were not evaluated within these comparisons. </p> <p>Although very few events were reported in the single study, there appeared to be decreased mortality in the ASA/DIP treatment group, compared with LMWH. </p> <p>In conclusion, the results of our meta‐analysis suggest that the administration of platelet inhibitors such as ASA or ASA/DIP could result in improved venous and prosthetic graft patency compared to no treatment. However, subgroup analysis by graft type, i.e. venous versus PTFE or Dacron, shows that participants receiving a prosthetic graft are likely to benefit more from ASA or ASA and DIP administration than those treated with a venous graft. For most of the comparisons included in this review, there is currently not enough data to draw any conclusions. </p> </section> </section> <section id="CD000535-sec-0097"> <h3 class="title" id="CD000535-sec-0097">Overall completeness and applicability of evidence</h3> <p>With 16 studies included in the review and meta‐analysis, there was much relevant data available to provide evidence for the review question. However, we separately evaluated a total of nine different comparisons, with only one comparison having more than two studies providing data for meta‐analysis. Therefore, while this review does bring many trials together touching on many antiplatelet treatments, the review does not reach a meaningful level of evidence for all of the predefined comparisons. Also, none of the included studies addressed the outcomes of assisted primary patency, objective assessment of blood flow or quality of life, and many studies did not report on any of the other outcomes. Assisted primary patency as an outcome is of specific importance, as even a highly stenotic graft may remain patent, and a graft at a highly stenotic stage would be more easily treated, both technically and for the patient, than a fully occluded graft. Therefore, knowing whether antiplatelet treatments help reduce full occlusion and allow treatment at a stenotic but not occluded stage would be of clinical importance. </p> <p>Data presentation did not distinguish by graft type for the site of the distal anastomosis. Furthermore, the number of grafts frequently differed from the number of participants, without appropriate explanation. Insufficient information was available in the included studies to assess the effects of antiplatelet agents in different clinical settings such as diabetes and other co‐morbidities. Another concern with the applicability of evidence is the fact that different dosages of the various treatments were used between the included studies. Further information on the dosages can be found in <a href="./references#CD000535-sec-0121" title="">Characteristics of included studies</a> tables. </p> </section> <section id="CD000535-sec-0098"> <h3 class="title" id="CD000535-sec-0098">Quality of the evidence</h3> <p>This review included 16 studies with a total of 5683 randomised participants. Currently we can only draw a robust conclusion regarding antiplatelet agents for preventing thrombosis after peripheral arterial bypass surgery for the comparison between ASA or ASA/DIP versus placebo or nothing, showing a positive reduction in occlusion at 12 months in participants who received ASA or ASA/DIP. The comparisons of ASA or ASA/DIP versus vitamin K antagonists and of clopidogrel and ASA versus ASA alone only included one or two studies, but they encompassed a large number of participants. Neither comparison found any difference in primary graft patency at any of the time points. All other comparisons only included one or two smaller studies. Also limiting the quality of the evidence is the fact that several included studies provided their results by the number of bypasses and not by the number of participants, indicating bilaterally‐treated patients. This could alter results, although currently only a few studies provided results in this manner, with few participants in their study population receiving multiple bypasses. Also of concern is the reporting of outcomes at varying time points, which vary between studies. This reduces our ability to combine outcome data in the most robust way possible. </p> <p>Overall, study quality was moderate, with the largest problem being that the majority of studies did not adequately describe their methods of randomisation or outcome assessor blinding. The other main issue with study quality was not blinding participants or personnel to the treatment received. These concerns, along with the previously reported issues with paucity of data for many of the comparisons, unit of analysis issues, variation of treatment dosages and lack of data on our review's prespecified outcomes, leaves the quality of the evidence of the review moderate to low. We expect that with future updates and more high‐quality studies, the quality of evidence will improve. </p> </section> <section id="CD000535-sec-0099"> <h3 class="title" id="CD000535-sec-0099">Potential biases in the review process</h3> <p>In order to reduce potential bias two review authors assessed studies for inclusion and performed data extraction and quality assessment. We made every attempt to include all relevant studies, but it is still possible that we did not identify all studies. </p> <p>The majority of included studies randomised individuals as the unit for analysis, but four studies included participants with multiple or bilateral reconstructions or re‐randomised participants, and used grafts as the unit of analysis. In order to include these data we performed analyses with the four studies with unit of analyses issues, but also performed sensitivity analyses by excluding them to see if the results were affected. Only the comparison between ASA or ASA/DIP versus nothing or placebo contained enough studies to evaluate the effects of the unit of analysis issues by sensitivity analysis, and within this comparison we could not evaluate all outcomes. Overall there was very little change in the results when the studies were removed, but when the odds ratios (ORs) did change, it was an expected attenuation and decreasing of power due to a reduction in the overall number of participants included in the calculation. Readers should keep in mind our methods of addressing these unit of analysis issues when evaluating the results of this review, as other reviews may take a different approach. </p> <p>For the outcome 'primary patency', the numbers recorded for analyses were actually the number of grafts that occluded during the specified time period as reported by the trialists. Both patency and occlusion are used to describe the treatment outcomes within the included studies and within this review, which should be kept in mind when interpreting the presented data. As assisted primary patency was not reported by the trialists of the included studies, it is unclear if the reported occlusion is actual occlusion i.e. thrombosis of the graft, or if it also includes participants whose grafts were revised prior to occlusion/thrombosis. </p> <p>We calculated data for graft failure from the survival curves if raw data were not reported or were unavailable after contacting the authors of the trials. </p> </section> <section id="CD000535-sec-0100"> <h3 class="title" id="CD000535-sec-0100">Agreements and disagreements with other studies or reviews</h3> <p>A systematic review and meta‐analysis that was published in 1999 also set out to evaluate antiplatelet therapy (specifically aspirin) in the prevention of graft occlusion after infrainguinal bypass surgery (<a href="./references#CD000535-bbs2-0048" title="TangelderMJ , LawsonJA , AlgraA , EikelboomBC . Systematic review of randomized controlled trials of aspiring and oral anticoagulants in the prevention of graft occlusion and ischemic events after infrainguinal bypass surgery. Journal of Vascular Surgery1999;30(4):701-9.">Tangelder 1999</a>). This review differs from our own, as it was interested in oral anticoagulants, as well as antiplatelet agents, and they used risk ratios (RRs) and not odds ratios for their dichotomous outcomes. The <a href="./references#CD000535-bbs2-0048" title="TangelderMJ , LawsonJA , AlgraA , EikelboomBC . Systematic review of randomized controlled trials of aspiring and oral anticoagulants in the prevention of graft occlusion and ischemic events after infrainguinal bypass surgery. Journal of Vascular Surgery1999;30(4):701-9.">Tangelder 1999</a> review included five studies that we also included in our own review, and an additional two studies, one of which was specific to oral anticoagulants, while the other compared an anticoagulant with aspirin to aspirin alone. The findings in <a href="./references#CD000535-bbs2-0048" title="TangelderMJ , LawsonJA , AlgraA , EikelboomBC . Systematic review of randomized controlled trials of aspiring and oral anticoagulants in the prevention of graft occlusion and ischemic events after infrainguinal bypass surgery. Journal of Vascular Surgery1999;30(4):701-9.">Tangelder 1999</a> were similar to our own meta‐analyses findings for the comparison between ASA or ASA/DIP versus nothing or placebo. They found a decrease in bypass occlusions in the aspirin group (RR 0.78, 95% CI 0.64 to 0.95), and no difference between the treatment groups for total mortality (RR 0.92, 95% CI 0.64 to 1.32). </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD000535-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/urn:x-wiley:14651858:media:CD000535:CD000535-FIG-01" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD000535-fig-0001" src="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/image_n/nCD000535-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/image_t/tCD000535-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/full#CD000535-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/image_n/nCD000535-FIG-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000535-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/urn:x-wiley:14651858:media:CD000535:CD000535-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD000535-fig-0002" src="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/image_n/nCD000535-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/image_t/tCD000535-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/full#CD000535-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/image_n/nCD000535-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000535-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/urn:x-wiley:14651858:media:CD000535:CD000535-FIG-03" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD000535-fig-0003" src="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/image_n/nCD000535-FIG-03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/image_t/tCD000535-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/full#CD000535-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/image_n/nCD000535-FIG-03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000535-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/urn:x-wiley:14651858:media:CD000535:CD000535-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: ASA or ASA/DIP vs placebo or nothing, all grafts, Outcome 1: Primary graft patency at 12 months" data-id="CD000535-fig-0004" src="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/image_n/nCD000535-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/image_t/tCD000535-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: ASA or ASA/DIP vs placebo or nothing, all grafts, Outcome 1: Primary graft patency at 12 months </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/references#CD000535-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/image_n/nCD000535-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000535-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/urn:x-wiley:14651858:media:CD000535:CD000535-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: ASA or ASA/DIP vs placebo or nothing, all grafts, Outcome 2: Side effects and complications" data-id="CD000535-fig-0005" src="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/image_n/nCD000535-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/image_t/tCD000535-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: ASA or ASA/DIP vs placebo or nothing, all grafts, Outcome 2: Side effects and complications </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/references#CD000535-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/image_n/nCD000535-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000535-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/urn:x-wiley:14651858:media:CD000535:CD000535-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: ASA or ASA/DIP vs placebo or nothing, all grafts, Outcome 3: Limb amputation" data-id="CD000535-fig-0006" src="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/image_n/nCD000535-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/image_t/tCD000535-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: ASA or ASA/DIP vs placebo or nothing, all grafts, Outcome 3: Limb amputation</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/references#CD000535-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/image_n/nCD000535-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000535-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/urn:x-wiley:14651858:media:CD000535:CD000535-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: ASA or ASA/DIP vs placebo or nothing, all grafts, Outcome 4: Cardiovascular events" data-id="CD000535-fig-0007" src="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/image_n/nCD000535-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/image_t/tCD000535-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: ASA or ASA/DIP vs placebo or nothing, all grafts, Outcome 4: Cardiovascular events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/references#CD000535-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/image_n/nCD000535-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000535-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/urn:x-wiley:14651858:media:CD000535:CD000535-CMP-001.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: ASA or ASA/DIP vs placebo or nothing, all grafts, Outcome 5: Mortality" data-id="CD000535-fig-0008" src="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/image_n/nCD000535-CMP-001.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/image_t/tCD000535-CMP-001.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1: ASA or ASA/DIP vs placebo or nothing, all grafts, Outcome 5: Mortality</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/references#CD000535-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/image_n/nCD000535-CMP-001.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000535-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/urn:x-wiley:14651858:media:CD000535:CD000535-CMP-002.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: ASA or ASA/DIP vs placebo or nothing, subgroups, Outcome 1: Primary graft patency, venous grafts, 1 month" data-id="CD000535-fig-0009" src="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/image_n/nCD000535-CMP-002.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/image_t/tCD000535-CMP-002.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2: ASA or ASA/DIP vs placebo or nothing, subgroups, Outcome 1: Primary graft patency, venous grafts, 1 month </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/references#CD000535-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/image_n/nCD000535-CMP-002.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000535-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/urn:x-wiley:14651858:media:CD000535:CD000535-CMP-002.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: ASA or ASA/DIP vs placebo or nothing, subgroups, Outcome 2: Primary graft patency, venous grafts, 3 months" data-id="CD000535-fig-0010" src="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/image_n/nCD000535-CMP-002.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/image_t/tCD000535-CMP-002.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2: ASA or ASA/DIP vs placebo or nothing, subgroups, Outcome 2: Primary graft patency, venous grafts, 3 months </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/references#CD000535-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/image_n/nCD000535-CMP-002.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000535-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/urn:x-wiley:14651858:media:CD000535:CD000535-CMP-002.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: ASA or ASA/DIP vs placebo or nothing, subgroups, Outcome 3: Primary graft patency, venous grafts, 6 months" data-id="CD000535-fig-0011" src="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/image_n/nCD000535-CMP-002.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/image_t/tCD000535-CMP-002.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2: ASA or ASA/DIP vs placebo or nothing, subgroups, Outcome 3: Primary graft patency, venous grafts, 6 months </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/references#CD000535-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/image_n/nCD000535-CMP-002.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000535-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/urn:x-wiley:14651858:media:CD000535:CD000535-CMP-002.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: ASA or ASA/DIP vs placebo or nothing, subgroups, Outcome 4: Primary graft patency, venous grafts, 12 months" data-id="CD000535-fig-0012" src="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/image_n/nCD000535-CMP-002.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/image_t/tCD000535-CMP-002.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2: ASA or ASA/DIP vs placebo or nothing, subgroups, Outcome 4: Primary graft patency, venous grafts, 12 months </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/references#CD000535-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/image_n/nCD000535-CMP-002.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000535-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/urn:x-wiley:14651858:media:CD000535:CD000535-CMP-002.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: ASA or ASA/DIP vs placebo or nothing, subgroups, Outcome 5: Primary graft patency, venous grafts, 24 months" data-id="CD000535-fig-0013" src="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/image_n/nCD000535-CMP-002.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/image_t/tCD000535-CMP-002.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2: ASA or ASA/DIP vs placebo or nothing, subgroups, Outcome 5: Primary graft patency, venous grafts, 24 months </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/references#CD000535-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/image_n/nCD000535-CMP-002.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000535-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/urn:x-wiley:14651858:media:CD000535:CD000535-CMP-002.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: ASA or ASA/DIP vs placebo or nothing, subgroups, Outcome 6: Primary graft patency, prosthetic grafts, 1 month" data-id="CD000535-fig-0014" src="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/image_n/nCD000535-CMP-002.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/image_t/tCD000535-CMP-002.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2: ASA or ASA/DIP vs placebo or nothing, subgroups, Outcome 6: Primary graft patency, prosthetic grafts, 1 month </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/references#CD000535-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/image_n/nCD000535-CMP-002.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000535-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/urn:x-wiley:14651858:media:CD000535:CD000535-CMP-002.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: ASA or ASA/DIP vs placebo or nothing, subgroups, Outcome 7: Primary graft patency, prosthetic grafts, 3 months" data-id="CD000535-fig-0015" src="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/image_n/nCD000535-CMP-002.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/image_t/tCD000535-CMP-002.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.7</div> <div class="figure-caption"> <p>Comparison 2: ASA or ASA/DIP vs placebo or nothing, subgroups, Outcome 7: Primary graft patency, prosthetic grafts, 3 months </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/references#CD000535-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/image_n/nCD000535-CMP-002.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000535-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/urn:x-wiley:14651858:media:CD000535:CD000535-CMP-002.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: ASA or ASA/DIP vs placebo or nothing, subgroups, Outcome 8: Primary graft patency, prosthetic grafts, 6 months" data-id="CD000535-fig-0016" src="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/image_n/nCD000535-CMP-002.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/image_t/tCD000535-CMP-002.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.8</div> <div class="figure-caption"> <p>Comparison 2: ASA or ASA/DIP vs placebo or nothing, subgroups, Outcome 8: Primary graft patency, prosthetic grafts, 6 months </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/references#CD000535-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/image_n/nCD000535-CMP-002.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000535-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/urn:x-wiley:14651858:media:CD000535:CD000535-CMP-002.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: ASA or ASA/DIP vs placebo or nothing, subgroups, Outcome 9: Primary graft patency, prosthetic grafts, 9 months" data-id="CD000535-fig-0017" src="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/image_n/nCD000535-CMP-002.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/image_t/tCD000535-CMP-002.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.9</div> <div class="figure-caption"> <p>Comparison 2: ASA or ASA/DIP vs placebo or nothing, subgroups, Outcome 9: Primary graft patency, prosthetic grafts, 9 months </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/references#CD000535-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/image_n/nCD000535-CMP-002.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000535-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/urn:x-wiley:14651858:media:CD000535:CD000535-CMP-002.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: ASA or ASA/DIP vs placebo or nothing, subgroups, Outcome 10: Primary graft patency, prosthetic grafts, 12 months" data-id="CD000535-fig-0018" src="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/image_n/nCD000535-CMP-002.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/image_t/tCD000535-CMP-002.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.10</div> <div class="figure-caption"> <p>Comparison 2: ASA or ASA/DIP vs placebo or nothing, subgroups, Outcome 10: Primary graft patency, prosthetic grafts, 12 months </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/references#CD000535-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/image_n/nCD000535-CMP-002.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000535-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/urn:x-wiley:14651858:media:CD000535:CD000535-CMP-003.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: ASA or ASA/DIP versus pentoxifylline (PTX), all grafts, Outcome 1: Primary graft patency, 1 month" data-id="CD000535-fig-0019" src="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/image_n/nCD000535-CMP-003.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/image_t/tCD000535-CMP-003.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3: ASA or ASA/DIP versus pentoxifylline (PTX), all grafts, Outcome 1: Primary graft patency, 1 month </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/references#CD000535-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/image_n/nCD000535-CMP-003.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000535-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/urn:x-wiley:14651858:media:CD000535:CD000535-CMP-003.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: ASA or ASA/DIP versus pentoxifylline (PTX), all grafts, Outcome 2: Primary graft patency, 3 months" data-id="CD000535-fig-0020" src="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/image_n/nCD000535-CMP-003.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/image_t/tCD000535-CMP-003.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3: ASA or ASA/DIP versus pentoxifylline (PTX), all grafts, Outcome 2: Primary graft patency, 3 months </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/references#CD000535-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/image_n/nCD000535-CMP-003.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000535-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/urn:x-wiley:14651858:media:CD000535:CD000535-CMP-003.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: ASA or ASA/DIP versus pentoxifylline (PTX), all grafts, Outcome 3: Primary graft patency, 6 months" data-id="CD000535-fig-0021" src="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/image_n/nCD000535-CMP-003.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/image_t/tCD000535-CMP-003.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3: ASA or ASA/DIP versus pentoxifylline (PTX), all grafts, Outcome 3: Primary graft patency, 6 months </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/references#CD000535-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/image_n/nCD000535-CMP-003.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000535-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/urn:x-wiley:14651858:media:CD000535:CD000535-CMP-003.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: ASA or ASA/DIP versus pentoxifylline (PTX), all grafts, Outcome 4: Primary graft patency, 12 months" data-id="CD000535-fig-0022" src="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/image_n/nCD000535-CMP-003.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/image_t/tCD000535-CMP-003.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3: ASA or ASA/DIP versus pentoxifylline (PTX), all grafts, Outcome 4: Primary graft patency, 12 months </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/references#CD000535-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/image_n/nCD000535-CMP-003.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000535-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/urn:x-wiley:14651858:media:CD000535:CD000535-CMP-003.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: ASA or ASA/DIP versus pentoxifylline (PTX), all grafts, Outcome 5: Side effects" data-id="CD000535-fig-0023" src="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/image_n/nCD000535-CMP-003.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/image_t/tCD000535-CMP-003.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.5</div> <div class="figure-caption"> <p>Comparison 3: ASA or ASA/DIP versus pentoxifylline (PTX), all grafts, Outcome 5: Side effects </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/references#CD000535-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/image_n/nCD000535-CMP-003.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000535-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/urn:x-wiley:14651858:media:CD000535:CD000535-CMP-003.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: ASA or ASA/DIP versus pentoxifylline (PTX), all grafts, Outcome 6: Limb amputation" data-id="CD000535-fig-0024" src="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/image_n/nCD000535-CMP-003.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/image_t/tCD000535-CMP-003.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.6</div> <div class="figure-caption"> <p>Comparison 3: ASA or ASA/DIP versus pentoxifylline (PTX), all grafts, Outcome 6: Limb amputation </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/references#CD000535-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/image_n/nCD000535-CMP-003.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000535-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/urn:x-wiley:14651858:media:CD000535:CD000535-CMP-003.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: ASA or ASA/DIP versus pentoxifylline (PTX), all grafts, Outcome 7: Mortality" data-id="CD000535-fig-0025" src="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/image_n/nCD000535-CMP-003.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/image_t/tCD000535-CMP-003.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.7</div> <div class="figure-caption"> <p>Comparison 3: ASA or ASA/DIP versus pentoxifylline (PTX), all grafts, Outcome 7: Mortality</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/references#CD000535-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/image_n/nCD000535-CMP-003.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000535-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/urn:x-wiley:14651858:media:CD000535:CD000535-CMP-004.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: ASA/DIP versus indobufen, prosthetic grafts, Outcome 1: Primary graft patency, 3 months" data-id="CD000535-fig-0026" src="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/image_n/nCD000535-CMP-004.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/image_t/tCD000535-CMP-004.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4: ASA/DIP versus indobufen, prosthetic grafts, Outcome 1: Primary graft patency, 3 months </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/references#CD000535-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/image_n/nCD000535-CMP-004.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000535-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/urn:x-wiley:14651858:media:CD000535:CD000535-CMP-004.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: ASA/DIP versus indobufen, prosthetic grafts, Outcome 2: Primary graft patency, 6 months" data-id="CD000535-fig-0027" src="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/image_n/nCD000535-CMP-004.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/image_t/tCD000535-CMP-004.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4: ASA/DIP versus indobufen, prosthetic grafts, Outcome 2: Primary graft patency, 6 months </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/references#CD000535-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/image_n/nCD000535-CMP-004.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000535-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/urn:x-wiley:14651858:media:CD000535:CD000535-CMP-004.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: ASA/DIP versus indobufen, prosthetic grafts, Outcome 3: Primary graft patency, 9 months" data-id="CD000535-fig-0028" src="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/image_n/nCD000535-CMP-004.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/image_t/tCD000535-CMP-004.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4: ASA/DIP versus indobufen, prosthetic grafts, Outcome 3: Primary graft patency, 9 months </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/references#CD000535-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/image_n/nCD000535-CMP-004.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000535-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/urn:x-wiley:14651858:media:CD000535:CD000535-CMP-004.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: ASA/DIP versus indobufen, prosthetic grafts, Outcome 4: Primary graft patency, 12 months" data-id="CD000535-fig-0029" src="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/image_n/nCD000535-CMP-004.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/image_t/tCD000535-CMP-004.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.4</div> <div class="figure-caption"> <p>Comparison 4: ASA/DIP versus indobufen, prosthetic grafts, Outcome 4: Primary graft patency, 12 months </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/references#CD000535-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/image_n/nCD000535-CMP-004.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000535-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/urn:x-wiley:14651858:media:CD000535:CD000535-CMP-005.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: ASA or ASA/DIP versus vitamin K antagonists, all grafts, Outcome 1: Primary graft patency, 3 months" data-id="CD000535-fig-0030" src="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/image_n/nCD000535-CMP-005.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/image_t/tCD000535-CMP-005.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5: ASA or ASA/DIP versus vitamin K antagonists, all grafts, Outcome 1: Primary graft patency, 3 months </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/references#CD000535-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/image_n/nCD000535-CMP-005.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000535-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/urn:x-wiley:14651858:media:CD000535:CD000535-CMP-005.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: ASA or ASA/DIP versus vitamin K antagonists, all grafts, Outcome 2: Primary graft patency, 6 months" data-id="CD000535-fig-0031" src="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/image_n/nCD000535-CMP-005.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/image_t/tCD000535-CMP-005.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.2</div> <div class="figure-caption"> <p>Comparison 5: ASA or ASA/DIP versus vitamin K antagonists, all grafts, Outcome 2: Primary graft patency, 6 months </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/references#CD000535-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/image_n/nCD000535-CMP-005.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000535-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/urn:x-wiley:14651858:media:CD000535:CD000535-CMP-005.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: ASA or ASA/DIP versus vitamin K antagonists, all grafts, Outcome 3: Primary graft patency, 12 months" data-id="CD000535-fig-0032" src="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/image_n/nCD000535-CMP-005.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/image_t/tCD000535-CMP-005.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.3</div> <div class="figure-caption"> <p>Comparison 5: ASA or ASA/DIP versus vitamin K antagonists, all grafts, Outcome 3: Primary graft patency, 12 months </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/references#CD000535-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/image_n/nCD000535-CMP-005.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000535-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/urn:x-wiley:14651858:media:CD000535:CD000535-CMP-005.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: ASA or ASA/DIP versus vitamin K antagonists, all grafts, Outcome 4: Primary graft patency, 24 months" data-id="CD000535-fig-0033" src="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/image_n/nCD000535-CMP-005.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/image_t/tCD000535-CMP-005.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.4</div> <div class="figure-caption"> <p>Comparison 5: ASA or ASA/DIP versus vitamin K antagonists, all grafts, Outcome 4: Primary graft patency, 24 months </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/references#CD000535-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/image_n/nCD000535-CMP-005.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000535-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/urn:x-wiley:14651858:media:CD000535:CD000535-CMP-005.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: ASA or ASA/DIP versus vitamin K antagonists, all grafts, Outcome 5: Limb amputation" data-id="CD000535-fig-0034" src="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/image_n/nCD000535-CMP-005.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/image_t/tCD000535-CMP-005.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.5</div> <div class="figure-caption"> <p>Comparison 5: ASA or ASA/DIP versus vitamin K antagonists, all grafts, Outcome 5: Limb amputation </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/references#CD000535-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/image_n/nCD000535-CMP-005.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000535-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/urn:x-wiley:14651858:media:CD000535:CD000535-CMP-005.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: ASA or ASA/DIP versus vitamin K antagonists, all grafts, Outcome 6: Cardiovascular events" data-id="CD000535-fig-0035" src="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/image_n/nCD000535-CMP-005.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/image_t/tCD000535-CMP-005.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.6</div> <div class="figure-caption"> <p>Comparison 5: ASA or ASA/DIP versus vitamin K antagonists, all grafts, Outcome 6: Cardiovascular events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/references#CD000535-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/image_n/nCD000535-CMP-005.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000535-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/urn:x-wiley:14651858:media:CD000535:CD000535-CMP-005.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: ASA or ASA/DIP versus vitamin K antagonists, all grafts, Outcome 7: Mortality" data-id="CD000535-fig-0036" src="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/image_n/nCD000535-CMP-005.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/image_t/tCD000535-CMP-005.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.7</div> <div class="figure-caption"> <p>Comparison 5: ASA or ASA/DIP versus vitamin K antagonists, all grafts, Outcome 7: Mortality </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/references#CD000535-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/image_n/nCD000535-CMP-005.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000535-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/urn:x-wiley:14651858:media:CD000535:CD000535-CMP-006.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: ASA/DIP versus LMWH, all grafts, Outcome 1: Primary graft patency, 6 months" data-id="CD000535-fig-0037" src="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/image_n/nCD000535-CMP-006.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/image_t/tCD000535-CMP-006.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.1</div> <div class="figure-caption"> <p>Comparison 6: ASA/DIP versus LMWH, all grafts, Outcome 1: Primary graft patency, 6 months </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/references#CD000535-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/image_n/nCD000535-CMP-006.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000535-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/urn:x-wiley:14651858:media:CD000535:CD000535-CMP-006.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: ASA/DIP versus LMWH, all grafts, Outcome 2: Primary graft patency, 12 months" data-id="CD000535-fig-0038" src="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/image_n/nCD000535-CMP-006.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/image_t/tCD000535-CMP-006.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.2</div> <div class="figure-caption"> <p>Comparison 6: ASA/DIP versus LMWH, all grafts, Outcome 2: Primary graft patency, 12 months </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/references#CD000535-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/image_n/nCD000535-CMP-006.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000535-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/urn:x-wiley:14651858:media:CD000535:CD000535-CMP-006.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: ASA/DIP versus LMWH, all grafts, Outcome 3: Mortality" data-id="CD000535-fig-0039" src="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/image_n/nCD000535-CMP-006.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/image_t/tCD000535-CMP-006.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.3</div> <div class="figure-caption"> <p>Comparison 6: ASA/DIP versus LMWH, all grafts, Outcome 3: Mortality</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/references#CD000535-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/image_n/nCD000535-CMP-006.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000535-fig-0040"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/urn:x-wiley:14651858:media:CD000535:CD000535-CMP-007.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Ticlopidine versus placebo, venous grafts, Outcome 1: Primary graft patency, 1 month" data-id="CD000535-fig-0040" src="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/image_n/nCD000535-CMP-007.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/image_t/tCD000535-CMP-007.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.1</div> <div class="figure-caption"> <p>Comparison 7: Ticlopidine versus placebo, venous grafts, Outcome 1: Primary graft patency, 1 month </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/references#CD000535-fig-0040">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/image_n/nCD000535-CMP-007.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000535-fig-0041"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/urn:x-wiley:14651858:media:CD000535:CD000535-CMP-007.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Ticlopidine versus placebo, venous grafts, Outcome 2: Primary graft patency, 6 months" data-id="CD000535-fig-0041" src="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/image_n/nCD000535-CMP-007.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/image_t/tCD000535-CMP-007.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.2</div> <div class="figure-caption"> <p>Comparison 7: Ticlopidine versus placebo, venous grafts, Outcome 2: Primary graft patency, 6 months </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/references#CD000535-fig-0041">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/image_n/nCD000535-CMP-007.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000535-fig-0042"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/urn:x-wiley:14651858:media:CD000535:CD000535-CMP-007.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Ticlopidine versus placebo, venous grafts, Outcome 3: Primary graft patency, 12 months" data-id="CD000535-fig-0042" src="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/image_n/nCD000535-CMP-007.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/image_t/tCD000535-CMP-007.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.3</div> <div class="figure-caption"> <p>Comparison 7: Ticlopidine versus placebo, venous grafts, Outcome 3: Primary graft patency, 12 months </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/references#CD000535-fig-0042">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/image_n/nCD000535-CMP-007.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000535-fig-0043"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/urn:x-wiley:14651858:media:CD000535:CD000535-CMP-007.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Ticlopidine versus placebo, venous grafts, Outcome 4: Primary graft patency, 24 months" data-id="CD000535-fig-0043" src="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/image_n/nCD000535-CMP-007.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/image_t/tCD000535-CMP-007.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.4</div> <div class="figure-caption"> <p>Comparison 7: Ticlopidine versus placebo, venous grafts, Outcome 4: Primary graft patency, 24 months </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/references#CD000535-fig-0043">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/image_n/nCD000535-CMP-007.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000535-fig-0044"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/urn:x-wiley:14651858:media:CD000535:CD000535-CMP-008.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: ASA versus prostaglandin (PGE1), venous grafts, Outcome 1: Early occlusion" data-id="CD000535-fig-0044" src="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/image_n/nCD000535-CMP-008.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/image_t/tCD000535-CMP-008.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.1</div> <div class="figure-caption"> <p>Comparison 8: ASA versus prostaglandin (PGE1), venous grafts, Outcome 1: Early occlusion</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/references#CD000535-fig-0044">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/image_n/nCD000535-CMP-008.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000535-fig-0045"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/urn:x-wiley:14651858:media:CD000535:CD000535-CMP-009.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 9: ASA versus naftidrofuryl, Outcome 1: Primary graft patency at 12 months" data-id="CD000535-fig-0045" src="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/image_n/nCD000535-CMP-009.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/image_t/tCD000535-CMP-009.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.1</div> <div class="figure-caption"> <p>Comparison 9: ASA versus naftidrofuryl, Outcome 1: Primary graft patency at 12 months</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/references#CD000535-fig-0045">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/image_n/nCD000535-CMP-009.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000535-fig-0046"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/urn:x-wiley:14651858:media:CD000535:CD000535-CMP-009.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 9: ASA versus naftidrofuryl, Outcome 2: Side effects" data-id="CD000535-fig-0046" src="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/image_n/nCD000535-CMP-009.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/image_t/tCD000535-CMP-009.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.2</div> <div class="figure-caption"> <p>Comparison 9: ASA versus naftidrofuryl, Outcome 2: Side effects</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/references#CD000535-fig-0046">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/image_n/nCD000535-CMP-009.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000535-fig-0047"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/urn:x-wiley:14651858:media:CD000535:CD000535-CMP-009.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 9: ASA versus naftidrofuryl, Outcome 3: Mortality" data-id="CD000535-fig-0047" src="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/image_n/nCD000535-CMP-009.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/image_t/tCD000535-CMP-009.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.3</div> <div class="figure-caption"> <p>Comparison 9: ASA versus naftidrofuryl, Outcome 3: Mortality</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/references#CD000535-fig-0047">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/image_n/nCD000535-CMP-009.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000535-fig-0048"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/urn:x-wiley:14651858:media:CD000535:CD000535-CMP-010.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 10: Clopidogrel and ASA versus ASA alone, all grafts, Outcome 1: Primary graft patency at 24 months" data-id="CD000535-fig-0048" src="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/image_n/nCD000535-CMP-010.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/image_t/tCD000535-CMP-010.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.1</div> <div class="figure-caption"> <p>Comparison 10: Clopidogrel and ASA versus ASA alone, all grafts, Outcome 1: Primary graft patency at 24 months </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/references#CD000535-fig-0048">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/image_n/nCD000535-CMP-010.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000535-fig-0049"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/urn:x-wiley:14651858:media:CD000535:CD000535-CMP-010.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 10: Clopidogrel and ASA versus ASA alone, all grafts, Outcome 2: Side effects" data-id="CD000535-fig-0049" src="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/image_n/nCD000535-CMP-010.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/image_t/tCD000535-CMP-010.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.2</div> <div class="figure-caption"> <p>Comparison 10: Clopidogrel and ASA versus ASA alone, all grafts, Outcome 2: Side effects</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/references#CD000535-fig-0049">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/image_n/nCD000535-CMP-010.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000535-fig-0050"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/urn:x-wiley:14651858:media:CD000535:CD000535-CMP-010.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 10: Clopidogrel and ASA versus ASA alone, all grafts, Outcome 3: Limb amputation" data-id="CD000535-fig-0050" src="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/image_n/nCD000535-CMP-010.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/image_t/tCD000535-CMP-010.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.3</div> <div class="figure-caption"> <p>Comparison 10: Clopidogrel and ASA versus ASA alone, all grafts, Outcome 3: Limb amputation</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/references#CD000535-fig-0050">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/image_n/nCD000535-CMP-010.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000535-fig-0051"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/urn:x-wiley:14651858:media:CD000535:CD000535-CMP-010.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 10: Clopidogrel and ASA versus ASA alone, all grafts, Outcome 4: Mortality" data-id="CD000535-fig-0051" src="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/image_n/nCD000535-CMP-010.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/image_t/tCD000535-CMP-010.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.4</div> <div class="figure-caption"> <p>Comparison 10: Clopidogrel and ASA versus ASA alone, all grafts, Outcome 4: Mortality</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/references#CD000535-fig-0051">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/image_n/nCD000535-CMP-010.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000535-fig-0052"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/urn:x-wiley:14651858:media:CD000535:CD000535-CMP-011.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 11: Clopidogrel and ASA versus ASA alone, subgroups, Outcome 1: Primary graft patency, venous grafts, 24 months" data-id="CD000535-fig-0052" src="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/image_n/nCD000535-CMP-011.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/image_t/tCD000535-CMP-011.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.1</div> <div class="figure-caption"> <p>Comparison 11: Clopidogrel and ASA versus ASA alone, subgroups, Outcome 1: Primary graft patency, venous grafts, 24 months </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/references#CD000535-fig-0052">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/image_n/nCD000535-CMP-011.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000535-fig-0053"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/urn:x-wiley:14651858:media:CD000535:CD000535-CMP-011.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 11: Clopidogrel and ASA versus ASA alone, subgroups, Outcome 2: Primary graft patency, prosthetic grafts, 24 months" data-id="CD000535-fig-0053" src="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/image_n/nCD000535-CMP-011.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/image_t/tCD000535-CMP-011.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.2</div> <div class="figure-caption"> <p>Comparison 11: Clopidogrel and ASA versus ASA alone, subgroups, Outcome 2: Primary graft patency, prosthetic grafts, 24 months </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/references#CD000535-fig-0053">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/image_n/nCD000535-CMP-011.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000535-fig-0054"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/urn:x-wiley:14651858:media:CD000535:CD000535-CMP-011.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 11: Clopidogrel and ASA versus ASA alone, subgroups, Outcome 3: Side effects" data-id="CD000535-fig-0054" src="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/image_n/nCD000535-CMP-011.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/image_t/tCD000535-CMP-011.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.3</div> <div class="figure-caption"> <p>Comparison 11: Clopidogrel and ASA versus ASA alone, subgroups, Outcome 3: Side effects</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/references#CD000535-fig-0054">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/image_n/nCD000535-CMP-011.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000535-fig-0055"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/urn:x-wiley:14651858:media:CD000535:CD000535-CMP-011.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 11: Clopidogrel and ASA versus ASA alone, subgroups, Outcome 4: Limb amputation" data-id="CD000535-fig-0055" src="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/image_n/nCD000535-CMP-011.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/image_t/tCD000535-CMP-011.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.4</div> <div class="figure-caption"> <p>Comparison 11: Clopidogrel and ASA versus ASA alone, subgroups, Outcome 4: Limb amputation</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/references#CD000535-fig-0055">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/image_n/nCD000535-CMP-011.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000535-fig-0056"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/urn:x-wiley:14651858:media:CD000535:CD000535-CMP-011.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 11: Clopidogrel and ASA versus ASA alone, subgroups, Outcome 5: Mortality" data-id="CD000535-fig-0056" src="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/image_n/nCD000535-CMP-011.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/image_t/tCD000535-CMP-011.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.5</div> <div class="figure-caption"> <p>Comparison 11: Clopidogrel and ASA versus ASA alone, subgroups, Outcome 5: Mortality</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/references#CD000535-fig-0056">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/media/CDSR/CD000535/image_n/nCD000535-CMP-011.05.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table data-id="CD000535-tbl-0001"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Patient characteristics</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study ID</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>% CLI</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>% below knee</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>% vein</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>% 1‐vessel run‐off</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>dose</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>preoperative start of treatment</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>treatment duration</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>randomisation</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>ABI pre‐op to postop</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000535-bbs2-0001" title="BecqueminJP . Effect of ticlopidine on the long-term patency of saphenous-vein bypass grafts in the legs. New England Journal of Medicine1997;337(24):1726-31. ">Becquemin 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>nd</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>nd</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>TIC 250 mg vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>between the 3rd and 14th post‐op day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>post‐op</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>nd</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000535-bbs2-0002" title="AlgraA . A randomised trial of oral anticoagulants versus aspirin after infrainguinal bypass surgery. Tijdschrift voor Sociale Gezondheidszorg1999;77(4):11. AriesenMJ , TangelderMJD , LawsonJA , EikelboomBC , GrobbeeDE , AlgraA . Risk of major haemorrhage in patients after infrainguinal venous bypass surgery: Therapeutic consequences? The Dutch BOA (Bypass Oral Anticoagulants or Aspirin) study. European Journal of Vascular and Endovascular Surgery2005;30(2):154-9. Dutch Bypass Oral anticoagulants of Aspirin (BOA) Study Group. Efficacy of oral anticoagulants compared with aspirin after infrainguinal bypass surgery (The Dutch Bypass Oral anticoagulants or Aspirin study): a randomised trial. Lancet2000;355(9201):346-51. EikelboomBC . Prevention of occlusions after infrainguinal bypass surgery with oral anticoagulants or acetylsalicylic acid: A randomised trial. Nederlands Tijdschrift voor Geneeskunde2001;145(22):1060-7. OostenbrinkJB , TangelderMJ , BusschbachJJ , Van HoutBA , BuskensE , AlgraA , et al. Cost effectiveness of oral anticoagulants versus aspirin in patients after infrainguinal bypass grafting surgery. Journal of Vascular Surgery2001;34(2):254-62. SmeetsL , HoGH , TangelderMJ , AlgraA , LawsonJA , EikelboomBC , et al, Dutch BOA Study Group. Outcome after occlusion of infrainguinal bypasses in the Dutch BOA Study: comparison of amputation rate in venous and prosthetic grafts. European Journal of Vascular and Endovascular Surgery2005;30(6):604-9. TangelderMJ , AlgraA , LawsonJA , EikelboomBC . Risk factors for occlusion of infrainguinal bypass grafts. European Journal of Vascular and Endovascular Surgery2000;20(2):118-24. TangelderMJ , AlgraA , LawsonJA , HennekesS , EikelboomBC . Optimal oral anticoagulant intensity to prevent secondary ischemic and hemorrhagic events in patients after infrainguinal bypass graft surgery. Dutch BOA Study Group. Journal of Vascular Surgery2001;33(3):522-7. TangelderMJ , EikelboomBC , LawsonJA , AlgraA . Prevention of occlusion following peripheral bypass surgery using oral anticoagulants or acetylsalicylic acid: a randomized comparison within the Dutch BOA study [Preventi van occlusies na perifere bypass-chirurgie met orale anticoagulantia of acetylsalicylzuur: een gerandomiseerde vergelijking in het Nederlands BOA-onderzoek]. Nederlands Tijdschrift voor Geneeskunde1995;139(29):1504-6. TangelderMJ , McDonnelJ , Van BusschbachJJ , BuskensE , AlgraA , LawsonJA , EikelboomBC . Quality of life after infrainguinal bypass grafting surgery. Dutch Bypass Oral Anticoagulants or Aspirin (BOA) Study Group. Journal of Vascular Surgery1999;29(5):913-9. Van HattumES , AlgraA , LawsonJA , EikelboomBC , MollFL , TangelderMJD . Bleeding increases the risk of ischemic events in patients with peripheral arterial disease. Circulation2009;120(16):1569-76. Van HattumES , TangelderMJD , LawsonJA , MollFL , AlgraA . The quality of life in patients after peripheral bypass surgery deteriorates at long-term follow-up. Journal of Vascular Surgery2011;53(3):643-50. ">BOA 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>58.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>nd</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ASA 80 mg vs coumarin INR 3.0 ‐ 4.5 reached in 50%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>within 5 days until 1 month post‐op</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>before surgery</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>nd</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000535-bbs2-0003" title="Anonymous. Clopidogrel and acetyl salicylic acid in bypass surgery for peripheral arterial disease. clinicaltrials.gov/ct2/show/NCT00174759?term=CASPAR&amp;rank=2 (accessed 5 May 2014). Anonymous. Dual antiplatelet therapy benefits prosthetic but not venous grafts. Vascular News2009;Feb:17. BelchJJ , DormandyJ . Results of the randomized, placebo-controlled clopidogrel and acetylsalicylic acid in bypass surgery for peripheral arterial disease (CASPAR) trial. Journal of Vascular Surgery2010;52(4):825-33. The Caspar Investigators, BelchJ . Effect of adding clopidogrel to aspirin on the success of below knee arterial bypass grafts. A randomised placebo controlled study. In: Vascular Annual Meeting; 2007 Jun; Baltimore, USA. 2007. ">CASPAR 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>nd</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ASA 75 ‐ 100 mg plus clopidogrel 75 mg vs ASA 75 ‐ 100 mg plus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 to 4 days post‐op</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>post‐op</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>nd</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000535-bbs2-0004" title="ClyneCA , ArcherTJ , AtuhaireLK , ChantAD , WebsterJH . Random control trial of a short course of aspirin and dipyridamole (Persantin) for femorodistal grafts. British Journal of Surgery1987;74(4):246-8. ">Clyne 1987</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ASA 2 x 300 mg, DIP 2 x 200 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>48 hours pre‐op</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>before surgery</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.38 to 0.78</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000535-bbs2-0005" title="D'AddatoM , CurtiT , BertiniD , DoniniI , FerreroR , FioraniP , et al. Indobufen vs acetylsalicylic acid plus dipyridamole in long-term patency after femoropopliteal bypass. International Angiology1992;11(2):106-12. ">D'Addato 1992</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ASA 900 mg plus DIP 225 mg vs 400 mg IND</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>48 h</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>before surgery</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>nd</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000535-bbs2-0006" title="DonaldsonDR , SalterMC , KesterRC , RajahSM , HallTJ , SreeharanN , et al. The influence of platelet inhibition on the patency of femoro-popliteal Dacron bypass grafts. Vascular Surgery1985;19(4):224-30. ">Donaldson 1985</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ASA 3 x 330 mg plus DIP 75 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Evening prior to surgery</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>before surgery</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.62 to nd</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000535-bbs2-0007" title="EdmondsonRA , CohenAT , DasSK , WagnerBM , KakkarVV . Low-molecular weight heparin versus aspirin and dipyridamole after femoropopliteal bypass grafting. Lancet1994;344(8927):914-8. ">Edmondson 1994</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 x 300 mg ASA plus 3 x 100 mg DIP versus 2500 IU LMWH</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>LMWH 2 hours pre‐op; ASA/DIP 1 week post‐op</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>post‐op</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>nd</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000535-bbs2-0008" title="GoldmanM , McCollumC . A prospective randomized study to examine the effect of aspirin plus dipyridamole on the patency of prosthetic femoro-popliteal grafts. Vascular Surgery1984;18(4):217-21. ">Goldman 1984</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>nd</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ASA 3 x 300 mg plus DIP 3 x 75 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 days ASA/DIP</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>before surgery</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>nd</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000535-bbs2-0009" title="GreenRM , RoedersheimerRL , DeWeeseJA . Effects of aspirin and dipyridamole on expanded polytetrafluoethylene graft patency. Surgery1982;92(6):1016-26. ">Green 1982</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>82</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>nd</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ASA 3 x 325 mg, or ASA 3 x 325 mg plus DIP 3 x 75 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 days ASA/DIP</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>before surgery</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.42 to 1.01</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000535-bbs2-0010" title="GrussJD , HiemerW , KroissA , GeisslerC . Experiences with adjuvant prostaglandin therapy in vascular surgery interventions. Vasa-Supplementum1991;33:353-4. ">Gruss 1991</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>nd</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>nd</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>nd</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 x 0.5 g ASA plus 15,000 IU heparin versus PGE1, 0.2 ng per kg body weight/min plus 15,000 IU heparin </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>post‐op</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>nd</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>nd</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000535-bbs2-0011" title="KohlerTR , KaufmanJL , KacoyanisG , ClowesA , DonaldsonMC , KellyE , et al. Effect of aspirin and dipyridamole on the patency of lower extremity bypass grafts. Surgery1984;96(3):462-6. ">Kohler 1984</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>76</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>nd</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ASA 3 x 325 mg plus DIP 3 x 75 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>first post‐op day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>before surgery</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>nd</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000535-bbs2-0012" title="LucasMA . Prevention of post-operative thrombosis in peripheral arteriopathies. Pentoxifylline vs conventional antiaggregants: a six-month randomized follow-up study. Angiology1984;35(7):443-50. ">Lucas 1984</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>nd</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>nd</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ASA 1050 mg, DIP 150 mg or 1200 mg PTX</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>pre‐op</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>before surgery</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.4</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000535-bbs2-0013" title="FranksPJ , SianM , KenchingtonGF , AlexanderCE , PowellJT . Aspirin usage and its influence on femoro-popliteal vein graft patency. European Journal of Vascular Surgery1992;6(2):185-8. FranksPJ , SianM , KenchingtonGF , AlexanderCE , PowellJT . Aspirin usage and its influence on femoropopliteal vein graft patency. In: European Society for Vascular Surgery 5th Annual Meeting, 25-27 September 1991; Warsaw, Poland. 1991. McCollumC , AlexanderC , KenchingtonG , FranksPJ , GreenhalghR . Antiplatelet drugs in femoropopliteal vein bypasses: A multicenter trial. Journal of Vascular Surgery1991;13(1):150-62. PowellJT , GreenhalghRM . Smoking and factors influencing the outcome of arterial reconstruction. Annales Chirurgiae et Gynaecologiae1992;81(2):236-41. ">McCollum 1991</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>nd; vein &lt; 4 mm:38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ASA 2 x 300 mg plus DIP 2 x 150 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 days ASA/DIP</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>continuing indefinitely</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>before surgery</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.47 to nd</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000535-bbs2-0014" title="NoppeneyT , KasprzakP , RaithelD , HircheH . Naftidrofuryl in postoperative treatment after femoropopliteal bypass. Die Medizinische Welt1988;39:1545-50. ">Noppeney 1988</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>nd</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>nd</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>nd</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>nd</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ASA 1500 mg vs naftidrofuryl 600 mg daily orally</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>day 1 post‐op</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>before surgery</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>nd</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000535-bbs2-0015" title="RaithelD , KasprzakP , Noppeney Th. Relapse prophylaxis after femoropopliteal reconstruction with PTFE-prostheses. Die Medizinische Welt1986;37:664-7. RaithelD . Prevention of reocclusion after prosthetic bypass operations in the femoro-popliteal region: a comparative study of pentoxifylline versus acetylsalicylic acid. Vascular Surgery1987;21(3):208-14. ">Raithel 1987</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>nd</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ASA 1500 mg vs PTX 1200 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>48 h</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>before surgery</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>nd</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000535-bbs2-0016" title="SchneiderE , BrunnerU , BollingerA . No English title available [Medikamentose Rezidivprophylaxe nach femoro-poplitealer Arterienrekonstruktion]. Angio1979;2(1):73-7. ">Schneider 1979</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>nd</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>nd</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>nd</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ASA 1000 mg, or ASA 1000 mg plus DIP 225 mg vs coumarin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>post‐op</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>post‐op</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>nd</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="10"> <div class="table-footnote"> <p>ASA: Aspirin<br/>CLI: critical limb ischaemia<br/>DIP: dipyridamole<br/>h: hour<br/>IU: international unit<br/>LMWH: low molecular weight heparin<br/>mg: milligram<br/>nd: no data<br/>ng: nanogram<br/>PGE1: prostaglandin E1<br/>PTX: pentoxifylline<br/>TIC: ticlopidine<br/>vs: versus </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Patient characteristics</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/full#CD000535-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD000535-tbl-0002"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">ASA or ASA/DIP vs placebo or nothing, all grafts</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Primary graft patency at 12 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>952</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.42 [0.22, 0.83]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Side effects and complications <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.1 Side effects‐ general</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>913</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.55 [1.00, 2.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.2 Gastrointestinal side effects</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>952</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.44 [0.92, 2.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.3 Major bleeding</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>598</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.88 [0.85, 4.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.4 Minor bleeding</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>148</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.73 [0.31, 1.70]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.5 Wound or graft infection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>549</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.07 [0.67, 1.71]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Limb amputation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 Cardiovascular events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>811</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.27 [0.43, 3.80]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.5 Mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>799</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.56, 1.26]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">ASA or ASA/DIP vs placebo or nothing, all grafts</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/references#CD000535-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD000535-tbl-0003"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">ASA or ASA/DIP vs placebo or nothing, subgroups</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.1 Primary graft patency, venous grafts, 1 month <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>642</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.76 [0.26, 2.25]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.2 Primary graft patency, venous grafts, 3 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>642</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.54, 1.35]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.3 Primary graft patency, venous grafts, 6 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>642</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.59, 1.31]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.4 Primary graft patency, venous grafts, 12 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>642</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.69 [0.48, 0.99]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.5 Primary graft patency, venous grafts, 24 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>620</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.32, 3.28]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.6 Primary graft patency, prosthetic grafts, 1 month <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>157</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.14 [0.04, 0.51]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.7 Primary graft patency, prosthetic grafts, 3 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>222</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.31 [0.14, 0.66]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.8 Primary graft patency, prosthetic grafts, 6 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>222</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.21 [0.11, 0.41]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.9 Primary graft patency, prosthetic grafts, 9 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.10 Primary graft patency, prosthetic grafts, 12 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>222</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.19 [0.10, 0.36]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">ASA or ASA/DIP vs placebo or nothing, subgroups</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/references#CD000535-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD000535-tbl-0004"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">ASA or ASA/DIP versus pentoxifylline (PTX), all grafts</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.1 Primary graft patency, 1 month <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.2 Primary graft patency, 3 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.3 Primary graft patency, 6 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>151</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.32 [0.56, 3.11]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.4 Primary graft patency, 12 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.5 Side effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.5.1 Gastric intolerance</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.5.2 Gastric haemorrhage</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.5.3 Vertigo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.6 Limb amputation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.7 Mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">ASA or ASA/DIP versus pentoxifylline (PTX), all grafts</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/references#CD000535-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD000535-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">ASA/DIP versus indobufen, prosthetic grafts</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.1 Primary graft patency, 3 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.2 Primary graft patency, 6 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.3 Primary graft patency, 9 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.4 Primary graft patency, 12 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">ASA/DIP versus indobufen, prosthetic grafts</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/references#CD000535-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD000535-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">ASA or ASA/DIP versus vitamin K antagonists, all grafts</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.1 Primary graft patency, 3 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2781</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.68, 1.14]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.2 Primary graft patency, 6 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2781</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.27, 1.96]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.3 Primary graft patency, 12 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2781</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.68 [0.27, 1.69]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.4 Primary graft patency, 24 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2781</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.64 [0.25, 1.63]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.5 Limb amputation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.6 Cardiovascular events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.6.1 Myocardial infarction</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.6.2 Stroke</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.7 Mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">ASA or ASA/DIP versus vitamin K antagonists, all grafts</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/references#CD000535-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD000535-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">ASA/DIP versus LMWH, all grafts</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.1 Primary graft patency, 6 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.2 Primary graft patency, 12 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.3 Mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">ASA/DIP versus LMWH, all grafts</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/references#CD000535-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD000535-tbl-0008"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Ticlopidine versus placebo, venous grafts</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.1 Primary graft patency, 1 month <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.2 Primary graft patency, 6 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.3 Primary graft patency, 12 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.4 Primary graft patency, 24 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Ticlopidine versus placebo, venous grafts</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/references#CD000535-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD000535-tbl-0009"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">ASA versus prostaglandin (PGE1), venous grafts</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.1 Early occlusion <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">ASA versus prostaglandin (PGE1), venous grafts</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/references#CD000535-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD000535-tbl-0010"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">ASA versus naftidrofuryl</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.1 Primary graft patency at 12 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.2 Side effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2.1 Side effects‐ general</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2.2 Gastrointestinal side effects</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2.3 Vertigo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2.4 Stomach bleeding</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.3 Mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">ASA versus naftidrofuryl</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/references#CD000535-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD000535-tbl-0011"> <div class="table-heading"><span class="table-label">Comparison 10.</span> <span class="table-title">Clopidogrel and ASA versus ASA alone, all grafts</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10.1 Primary graft patency at 24 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10.2 Side effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2.1 Bleeding‐ total</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2.2 Bleeding‐ mild</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2.3 Bleeding‐ moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2.4 Bleeding‐ severe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2.5 Bleeding‐ fatal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10.3 Limb amputation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10.4 Mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 10.</span> <span class="table-title">Clopidogrel and ASA versus ASA alone, all grafts</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/references#CD000535-tbl-0011">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD000535-tbl-0012"> <div class="table-heading"><span class="table-label">Comparison 11.</span> <span class="table-title">Clopidogrel and ASA versus ASA alone, subgroups</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11.1 Primary graft patency, venous grafts, 24 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11.2 Primary graft patency, prosthetic grafts, 24 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11.3 Side effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.3.1 Bleeding‐ mild, venous grafts</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.3.2 Bleeding‐ mild, prosthetic grafts</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.3.3 Bleeding‐ moderate, venous grafts</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.3.4 Bleeding‐ moderate, prosthetic grafts</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.3.5 Bleeding‐ severe, venous grafts</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.3.6 Bleeding‐ severe, prosthetic grafts</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11.4 Limb amputation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.4.1 Amputation, venous grafts</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.4.2 Amputation, prosthetic grafts</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11.5 Mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.5.1 Mortality, venous grafts</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.5.2 Mortality, prosthetic grafts</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 11.</span> <span class="table-title">Clopidogrel and ASA versus ASA alone, subgroups</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000535.pub3/references#CD000535-tbl-0012">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD000535.pub3&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD000535-note-0010">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD000535-note-0008">فارسی</a> </li> <li class="section-language"> <a class="" href="ms#CD000535-note-0009">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="ru#CD000535-note-0007">Русский</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD000535-note-0005">简体中文</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD000535-note-0006">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000535\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD000535\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000535\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD000535\x2epub3"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000535\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD000535\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000535\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD000535\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000535\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD000535\x2epub3"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000535\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD000535\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000535\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD000535\x2epub3"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000535\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD000535\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000535\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD000535\x2epub3"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=STpJR8yz&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD000535.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD000535.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD000535.pub3/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD000535.pub3/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD000535.pub3%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740714670972"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD000535.pub3/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740714670976"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD000535.pub3/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918d745c6b3a937f',t:'MTc0MDcxNDY3MS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 